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Abstract: The first part of this work involved the synthesis of small molecules as potential 
inhibitors of the bacterioferritin B–bacterioferritin-associated ferredoxin (BfrB–Bfd) protein–
protein interaction in Pseudomonas aeruginosa. BfrB is the main iron storage protein, which is 
central to bacterial iron homeostasis. The mobilization of iron from BfrB requires binding by a 
cognate ferredoxin (Bfd), thus BfrB–Bfd interaction is essential to the regulation of cytosolic iron 
levels in P. aeruginosa. The purpose of this project was to develop small molecules which could 
inhibit this protein–protein interaction and elicit perturbations in iron homeostasis that decrease 
bacterial fitness. Previous work from our research group involved the synthesis of 4-
(alkylamino)isoindoline-1,3-diones which demonstrated promising inhibition of the BfrB–Bfd 
interaction. The current project focused on the synthesis of analogs that could be effective in a 
relatively low micromolar range. Consequently, 1- and 3-carbon linker analogs of the 4-
(alkylamino)isoindoline-1,3-diones were synthesized and characterized. Based on molecular 
modeling, the following modifications below led to the synthesis of a series of twelve (12) new 
compounds. 
• Incorporation of new benzaldehyde components: Relatively inexpensive starting 
materials were used for the reaction. It was envisioned that the incorporation of these 
functionalities in the analogs of the 4-(alkylamino)isoindoline-1,3-diones would possibly 
increase the inhibitory effect. 
• Altering the carbon linker: Other modifications were made to the 4-(alkylamino)isoindo-
line-1,3-diones by decreasing the 3-carbon linker to a 1-carbon linker with similar 
aromatic substitution patterns and comparing their activity data. 
• Substitution of the benzaldehyde component with other heterocyclic groups: The 
benzaldehyde component for both 1- and 3-carbon linkers was replaced with 2- and 3-
furaldehyde and tetrahydrofuran analogs. 
 
The second part of this work involved the design of new methods for the synthesis of bioactive 
heterocyclic scaffolds. A summary of these methods follows: 
• An efficient one-pot approach to 1-aryl-5-nitro-1H-indazoles and 1-aryl-1H-indazoles 
was developed and optimized. 
• A one-pot route to 4H-benzo[d][1,3]-oxazin-4-ones and dihydro analogs was designed 
from substituted anthranilic acid and ortho esters. 
• An efficient, inexpensive approach to bis-1,3,4-oxadiazoles was established using NH4Cl 
as a catalyst. 
• An efficient synthesis of naphthalene, dihydroquinoline and naphthyridine carboxylates 
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SYNTHESIS OF SMALL MOLECULES AS POTENTIAL ANTIBIOTICS 
1.1. Introduction 
Infections due to antibiotic-resistant bacteria remain a worldwide threat to public health.1 The 
ability of bacteria to develop antibiotic-resistant strains has overwhelmed our ability to develop 
new antibiotics and validate other targets.1-4 Hence, new strategies and targets are critical and 
urgently needed to effectively overcome this challenge. In modern medicine, many achievements, 
such as organ transplantation, cancer chemotherapy and major surgery, have not received the 
deserved recognition due to antibiotic resistant infections.1 The battle between new antibiotics 
and bacteria resistance mechanisms has always existed since the invention of the first antibiotic, 
Penicillin (1, Figure 1.1).  
 















































Most antibiotics are derived from natural products, and thus, antibacterial defense mechanisms of 
some sort often already exist. A typical example of an ancient antibiotic resistance is when genes 
coding for resistance against Vancomycin 2 (Figure 1.1) were observed in bacterial samples 
isolated from 10,000-year-old permafrost.3,5 Modern antibiotics and bacterial resistance are 
caused by several factors, including diminished pharmaceutical investments, antibiotic misuse by 
individuals and the food industry, chronic clinical over-prescription and public misconceptions.6 
In response to this resistance, efforts were channeled towards the design of antibiotics that were 
semi-synthetically derived from natural products. Within the last 30 years, the majority of the 
semi-synthetic antibiotics introduced have demonstrated promising activities. These include the 
b-lactams meropenem 3 and tazobactam 4 as well as the aminoglycoside amikacin 5 (Figure 1.2) 
among others.6,7 Nevertheless, recent resistance developed against natural product antibiotics has 
necessitated the search for new classes of antibiotics. The ease with which many resistance genes 
are disseminated has made totally synthetic antibiotics better and attractive options to explore. 
Until recently, synthetic antibiotics remained extremely rare with sulfa drugs, quinolones, 
oxazolidinones and diarylquinolines being the only examples.6 
 
Figure 1.2. Examples of semi-synthetic antibiotics.6 
Since 2016, the World Health Organization (WHO) has encouraged investment in new drugs by 
publishing a priority list for research and development of new antibiotics to combat multidrug 








































Acinetobacter baumannii and Pseudomonas aeruginosa, and third-generation cephalosporin 
resistant Enterobacteriaceae.8 Gram-negatives are naturally resistant to many antibiotics because 
their outer membranes are designed to prevent the entry of many amphipathic drugs. Similarly, 
the inner membranes and highly active efflux pumps often recognize highly hydrophilic 
molecules. Thus, the issue of bacterial cell penetration poses an immense challenge to finding 
new synthetic scaffolds.6,9,10 P. aeruginosa remains one of the leading Gram-negative pathogens 
associated with hospital infections. Such pathogens easily colonize urinary catheters and 
endotracheal tubes,11,12 and accelerate lung function decay in patients with cystic fibrosis.13,14 An 
effective response to this menace will require vibrant research and continued investment in the 
early stages of drug development in order to establish a conduit of novel ideas and strategies.1 In 
this context, a new therapeutic intervention recently developed involves potential strategies that 
interfere with bacterial iron acquisition and homeostasis.15-19 Bacteria rely heavily on iron for 
multiple metabolic processes such as respiration and fundamental enzymatic reactions.20 The host 
usually serves as the source of iron for the pathogenic bacteria, however, its nutritional immunity 
maintains an extremely low concentration of free iron. Thus, the essential nutrient needed by the 
invading pathogens is denied.1,21-24 Typically, iron exists in two oxidation states, Fe3+ and Fe2+. 
The ferric iron (Fe3+) exhibits reduced bioavailability due to its minimal solubility. Ferrous iron 
(Fe2+), on the other hand, is soluble in aqueous solution, however, it can readily be converted to 
Fe3+ via an oxygen (O2) or hydrogen peroxide oxidation mechanism. In response to the 
insufficient availability of iron, bacteria express a variety of uptake systems, and also evolve a 
number of mechanisms to highly regulate the process of bacterial iron homeostasis (acquisition, 
storage and utilization) ensuring sufficiency for metabolic needs while preventing iron-induced 
toxicity.25,26 One of the mechanisms involves the production of a ferric-siderophore complex, 
which plays a key role in the transportation of iron to the bacterial cytoplasm. Siderophores, also 
known as Fe2+ importers, contain oxygen atoms which selectively bind to ferric iron (Fe3+), 
making it water soluble and allowing cellular uptake.27-29 Bacteria secrete iron chelating 
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siderophores via an active efflux mechanism which involves inner membrane transporters such as 
EntS and IroC and the outer protein TolC (Figure 1.3).30  
 
Figure 1.3. Maintenance of cellular iron homeostasis under deficient and replete conditions.30 
FeoAB and SitABCD are examples of uptake systems that bacteria employ in the acquisition of 
Fe2+ and/or other transition metals. FeoAB consists of a cytosolic protein and an inner membrane 
transporter that allows the uptake of only ferrous iron (Fe2+)31 whereas SitABCD is an ABCD 
family transporter that enables the acquisition of both Fe2+ and manganese.32 Bacteria maintain 
proper iron storage in several iron storage proteins. Two of the most studied proteins in P. 
aeruginosa cells are the bacterial ferritin (Ftn) and bacterioferritin (Bfr).1 The ftnA and bfrB 
genes encode bacterial ferritin (FtnA) and bacterioferritin B (BfrB), respectively.33,34 However, 
BfrB functions as the main iron storage protein.25 Recent research has shown that the 
mobilization of iron stored in BfrB requires specific interactions between BfrB and its cognate 
partner, bacterioferritin-associated ferredoxin (Bfd).25,35,36 BfrB stores iron in the form of a Fe3+ 
mineral. When P. aeruginosa needs iron, Bfd binds to the outer shell of BfrB and facilitates the 
transfer of an electron from ferredoxin NADp reductase (Fpr) into BfrB for the reduction of Fe3+ 
to Fe2+. Ferrous iron (Fe2+) is essential for the normal growth and function of the Gram-negative 
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bacteria, P. aeruginosa. Therefore, when the BfrB–Bfd interaction is interrupted, the bacteria are 
deprived of Fe2+, and consequently, bacterial death occurs.25,28-30,37,38  
1.2. Statement of work 
Recent investigations have established the BfrB–Bfd interaction as a novel target to rationally 
induce iron homeostasis dysregulation in bacteria.1,25 These investigations involved the deleting 
of the bfd gene in P. aeruginosa to observe the effect on the bacterial iron metabolism. The 
outcome of these investigations showed an irreversible accumulation of Fe3+ in BfrB with 
concomitant iron deprivation in the cytosol.25 Consequently, it was imperative to design small 
molecule inhibitors of the BfrB–Bfd interaction as chemical probes to study iron homeostasis in 
bacteria and possibly uncover additional vulnerabilities in the bacterial cell.1 The focus of current 
work involved the synthesis and optimization of 4-(alkylamino)isoindoline-1,3-diones as 
chemical probes to dysregulate iron homeostasis in P. aeruginosa. These small molecules were 
designed to block the BfrB–Bfd protein–protein interaction by selectively binding BfrB at the Bfd 
binding site. 
1.3. Screening of fragments that bind BfrB at the Bfd-binding site.  
Initial work from our collaborators began with the screening and detection of fragments that bind 
BfrB at the Bfd-binding site. Structural information obtained from the BfrB–Bfd interaction 
showed that Bfd residues M1 (i.e. Met 5), Y2 (i.e. Tyr 2), and L5 (i.e. Leu 5)  and BfrB residues 
L68 (i.e. Leu 68)  and E81 (i.e. Glu 81)  dominate the buried surface area at the protein-protein 
interface (Figure 1.4) and contribute significantly to the binding energy of the BfrB–Bfd 
complex.1,39 Thus, fragments that may bind at the sites occupied by Y2 and L5 were potential 
candidates. Moreover, fragments capable of π-π stacking were included with both electron-rich 
and electron-deficient aromatic rings.1 Additionally, groups possessing similar chemical 
properties, such as the aromatic and aliphatic side chains of Tyr and Leu, were of great interest. 
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To screen for fragments, a competition assay that utilizes STD (saturation transfer difference) 
NMR spectroscopy was developed.1 This technique was found to be ideal because only low 
protein concentrations were required, and also protein resonance assignments were not necessary. 
Additionally, the large rotational correlation time (tc) of BfrB enhanced spin diffusion as well as 
saturation transfer within the protein and to the ligand.1,40   
 
Figure 1.4. Protein–protein interaction interface of the BfrB–Bfd complex. Subunits A and B of a 
BfrB subunit dimer were colored gray and green, respectively. (A) Residues Y2 and L5 of BfrB 
(cyan cylinders) are positioned within pockets at the BfrB subunit dimer interface. (B) Fo-Fc omit 
map (orange mesh) contoured at 3σ showing fragment 6 (Chart 1) bound within the cleft occupied 
by L5 in the BfrB-Bfd complex. (C) Hydrogen bond interactions (dashed lines) between fragment 
6 and BfrB. Water mediated contacts are indicated by the solid lines.1 
An STD spectrum of a solution containing a fragment and BfrB was used to assess each 
fragment’s binding. Eighteen (18) compounds were uncovered, consisting of fragments that bind 
BfrB specifically at the Bfd-binding site and nonspecific binders.1 Thus, a displacement strategy 
that utilizes Bfd as a specific competitor was implemented to identify and separate the specific 
binders. The strategy involved the acquisition of an STD spectrum from a solution containing 
fragment, BfrB and Bfd. Nearly complete disappearance of the STD signal indicated that the 
fragment binds BfrB at the Bfd-binding site. Consequently, of the 18 fragments, six (6) molecules 
bound BfrB at the Bfd-binding site (Chart 1). A structure-guided approach was further used to 
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synthetically elaborate these fragment binders into analogs that are capable of binding with higher 
affinity. The affinity and selectivity of molecules and analogs were investigated by X-ray 
crystallography, surface plasmon resonance (SPR), and fluorescence polarization methods.1  
Chart 1. Structures of fragments identified to bind BfrB at the Bfd-Binding site.1 
 
Based on an X-ray analysis, fragments and derived analogs that are shown in Figure 1.5B bound 
BfrB at the Bfd-binding site. In an effort to identify the “perfect” crystals for the study, crystals 
obtained from three (3) different BfrB constructs were tested in a ligand soaking experiment. 
Several analogs of ether 9, amines 11 and 14, and amides 12 and 15 were generated using a 
general synthetic approach as shown in Figure 1.5A. Preparation of the ether analogs 9 involved 
four steps. Esterification of the acid groups in 4-hydroxyphthalic acid (7), followed by alkylation 
of the phenolic oxygen gave 8. Subsequently, base cleavage of the ester groups in 8 and 
cyclization with (NH4)2CO3 afforded the isoindoline-1,3-dione ethers 9. Reductive amination of 
10 and 13, respectively, with a series of aldehydes afforded the amine analogs 11 and 14, whereas 
reactions of 10 and 13, respectively, with a series of acid chlorides produced the amide analogs 
12 and 15. Although crystal soaking experiments were conducted for each of the analog types 
shown in Figure 1.5B, structures of analog-bound BfrB were obtained only for analogs 16-21, 









































Figure 1.5. (A) Schematic summary of the synthetic procedures employed to prepare analogs of 
fragments 6, 10 and 13; ethers 9 derived from 5-hydroxyisoindoline-1,3-dione (6), amines 11 or 
amides 12 derived from 5-aminoisoindoline-1,3-dione (10), or amines 14 or amides 15 derived 
from 4-aminoisoindoline-1,3-dione (13). (B) Structures of fragment 6 and analogs of fragment 13 
have been shown by X-ray crystallography to bind BfrB at the Bfd-binding site.1  
 The driving force for any drug–receptor interaction can be expressed as a low-energy state of the 
drug-receptor complex [Eq. (1.0)], where kon represents the rate constant for formation of the 
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depends on the concentrations of the drug and receptor, whereas koff depends on the concentration 
of the drug–receptor complex as well as other forces. Typically, binding affinity is measured and 
reported by the equilibrium dissociation constant (Kd) [Eq. (1.1)], which is used to evaluate and 
rank order strengths of the ligand–target interactions. Therefore, the smaller the Kd value, the 
larger the concentration of the drug–receptor complex, and subsequently, the greater the binding 






Consequently, the Kd values (Table 1) show that analogs 16-21 exhibited significantly higher 
affinity than fragment 13. Importantly, most of these analogs bound BfrB at the Bfd-binding site 
with a strength comparable to that of BfrB–Bfd association (Kd = 3 µM), thus suggesting that they 
were capable of interfering with the BfrB–Bfd interaction in the cytosol of P. aeruginosa.1 
However, analogs with Kd values within the lower micromolar or nanomolar range are desired.  
1.4. Results and discussion for synthesis of 4-(alkylamino)isoindoline-1,3-dione derivatives. 
Herein, we present the synthesis, characterization and optimization of 4-(alkylamino)isoindoline-
1,3-dione analogs that are capable of decreasing the cytosolic iron levels in P. aeruginosa cells by 
inhibiting the BfrB–Bfd interaction within a reduced micromolar concentration range. The 
following changes were envisioned as a potential approach to improve the activity of the BfrB–
Bfd inhibitors:     
1) Incorporating new substituted benzaldehydes and altering the 3-carbon linker unit into a  
    1-carbon linker with similar substitution pattern 
2) Replacing the benzaldehyde component with a furan or tetrahydrofuran group 





Table 1. Structure and binding affinity of 4-aminoisoindoline-1,3-diones from previous work.1 
















































































Retrosynthetic analysis of potential targets 22 and 23 from precursors 24 and 25 involves a 
single- and multistep synthesis, respectively, as shown in Figure 1.6. 
 
Figure 1.6. Retrosynthetic route for 4-(alkylamino)isoindoline-1,3-diones. 
1.4.1. Binding effects of 4-(alkylamino)isoindoline-1,3-diones due to the incorporation of 
new benzaldehydes and altering of 3-carbon linker into 1-linker. 
Modifications to the substituents on the benzaldehyde component 24 have been found to enhance 
the inhibition of the BfrB–Bfd interaction.25,37,38 Careful analysis and consideration led to the 
utilization of fluorine-, chlorine- and bromine-substituted salicylaldehydes. These halogens have 
not only increased the molecular weight of our target molecules, but more importantly, allowed 
selective binding to BfrB at the Bfd binding site.  In addition, varying the position of the halogens 
on 24 was critical to our investigation. Replacing fluorine with chlorine and bromine at the R2 
position of the 1-carbon linker 23 enhanced the inhibitory effect of our target molecule 





























n = 0 or 2
R1 = H
R2 = H, OH, F, Br, Cl
R3 = H, Br
R4 = H, Cl














Table 2. Structure and binding affinity of current 4-(alkylamino)isoindoline-1,3-dione analogs. 






















































































Some of the 3-carbon linker analogs of 4-(alkylamino)isoindoline-1,3-diones have also shown 
promising inhibitory effects. An example is the target 4-(alkylamino)isoindoline-1,3-dione analog 
which was made from 3-hydroxybenzaldehyde. 5-Fluorosalicylaldehyde also gave a 3-carbon 
linker target with significant inhibitory ability. Generally, most of the synthesized analogs in 
Table 2 showed significantly lower Kd values compared to the analogs in Table 1. Thus, these 
compounds have relatively higher binding affinities for BfrB at the Bfd-binding site. Importantly, 
comparison of the BfrB-Bfd association (Kd = 3 µM) with the lower Kd values of analogs 31, 32, 
33, and 36 (Table 2) suggests that these compounds are capable of eliciting greater inhibition by 
interfering with the BfrB–Bfd interaction in the P. aeruginosa cytosol. Halogen and hydroxyl 
functionalities on the benzaldehyde component may shed light on the potential inhibition effects 
of hydrogen bonding versus an effect of electron withdrawing groups. A new series of 
compounds was also designed and synthesized by replacing the benzaldehyde component with 2- 
or 3-furaldehyde. However, these compounds showed no activity for both 1- and 3-carbon linker 
analogs. The size of the furaldehyde was presumably too small and prevented effective binding to 
the BfrB protein. The use of these small molecule inhibitors as chemical probes was necessary for 
our study because such probes offer dose-dependent, selective and temporal control over target 
proteins. Therefore, they can be used as complements to other synergistic or antagonistic 
probes.42,43 The novel probes presented herein are capable of the following: 
a) Penetrating the bacteria cells 
b) Inhibiting the mobilization of iron from BfrB by selectively binding at the Bfd binding site 
c) Decreasing bacterial fitness by eliciting perturbations in iron homeostasis 
d) Potentiating the bactericidal activity of fluoroquinolone antibiotics  
Current molecular modeling has shown that one of the carbonyl groups (C=O) at position 3 of the 
4-aminoisoindoline-1,3-dione (25) is not involved in binding or interaction at the BfrB–Bfd site. 
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Thus, replacing that C=O with a CH2 group should have no negative influence on the inhibition 
effect of the target molecule. The reductive amination step for both 1- and 3-carbon linker target 
molecules was found to give poor yields. Steric hindrance around the amino (NH2) group of 25 is 
one of the few explanations for such a poor result. Additionally, the C=O ortho to the amino 
group reduces the electron density of the amino nitrogen on 25 via resonance and subsequently 
decrease its nucleophilicity towards the corresponding aldehyde. Therefore, substituting the C=O 
functionality at position 3 with CH2 should not only reduce the sterics on 25, but may also allow 
an increase in the nucleophilicity of the amino group responsible for the nucleophilic attack 
towards the aldehyde component. Based on this study, future efforts will be channeled to develop, 
optimize and synthesize new classes of possible targets. 
1.4.2. Incorporation of new substituted benzaldehydes and altering of the 3-carbon linker to 
a 1-carbon linker. 
The syntheses of analogs with 3-carbon linker-substituted 4-(alkylamino)isoindoline-1,3-diones 
required six steps, and the 1-carbon linker analogs involved only one step (Scheme 1.1). 
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Protection of the hydroxyl group on 26 with tert-butyldimethylsilyl chloride was promoted by 
imidazole in DMF to afford 28 in 91% yield after purification by silica gel chromatograghy.44-49 
Horner-Wadsworth-Emmons (HWE) conditions were employed to obtain the acrylate 
intermediate 27. The HWE reaction required a slight excess of triethyl phosphonoacetate (TEPA) 
and 60% NaH dispersed in mineral oil to produce predominantly the (E)-enolate in good yield.50 
Importantly, the sequence of addition was critical since an increase in yield was only observed 
when NaH was added to a solution of TEPA in freshly distilled THF. The crude acrylate 28 was 
taken directly to the hydrogenation step under anhydrous conditions and with N2 to give a 
saturated ester after purification by silica gel column chromatography. The pure intermediate 
ester was further subjected to DIBAL-H reduction to afford the aldehyde intermediate 29. 
Reduction of the ester moiety using DIBAL-H was troublesome if the temperature and mode of 
addition were not carefully monitored.51 Slow dropwise addition of the DIBAL-H reagent and a 
temperature at or below -78 oC (dry ice-acetone) was critical for the success of this reaction. 
Failure to meet these conditions resulted in a mixture of products (i.e. the desired aldehyde 
product and an alcohol counterpart due to over reduction). The reductive amination step between 
25 and 26 (for 1-linker analogs) or 25 and 29 (for 3-linker analogs) was a one-pot reaction 
catalyzed by AcOH. The success of this reaction depended on the purity of the aldehyde 
component, the volume of anhydrous DMF solvent, and the mode of addition of the moisture-free 
NaB(OAc)3H reducing agent.52-55 The use of excess solvent impeded formation of the imine 
intermediate from 26 or 29, which was required for reduction by NaB(OAc)3H to give the desired 
products 27 or 30. Thus, it was important to use 1.2-1.5 mL of anhydrous DMF for reactions 
involving 2-3 mmol of the aldehyde component 26 or 29. For the 3-linker synthesis, the first part 
of the amination step, which involved formation of the imine intermediate, required stirring at 23 
oC for 1 h prior to the portionwise addition of the reducing agent.52 The coupled product 27 or 30 
was obtained in 30% yield after column chromatography on silica gel pretreated with 3-hydroxy-
2-methyl-4-pyrone to complex metals ions (especially iron). Silyl deprotection of 30 was 
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achieved by the addition of 2 equivalents of 1 M tetrabutylammonium fluoride (TBAF) in freshly 
distilled THF at 23 oC. The desired analog 31 was further obtained in 80% yield after purification 
using pyrone-treated silica gel column chromatography. A similar set of conditions was used to 
synthesize analogs 32-34 (Figure 1.7). Generally, 4-(alkylamino)isoindoline-1,3-diones (27, 30, 
31 and other analogs) have an affinity for iron. Thus, the use of untreated silica gel would 
deactivate the target molecules and consequently reduce their potency. The low yield recorded at 
the reductive amination step for both 1- and 3-carbon linker systems leading to 27 and 30, 
respectively, could be attributed to two factors: 
a) Steric hindrance around the 4-aminoisoindoline-1,3-dione imine bond  
b) Decreased nucleophilicity of the amino group on 25 due to the presence of two strong 
    electron withdrawing C=O groups 
 

































































Unlike the 3-carbon linker 31, reductive amination for the 1-carbon linker 27 synthesis did not 
proceed cleanly at room temperature.52 Initial attempts to use the previously mentioned conditions 
failed to afford 27 in good yield. To ensure maximum conversion, an acid-catalyzed reaction 
between 26 and 27 was heated at 90 oC for 2 h. Decreased flexibility and reactivity of 26 towards 
the nucleophilic attack of 25 could be a possible reason. However, the rate of reaction increased 
in the forward direction at the higher temperature. Addition of 25 to a solution of 26 in DMF 
under acidic conditions resulted in a thick slurry which turned clear at 90 oC. Heating the reaction 
at 90 oC for longer than 2 h did not improve the outcome. The mixture was gradually cooled to 0 
oC prior to the portion-wise addition of the reducing agent.52 The desired product 27 was obtained 
after purification with pyrone-treated silica gel column chromatography. Similar reaction 
conditions were used to synthesize analogs 35-41 (Figure 1.7). 
1.5. Conclusions 
In summary, we have synthesized several 4-(alkylamino)isoindoline-1,3-diones as potential 
antibiotic candidates that are capable of interfering with the BfrB–Bfd interaction in the cytosol 
of P. aeruginosa and inhibit iron mobilization.  
1.5.1. Incorporation of new substituted benzaldehydes and other heterocyclic groups. 
In this study, we have successfully prepared new derivatives of 22 and 23 (Figure 1.6) from 
substituted benzaldehydes. Additionally, analogs 34, 38, 39, and 40 (Figure 1.7) were made from 
2- and 3-furaldehyde. The synthesis of the 3-carbon linker derivatives of 22 required six (6) steps, 
whereas that of the 1-carbon linkers 23 involved a single step. The Kd values for most of the 
synthesized benzaldehyde derivatives were within the low micromolar concentration range, thus 
suggesting that they have greater binding affinities for BfrB. Importantly, analogs 31, 32, 33 and 
36 (Table 2) exhibited smaller Kd values compared to the BfrB–Bfd association (Kd = 3 µM), and 
thus these derivatives are capable of interfering with the BfrB–Bfd interaction to elicit 
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perturbations in iron homeostasis that decrease bacterial fitness. However, no activity was 
observed for analogs 34, 38, 39, and 40, possibly due to the small size of the furan ring.56  
1.5.2. Altering the carbon linker in the 4-(alkylamino)isoindoline-1,3-dione analogs. 
In an attempt to further expand the array of possible active 4-(alkylamino)isoindoline-1,3-diones, 
the synthesis of 1-carbon linker derivatives was considered. Results from the binding affinity 
experiment (Table 2) revealed that most of the 1-carbon linker analogs 27, 35, and 37 were not as 
promising as the 3-carbon linkers. Nonetheless, current docking studies have shown that 1-carbon 
linker analogs of 4-(alkylamino)isoindoline-1,3-dione with benzo-fused six membered 
heterocyclic components could be potential candidates. Moreover, analogs derived from 
substituted cinnamaldehydes are of major interest. As such, 4-(cinnamylamino)isoindoline-1,3-
dione (41) has been prepared from cinnamaldehyde using the one step route in Scheme 1.1, and 
we are awaiting its biological testing. Consequently, a promising result would facilitate the 
design, synthesis, and characterization of other potential derivatives.  
1.6. Chemistry 
1.6.1 Incorporation of new substituted benzaldehydes in BfrB–Bfd chemical probes. 
General procedure for pyrone-treated silica gel: A 3-L, sintered-glass funnel suspended on an 
O-ring was charged with one-kilogram of silica gel (Sorbent Technologies CA# 40940-25).  The 
silica gel was treated with a solution of 3-hydroxy-2-methyl-4-pyrone (20 mg) in 1 L of MeOH. 
The initial wash (yellow-orange coloring) was discarded. Additionally, the silica gel was washed 
with 500 mL of recycled MeOH (old washings) and finally 1.5 L of fresh MeOH was used to 
rinse the silica gel. The silica gel was transferred to a tray, covered with aluminum foil (poked 
holes for ventilation) and was set to air dry at room temperature overnight. Subsequently, the 
silica gel was dried in the oven at 90 °C in 3 h increments. Generally, derivatives of 4-
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(alkylamino)isoindoline-1,3-diones have an affinity for iron and earlier work showed that 
purification with untreated silica gel deactivated the target molecules and reduced their potency. 
General methods: Commercial anhydrous N,N-dimethylformamide was stored under dry N2 and 
transferred by syringe into reactions when needed. Tetrahydrofuran was dried over potassium 
hydroxide pellets and then distilled from lithium aluminum hydride prior to use. All other 
commercial reagents and solvents were used as received. Unless otherwise indicated, all reactions 
were carried out under dry N2 in oven-dried glassware. Reactions were monitored by thin layer 
chromatography (TLC, Analtech No 21521) using silica gel GF plates. Preparative separations for 
all final compounds were performed by column chromatography on silica gel (Davisil®, grade 62, 
60 - 200 mesh) pre-treated with 3-hydroxy-2-methyl-4-pyrone mixed with UV-active phosphor 
(Sorbent Technologies No UV-05) slurry packed into quartz columns. Band elution for all 
chromatographic separations was monitored using a hand-held UV lamp. Melting points were 
uncorrected. IR spectra were run as thin films on NaCl disks. The 1H- and 13C-NMR spectra were 
measured in the indicated solvent at 400 MHz and 100 MHz, respectively, using 
tetramethylsilane as the internal standard with coupling constants (J) given in Hz. 
 




4-((5-Fl uoro-2-hydroxybenzyl)amino)isoindoline-1,3-dione (27). To a solution of 5-
fluorosalicylaldehyde (26, 0.47 g, 3.34 mmol) in DMF (1.1 mL) was added AcOH (0.8 mL), and 
the solution was stirred for 10 min. To this reaction mixture, was added 4-aminoisoindoline-1,3-
dione (25, 0.27 g, 1.67 mmol) and stirring was continued at 23 oC for 1 h. An additional 1 mL of 









then cooled to room temperature. NaB(OAc)3H (1.1 g, 5.01 mmol) was added portionwise to the 
reaction at 0 oC and stirring was continued at this temperature for 30 min. The reaction was 
gradually warmed to 23 oC and stirred for 18 h.  The crude reaction mixture was poured into de-
ionized water, the mixture of which was extracted with EtOAc (3 × 75 mL). The combined 
organic layers were washed with NaHCO3 (2 × 50 mL) and NaCl (50 mL). The organic layer was 
dried (Na2SO4) and concentrated under vacuum. The crude product was subjected to column 
chromatography (using silica gel pre-treated with 3-hydroxy-2-methyl-4-pyrone) eluted with 20% 
EtOAc/hexane to afford 27 (0.56 g, 58%) as an orange solid, m.p. 216-217 oC. 1H NMR (400 
MHz, DMSO-d6): δ 10.97 (s, 1H), 9.75 (s, 1H), 7.50 (t, J = 7.7 Hz, 1H), 7.07 (br t, J = 6.4 Hz, 
1H), 7.02 (dd, J = 9.5, 3.2 Hz, 1H), 6.98-6.86 (complex, 3H), 6.82 (dd, J = 8.8, 4.7 Hz, 1H), 4.43 
(d, J = 6.3 Hz, 2H); 13C NMR (101 MHz, DMSO-d6): δ 171.8, 169.8, 155.9 (d, J = 233.9), 151.8, 
146.4, 136.3, 134.1, 126.9 (d, J = 6.6), 117.1, 116.3 (d, J = 8.0), 115.1 (d, J = 23.3), 114.6 (d, J = 
22.5), 111.7, 110.6, 41.1. 
The following compounds can also be prepared by the procedure above. 
 
4-((5-Bromo-2-hydroxybenzyl)amino)isoindoline-1,3-dione (35).  Orange solid, m.p. 219-220 
˚C. 1H NMR (400 MHz, DMSO-d6): δ 11.0 (s, 1H), 10.1 (s, 1H), 7.49 (t, J = 8.0 Hz, 1H), 7.35 (d, 















































6.93 (d, J = 7.1 Hz, 1H), 6.79 (d, J = 8.6 Hz, 1H), 4.41 (d, J = 6.4 Hz, 2H); 13C NMR (101 MHz, 
DMSO-d6): δ 171.8, 169.8, 155.0, 146.4, 136.3, 134.1, 131.1, 128.1, 117.7, 117.1, 111.7, 110.6, 
110.5, 41.1 (one aromatic carbon unresolved). 
4-((4-Bromo-2-hydroxybenzyl)amino)isoindoline-1,3-dione (36). Yellow solid, m.p. 226-227 
˚C. 1H NMR (400 MHz, DMSO-d6):  δ 11.0 (s, 1H), 10.3 (s, 1H), 7.48 (dd, J = 8.5, 7.1 Hz, 1H), 
7.14 (d, J = 8.1 Hz, 1H), 7.01 (t, J = 6.4 Hz, 1H), 7.00 (d, J = 2.0 Hz, 1H), 6.93 (m, 3H), 4.40 (d, 
J = 6.4 Hz, 2H); 13C NMR (101 MHz, DMSO-d6): δ 171.8, 169.8, 156.8, 146.4, 136.3, 134.1, 
130.6, 124.9, 122.1, 120.6, 118.1, 117.2, 111.7, 110.6, 41.1. 
4-((5-Chloro-2-hydroxybenzyl)amino)isoindoline-1,3-dione (37). Orange solid, m.p. 229-230 
oC. 1H NMR (400 MHz, DMSO-d6): δ 11.0 (s, 1H), 10.1 (s, 1H), 7.49 (dd, J = 8.2, 7.4 Hz, 1H), 
7.22 (d, J = 2.6 Hz, 1H), 7.12 (dd, J = 8.6, 2.6 Hz, 1H), 7.07 (t, J = 6.5 Hz, 1H), 6.96 (d, J = 8.6 
Hz, 1H), 6.93 (d, J = 7.0 Hz, 1H), 6.84 (d, J =  8.6 Hz, 1H), 4.42 (d, J = 6.4 Hz, 2H); 13C NMR 
(101 MHz, DMSO-d6): δ 171.3, 169.3, 154.1, 145.9, 135.9, 133.6, 127.8, 127.7, 127.0, 122.4, 
116.6, 111.3, 111.2, 110.2, 40.6. 
4-((Furan-2-ylmethyl)amino)isoindoline-1,3-dione (38). Yellow solid, m.p. 149-150 oC. 1H 
NMR (400 MHz, DMSO-d6): δ 10.98 (s, 1H), 7.59 (br s, 1H), 7.53 (t, J = 7.8 Hz, 1H), 7.12 (d, J 
= 8.5 Hz, 1H), 6.97 (d, J = 7.1 Hz, 1H), 6.91 (t, J = 6.4 Hz, 1H), 6.40 (br s, 1H), 6.34 (d, J = 3.2 
Hz, 1H), 4.54 (d, J =  6.3 Hz, 2H); 13C NMR (101 MHz, DMSO-d6): δ 171.8, 169.7, 152.6, 145.2, 
142.9, 136.2, 134.0, 117.4, 111.8, 110.9, 107.8, 39.3 (one aromatic carbon unresolved). 
4-((Furan-3-ylmethyl)amino)isoindoline-1,3-dione (39). Yellow solid, m.p. 133-134 oC. 1H 
NMR (400 MHz, DMSO-d6): δ 10.95 (s, 1H), 7.54 (t, J = 7.8 Hz, 1H), 7.08 (d, J = 8.5 Hz, 1H), 
6.94 (d, J = 7.1 Hz, 1H), 6.61 (br t, J = 6.5 Hz, 1H), 3.78 (m, 1H), 3.72 (t, J = 8.0 Hz, 1H), 3.63 
(q, J = 7.7 Hz, 1H), 3.47 (t, J =  6.8 Hz, 2H), 3.35-3.22 (complex, 2H), 1.97 (m, 1H), 1.62 (m, 
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2H); 13C NMR (101 MHz, DMSO-d6): δ 171.9, 169.8, 146.7, 136.4, 134.0, 117.0, 111.3, 110.4, 
70.8, 67.3, 45.1, 38.8, 29.9. 
4-(((Tetrahydrofuran-3-yl)methyl)amino)isoindoline-1,3-dione (40). Yellow solid, m.p. 154-
155 oC. 1H NMR (400 MHz, DMSO-d6): δ 10.95 (s, 1H), 7.65 (s, 1H), 7.60 (s, 1H), 7.51 (t, J = 
7.8 Hz, 1H), 7.13 (d, J = 8.3 Hz, 1H), 6.95 (d, J = 7.1 Hz, 1H), 6.83 (br t, J = 6.1 Hz, 1H), 6.50 (s, 
1H), 4.35 (d, J =  6.1 Hz, 2H); 13C NMR (101 MHz, DMSO-d6): δ 170.7, 168.7, 145.3, 143.0, 
139.7, 135.1, 132.9, 122.2, 116.3, 110.6, 109.7, 109.5, 36.3. 
 (E)-4-((3-(3-Hydroxyphenyl)allyl)amino)isoindoline-1,3-dione (41). Yellow solid, m.p. 187-
188 oC. 1H NMR (400 MHz, DMSO-d6): δ 10.97 (s, 1H), 7.53 (dd, J = 8.5, 7.1 Hz, 1H), 7.42 (d, J 
= 8.5 Hz, 2H), 7.31 (t, J = 7.4 Hz, 2H), 7.23 (t, J = 7.3 Hz, 1H), 7.04 (d, J = 8.5 Hz, 1H), 6.95 (d, 
J = 7.1 Hz, 1H), 6.81 (br t, J = 6.1 Hz, 1H), 6.61 (d, J = 16.0 Hz, 1H), 6.36 (dt, J = 16.0, 5.5  Hz, 
1H), 4.12 (dt, J =  5.8, 1.6 Hz, 2H); 13C NMR (101 MHz, DMSO-d6): δ 170.7, 168.8, 145.5, 
135.8, 135.2, 133.0, 130.0, 128.0, 126.9, 126.2, 125.6, 116.4, 110.5, 109.5, 43.3. 
 




tert-Butyldimethylsilyl chloride (TBDMSCl) protection and Horner-Wadsworth-Emmons 
reaction.  
Ethyl (E)-3-(2-((tert-Butyldimethylsilyl)oxy)-5-fluorophenyl)acrylate (28).  A stirred solution 
of 5-fluoro-2-hydroxybenzaldehyde (26, 1.21 g, 8.65 mmol) in DMF (10 mL) was cooled to 0 oC 
under nitrogen atmosphere, and imidazole (1.18 g, 17.3 mmol) was added.  The resulting solution 
was stirred for 20 min, and tert-butyldimethylsilyl chloride (1.96 g, 12.98 mmol) was added 









warmed to 23 oC and stirred until TLC analysis indicated the complete conversion of the phenolic 
compound. The crude reaction was poured into water (50 mL) and extracted with ether (3 × 40 
mL). The combined organic layers were washed with saturated NaCl (50 mL), dried (Na2SO4) 
and concentrated under vacuum. The crude product was purified by silica gel column 
chromatography to give 2-((tert-butyldimethylsilyl)oxy)-5-fluorobenzaldehyde (2.01 g, 91%)  as 
a colorless oil. 
To a stirred, ice-cold solution of triethyl phosphonoacetate (2.05 g, 1.83 mL, 9.16 mmol) in THF 
(5.0 mL) was added 60% NaH dispersed in mineral oil (367 mg, 9.16 mmol), and the mixture was 
stirred for 15 min.  To the resulting reaction mass was added dropwise TBS protected 5-
fluorobenzaldehyde (1.96 g, 7.70 mmol) in THF (15 mL), and the stirred reaction was allowed to 
warm to 23 oC.  After the TLC (5% ether/hexane) analysis indicated the complete consumption of 
starting material (2 h), the reaction mass was cooled and quenched by dropwise addition of ice-
cold water.  The product was extracted with ether (2 × 25 mL), and the organic layer was washed 
with saturated NaCl (15 mL), dried (Na2SO4) and evaporated to afford the acrylate (28, 2.25 g, 
90%) as colorless oil.  This compound was carried forward without further purification. 
Hydrogenation and DIBAL-H ester reduction. 
3-(2-((tert-Butyldimethylsilyl)oxy)-5-fluorophenyl)propanal (29).  A solution of ethyl (E)-3-
(2-((tert-butyldimethylsilyl)oxy)-5-fluorophenyl)acrylate (28, 2.23 g, 6.87 mmol) in ethanol (200 
proof, 15 mL) was flushed twice with nitrogen, and 10 wt% of PtO2 (223 mg) was added.  The 
reaction was stirred at room temperature under hydrogen gas (1 atm) for 12 h until TLC (5% 
ether/hexane) indicated complete reaction.  The reaction mass was filtered through Celite® bed 
and washed with ethanol (2 × 40 mL). The filtrate was concentrated under vacuum and subjected 
to column chromatography to afford the ethyl 3-(2-((tert-butyldimethylsilyl)oxy)-5-fluoro-
phenyl)propanoate (2.03 g, 91%) as a colorless oil. 
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The ethyl 3-(2-((tert-butyldimethylsilyl)oxy)-5-fluorophenyl)propanoate (1.03 g, 3.17 mmol) 
prepared above was dissolved in DCM (10 mL), and cooled to –78 oC under N2. The solution was 
treated via dropwise addition of 1.5 M DIBAL-H in toluene (2.11 mL, 3.17 mmol) over a period 
of 30 min. Stirring was continued for 2 h at –78 oC until TLC (5% ether/hexane) analysis 
indicated the complete absence of starting material. The reaction was quenched by dropwise 
addition of methanol (10 mL), followed by addition of 1 M HCl (15 mL). The organic layer was 
separated, and the aqueous layer was further extracted with DCM (2 × 50 mL). The combined 
organic layers were washed with saturated NaCl and dried (Na2SO4).  Removal of the solvent 
under reduced pressure afforded the 3-(2-((tert-butyldimethylsilyl)oxy)-5-fluorophenyl)propanal 
(29, 0.76 g, 85%) as a colorless oil. 
Reductive amination procedure  
4-((3-(2-((tert-Butyldimethylsilyl)oxy)-5-fluorophenyl)propyl)amino)isoindoline-1,3-dione 
(30).  To a solution of 3-(2-((tert-butyldimethylsilyl)oxy)-5-fluorophenyl)propanal (29, 1.16 g, 
4.11 mmol) in DMF (1.2 mL) was added AcOH (0.8 mL) and the solution was stirred for 10 min 
at room temperature.  To this mixture, was added 4-aminoisoindoline-1,3-dione (25, 0.33 g, 2.05 
mmol), and stirring was continued at 23 oC for 1 h.  An additional 3.8 mL of DMF was added to 
bring the volume to 5.0 mL over the 1 h period.  The reaction was cooled to 0 oC and 
NaB(OAc)3H (1.31 g, 6.16 mmol) was added portion-wise to the reaction over 25 min.  The 
reaction was further stirred at this temperature for 30 min, and then gradually warmed to 23 oC. 
Stirring was continued for 18 h until TLC (5-20% EtOAc/hexane) indicated complete conversion 
of the aldehyde. The crude reaction mixture was poured into de-ionized water, extracted with 
EtOAc (3 × 75 mL) and the combined organic layers were washed with NaHCO3 (2 × 50 mL), 
followed by saturated NaCl (50 mL). The organic layer was dried (Na2SO4) and concentrated 
under vacuum. The crude product was subjected to column chromatography (using silica gel pre-
treated with 3-hydroxy-2-methyl-4-pyrone) and eluted with 20% EtOAc/hexane to afford 4-((3-
25 
 
(2-((tert-butyldimethylsilyl)oxy)-5-fluorophenyl)propyl)amino)isoindoline-1,3-dione (30, 0.69 g, 
30%) as a yellow solid. 
Silyl deprotection 
4-((3-(5-Fluoro-2-hydroxyphenyl)propyl)amino)isoindoline-1,3-dione (31). A solution of 30 
(0.39 g, 0.92 mmol) in 7 mL of freshly distilled THF was stirred under N2 at 23 oC, then 1.0 M 
TBAF in THF (1.84 mL, 1.84 mmol) was added. Stirring was continued for 1 h and when TLC 
analysis (5-20% EtOAc/hexane) indicated the complete consumption of the silyl ether, de-ionized 
water (5.0 mL) was added. The THF was evaporated under vacuum and the aqueous layer was 
extracted with EtOAc (3 × 40 mL). The combined organic layers were washed with saturated 
NaCl (50 mL), dried (Na2SO4), and concentrated under vacuum. The crude product was purified 
by column chromatography (using silica gel pre-treated with 3-hydroxy-2-methyl-4-pyrone) 
using 20% EtOAc/hexane as the mobile phase to afford 31 (0.33 g, 80%) as an orange solid, m.p. 
163-164 oC. 1H NMR (400 MHz, DMSO-d6):  δ 10.9 (s, 1H), 9.33 (s, 1H), 7.51 (t, J = 7.8 Hz, 
1H), 6.98 (d, J = 8.5 Hz, 1H), 6.92 (d, J = 7.0 Hz, 2H), 6.81 (td, J = 8.5, 3.2 Hz, 1H), 6.76 (dd, J 
= 8.6, 5.2 Hz, 1H), 6.58 (t, J = 6.0 Hz, 1H), 3.28 (q, J = 6.6 Hz, 2H), 2.59 (t, J = 7.5 Hz, 2H), 
1.83 (quintet, J = 7.3 Hz, 2H); 13C NMR (101 MHz, DMSO-d6): δ 171.9, 168.8, 155.9 (d, J = 
238.9 Hz), 151.1 (d, J = 7.3 Hz), 146.7, 136.3, 134.1, 126.9 (d, J = 2.4 Hz), 117.2, 116.9, 115.1 
(d, J = 23.3 Hz), 111.2, 110.2, 41.9, 28.9, 27.2.  
The following compounds can also be prepared using the above procedures. 
 
4-((3-(3-Hydroxyphenyl)amino)isoindoline-1,3-dione (32). Yellow solid, m.p. 160-162 ˚C. 1H 




















J = 7.7 Hz, 1H), 6.97 (d, J = 8.5 Hz, 1H), 6.93 (d, J = 7.0 Hz, 1H), 6.65-6.55 (complex, 3H), 6.52 
(t, J = 6.0 Hz, 1H), 3.27 (q, J = 6.7 Hz, 2H), 2.57 (t, J = 7.6 Hz, 2H), 1.85 (quint, J = 7.8 Hz, 2H); 
13C NMR (101 MHz, DMSO-d6): δ 171.9, 169.8, 157.8, 146.7, 143.3, 136.4, 134.1, 129.7, 119.3, 
116.9, 115.6, 113.3, 111.2, 110.3, 41.8, 32.8, 30.7. 
4-((3-(3-Chloro-5-hydroxyphenyl)propyl)amino)isoindoline-1,3-dione (33).  Yellow solid, 
m.p. 186-188 ˚C; 1H NMR (400 MHz, DMSO-d6):  δ 10.93 (s, 1H), 9.77 (s, 1H), 7.52 (dd, J = 
8.2, 7.4 Hz, 1H), 6.98 (d, J = 8.5 Hz, 1H), 6.93 (d, J = 7.0 Hz, 1H), 6.70 (m, 1H), 6.61 (t, J = 2.0 
Hz, 1H), 6.57 (m, 1H), 6.52 (t, J = 5.8 Hz, 1H), 3.27 (q, J = 6.7 Hz, 2H), 2.57 (t, J = 7.5 Hz, 2H), 
1.84 (quint, J = 7.4 Hz, 2H); 13C NMR (101 MHz, DMSO-d6): δ 170.8, 168.7, 157.8, 145.6, 
144.2, 135.3, 133.0, 132.6, 118.2, 115.9, 113.5, 112.2, 110.2, 109.2, 40.7, 31.4, 29.3. 
4-((3-(Tetrahydrofuran-3-yl)propyl)amino)isoindoline-1,3-dione (34). Yellow solid, m.p. 111-
112 oC. 1H NMR (400 MHz, DMSO-d6):  δ 10.93 (s, 1H), 7.53 (t, J = 7.7 Hz, 1H), 7.02 (d, J = 8.5 
Hz, 1H), 6.93 (d, J = 7.0 Hz, 1H), 6.48 (t, J = 6.0 Hz, 1H), 3.79 (t, J = 7.6 Hz, 1H), 3.72 (m, 1H), 
3.61 (q, J = 7.7 Hz, 1H), 3.35-3.18 (complex, 3H), 2.14 (septet, J = 7.4 Hz, 1H), 1.98 (m, 1H), 
1.57 (m, 2H), 1.40 (m, 3H); 13C NMR (101 MHz, DMSO-d6): δ 171.9, 169.8, 146.7, 136.4, 134.1, 












SYNTHESIS OF BIOACTIVE HETEROCYCLIC SCAFFOLDS 
2.1 Introduction 
Heterocyclic compounds remain a fundamental division of organic chemistry accounting for 
nearly two-thirds of modern publications. These classes of compounds are cyclic and contain 
mostly carbon and hydrogen atoms, with at least one heteroatom in a ring formation. Although 
the most common heteroatoms are nitrogen, oxygen and sulfur, heterocyclic rings containing 
other heteroatoms such as phosphorus are also widely known.57 Heterocycles can be classified as 
aromatic or aliphatic. The aromatic analogs have properties similar to that of benzene in that they 
fulfill Huckel’s rule for aromaticity. Typical examples are pyrimidine and purine, the major 
components of DNA and RNA.58 Moreover, chlorophyll and heme, the oxygen carriers in plants 
and animals respectively, are also derivatives of large porphyrin rings.59 The aliphatic 
heterocycles, in contrast, are cyclic analogs of amines, ethers, thio-ethers and amides. Generally, 
these compounds consist of 3-7 membered ring systems, and the strain in the rings influence their 
properties.60  Among the various clinical applications, heterocycles are present in a wide variety 
of drugs, most vitamins, many natural products, and a wide range biological active compounds 
including anti-bacterial,61,62 anti-viral,63 anti-fungal,64 anti-inflammatory,65 and anti-tumor 
agents.66-68 Moreover, heterocycles are considered as useful synthetic intermediates,69 chiral 
auxiliaries,70 and metal ligands71 in catalytic asymmetric synthesis. Other important areas of 
application of heterocyclic compounds include polymer chemistry72 and materials science.73
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Therefore, substantial attention has been directed towards the synthesis and optimization of 
biologically active heterocyclic scaffolds. Synthetic chemists are in constant search of the most 
viable and cost-effective alternatives to simplify the synthesis of heterocyclic targets. More 
importantly, the development of high atom economy and eco-friendly methods to access these 
heterocyclic frameworks have recently been the primary focus of most researchers. In past years, 
transition metal catalysts have proven efficient in the synthesis of organic compounds especially 
heterocycles. However, the use of such catalysts in late-stage drug synthesis requires special 
purification techniques to completely remove these toxic metals from the final products. Thus, 
simple transition metal-free methodologies are necessary for the preparations of useful 
heterocyclic scaffolds. Sildenafil citrate, an active ingredient in RevatioTM is popular for the 
treatment erectile dysfunction and pulmonary arterial hypertension in adults and children. 
Evidently, an alternative strategy in a new synthetic route to Sildenafil citrate avoided tin (II) 
chloride and thus eliminated 30,000 tons of chemical waste between 1997 and 2003.74 In addition, 
the improvement in the synthesis of Zolpidem, a sedative, is noteworthy. The previous synthesis 
involved a 4-step reaction route using 4-methylacetophenone as a starting material to give 
Zolpidem in 66% yield.75 However, an improved strategy involving the reaction of 2-
aminopyridines and Morita-Baylis-Hillman (MBH) acetates of nitroalkenes afforded Zolpidem in 
96% yield.76 
Over the years, the design and optimization of new drug molecules as anti-cancer and antibiotic 
candidates has been the primary focus of our research group. Importantly, our expertise involves 
the development of cost-effective and atom efficient synthetic approaches to essential bioactive 
scaffolds such as quinazolinones, chromanones and isoquinolines. As an extension, this 
dissertation designed and optimized new methods to prepare 1-aryl-5-nitro-1H-indazoles, 4H-
benzo[d][1,3]oxazin-4-ones, bis-1,3,4-oxadiazoles, nitro-, cyano- or fluoro-substituted 2-
naphthoates, 1,8-naphthyridines, 1,2-dihydroquinolines, and 4-oxo-1,4-dihydroquinolines, as well 
as quinoline carboxylates and carbonitriles. These methods were developed using readily 
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available and economical starting materials. Thus, an alternative strategy to access most of these 
bioactive building blocks has been formulated without the use of transition metals. Initially, 
nucleophilic aromatic substitution (SNAr) reactions were adopted to generate 1-aryl-5-nitro-1H-
indazoles in good to excellent yields. In addition, a one-pot sequential protocol for a 1-aryl-1H-
indazole assembly, without the limiting substitution patterns required for SNAr cyclization, was 
achieved in decent yields.77 Encouraged by this outcome, we extended the SNAr mechanism to 
prepare nitro-, cyano- and fluoro-substituted  2-naphthoates, 1,2-dihydroquinolines, and 4-oxo-
1,4-dihydroquinolines as well as carboxylates and carbonitriles using Morita-Baylis-Hillman 
(MBH) acetates. The SNAr reaction has been known for more than 150 years, and its relevance is 
justified by its wide application in organic synthesis and industry.78 In this type of reaction, a 
nucleophile displaces a leaving group (usually a fluoride or chloride) on an electron deficient 
arene. Generally, substitution in SNAr reaction occurs by a two-step mechanism involving, an 
addition-elimination sequence. The first step is the rate determining (slow) step which involves a 
nucleophilic attack on the aromatic carbon that bears the halogen to form a resonance-stabilized 
carbanion intermediate known as a Meisenheimer complex. The second (fast) step involves 
elimination of the leaving group to restore aromaticity.79 For the SNAr mechanism to proceed, 
strong electron-withdrawing groups on the aromatic ring must be positioned ortho or para to the 
leaving group. The stronger the electron-withdrawing substituent, the easier it is for the SNAr 
reaction to occur (Figure 2.1). Similarly, the order of reactivity for the leaving group (X) is 




Figure 2.1. General mechanism for SNAr reaction.80 
2.2. Results and Discussion 
2.2.1.  1-Aryl-5-nitro-1H-indazoles and a general sequential route to 1-aryl-1H-indazoles. 
Our synthetic methods program has recently focused on the use of nucleophilic aromatic 
substitution (SNAr)-terminated tandem reactions as a means to prepare heterocyclic compounds.80 
This project has developed a synthesis of 1-aryl-1H-indazoles77, which are core ring structures in 
a broad range of biologically active compounds (Figure 2.2). Among the compounds pictured, 
benzydamine (42) is a well-known NSAID drug,81 while alcohol 43 has likewise shown promise 
as an anti-inflammatory agent.82 The urea-based structure 44 has recently been judged to possess 
significant tumor antiproliferative properties.83 Similarly, amide 45 has also demonstrated 
anticancer activity.84,85 
Several strategies have previously been disclosed as routes to 1-aryl-1H-indazoles. All required 
multiple steps. The closest work to that presented here utilized a two-step sequence involving 
acid catalyzed formation of the arylhydrazone, followed by a copper(I)-catalyzed Ullmann-type 
coupling to close the ring.86 Two related accounts described (1) the base-promoted SNAr 




















benzaldehydes87 and (2) the reaction of salicylaldehydes with arylhydrazine hydrochlorides.88 
Additional work examined the condensation of N-aroyl-N'-arylhydrazines with 2-bromoaryl 
ketones or aldehydes,89 and arylhydrazines with 2-haloaroyl esters,90 both followed by copper(I)-
assisted ring closure. Along a different line, another study has reported a [3+2]-type annulation 
involving arynes generated in the presence of hydrazones under mild basic conditions.91 Finally, 
syntheses promoted by palladium92 and rhodium93 catalysts have also furnished these targets. A 
full listing of methods to prepare 1H-indazoles, with and without the N1 aryl group, have been 




Figure 2.2. Drugs incorporating 1-aryl-1H-indazoles. 
 
A logical route to 1H-indazoles would involve the ring closure of an arylhydrazone anion derived 
from an appropriately substituted aromatic ketone or aldehyde. Although the arylhydrazones 
would form as two isomers, with the E isomer (less favorable for cyclization) predominating, 
these should readily interconvert with heat97 and allow access to the Z isomer required for ring 
closure. Furthermore, the pKa of the phenylhydrazone proton (Ar = Ph) is 21.5,98 and with slight 
variations due to substituents on the aromatic ring, should permit the use of K2CO3 in a polar 
aprotic solvent as the deprotonating agent.99 Optimally, these annulations would proceed in one 
pot, but we initially sought to determine the feasibility of the sequence by evaluating each 
transformation separately. Once each step was optimized, attempts were made to merge the two 































substitution patterns, we also aspired to generalize the process to include structures without SNAr 
activating groups. Although there are numerous examples of SNAr-type reactions to generate five-
membered rings fused to a benzene, some strain would be expected in ring formations involving 
closure of a fragment incorporating three sp2 atoms onto an aromatic nucleus.100,101 Thus, 2'-
fluoro-5'-nitroacetophenone (46) and 2-fluoro-5-nitrobenzaldehyde (47) were initially reacted 
with hydrazine hydrate (NH2NH2·H2O) to assess the feasibility of forming indazoles in this 
manner. Due to the a-effect,102 hydrazine is an exceptionally potent nucleophile and might be 
expected to react without added base. Indeed, treatment of 46 and 47 with NH2NH2·H2O (3.0 
equiv for 46 and 2.0 equiv for 47) in DMF at 23 oC for 2 h resulted in high yields of targets 48 
and 49, respectively (see Scheme 2.1). Encouraged by this result, we forged ahead to prepare 1-
aryl-5-nitro-1H-indazoles. 
 
Scheme 2.1. Reaction of 46 and 47 with hydrazine hydrate. 
Formation of the intermediate arylhydrazones 50 and 51 (see Table 2.1) was initially addressed. 
This involved warming a DMF solution of the carbonyl compound with an arylhydrazine 
hydrochloride (ArNHNH2·HCl) at 50 oC for 2-3 h. DMF was used as a solvent for this process 
since we anticipated that a one-pot procedure where the hydrazone was prepared, deprotonated, 
and cyclized would likely require the use of a polar aprotic solvent. Optimization studies 
indicated that DMF was a suitable medium and the use of 3.0 equiv of ArNHNH2·HCl with 
acetophenone 46 and 2.0 equiv with benzaldehyde 47 afforded the highest yields of 50 and 51. In 
all cases, the intermediate hydrazones were isolated in ≥70% yield from 46 and ≥50% yield from 









46  (R = Me)
47  (R = H)
48  (R = Me)  98%
49  (R = H)     90%
NH2NH2·H2O
DMF, 23 oC, 2 h
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arylhydrazine were not observed to any significant extent under these conditions. While the 
product of addition-elimination by hydrazine is known to cyclize to a 1H-indazole,103 ring closure 
of the analogous product from arylhydrazine would likely give a 2-aryl-2H-indazole, and this was 
not detected. 
Table 2.1. Yields for the two-step synthesis of 1-aryl-5-nitro-1H-indazoles. 
 
 
aAll hydrazones were generated in 2 h. Times given are for the final cyclization. bIsolated  
         yield of 1H-indazole for the two-step sequence. cOnly the hydrazone was isolated. 
 
ArNHNH2·HCl




46  (R = Me)
47  (R = H)
  50  (R = Me)  






52  (R = Me)  



















a   Ph-
b   2-MeOPh-
c   3-MeOPh-
d   4-MeOPh-
e   4-BrPh-
f    3-ClPh-
g   4-ClPh-
h   2,4-Cl2Ph-
i    3-CF3Ph-
j    4-CF3Ph-
k   4-CNPh-
l    4-H2NSO2Ph-
m  4-HO2CPh-
a   Ph-
b   2-MeOPh-
c    3-MeOPh-
d   4-MeOPh-
e    4-BrPh-
f    3-ClPh-
g   4-ClPh-
h   2,4-Cl2Ph-
i    3-CF3Ph-
j    4-CF3Ph-
k   4-CNPh-

































































































Cyclization of hydrazones 50 and 51 required base, higher temperature and occasionally extended 
reaction times. This reaction was performed in DMF at 90 oC and found to work best using 3.0 
equiv of K2CO3. Yields were slightly lower from the benzaldehyde since this substrate led to a 
product that was unhindered at C3 and possibly susceptible to nucleophilic attack by various 
species in the reaction. The results of our two-step synthesis of 1-aryl-5-nitro-1H-indazoles are 
summarized in Table 2.1. 
Modification of the protocol to allow for a one-pot procedure had to overcome several problems 
that could lead to unwanted impurities. Since water is produced during hydrazone formation, 
some conversion of the K2CO3 to KOH would be expected. Furthermore, KOH could hydrolyze 
the DMF solvent to form Me2NH. Both of these nucleophiles (OH– and Me2NH) could potentially 
undergo competitive SNAr addition to the carbonyl containing substrate. While no significant 
product resulting from OH– addition was observed, some of the Me2NH addition product was 
noted when prolonged heating was required. These side reactions were suppressed by adding 30 
wt% (relative to 46 or 47) of powdered 4Å molecular sieves to scavenge water produced during 
the initial condensation and using anhydrous 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone 
(DMPU) as the solvent to minimize hydrolysis (see Table 2.2). 
The one-step tandem process was successful for the conversion of ketone 46 to indazoles 52, and 
in most cases, the yield was superior to the two-step sequence. Reactions of aldehyde 47 to give 
53, however, were more limited and several of the substrates bearing acidic functions on the 
aromatic ring failed to react. For aldehydes that did generate a product, sequential treatment with 
ArNHNH2·HCl and base afforded yields that also surpassed the two-step process (see Table 2.2). 
In both one-pot procedures, it was often noted that the cyclization required a longer reaction time 
when the aryl group of the hydrazone was substituted by an electron-withdrawing group. This 
would be expected since the arylhydrazone anion would be less nucleophilic with a stabilizing 
group at C2 or C4 of the hydrazone aromatic ring.104 Conversely, this same anion with electron-
donating substituents at C2 or C4 should be more reactive with potentially shorter reaction times. 
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Table 2.2.  Yields for the modified one-pot synthesis of 1-aryl-5-nitro-1H-indazoles. 
  
aFor 46, time is the total reaction time. For 47, the hydrazone was allowed to form for  
1.5 h at 90 oC before base was added; time is for the final cyclization. bIsolated yield.  
 
Finally, we sought to develop a general approach to 1H-indazoles unrestricted by the substitution 
patterns needed for the SNAr ring closure (see Table 2.3). Protocol development efforts indicated 
that this variant of the reaction required sequential addition of the reagents. The hydrazone was 
initially generated using 1.5 equiv of the ArNHNH2·HCl and then cyclized by addition of 20 
mol% of copper(I) iodide (CuI) and 2.5 equiv of K2CO3, all in the same flask at 90 oC. Again, the 
key to success in this transformation was the inclusion of 30 wt% of powdered 4Å molecular 
sieves and the use of DMPU as the solvent. Without activating groups on the ring, Ullmann 
conditions (CuI and base) for the final ring closure were essential. An earlier paper noted that this 
copper(I)-catalyzed ring closure was facilitated by the addition of 20 mol% of L-proline or 4-




K2CO3, DMPU, 90 oC
R
ArNH2NH2·HCl, 30 wt% 4Å MS
Ar % Yieldb
a   Ph-
d   4-MeOPh-
g   4-ClPh-
h   2,4-Cl2Ph-
m  H2NSO2Ph-







46  (R = Me)








52  (R = Me)




















a   Ph-
d   4-MeOPh-
g   4-ClPh-
l    4-NCPh-
m  H2NSO2Ph-























on the yield of the reaction. The cyclization using 2'-bromoacetophenone (54), 2-
bromobenzaldehyde (55) and 2-chloronicotinaldehyde (56) was performed using phenylhydrazine 
as well as electron-rich and electron-poor arylhydrazines in relatively uniform yields. Though it 
was expected that the nicotinaldehyde derivatives would not need a copper catalyst, since it could 
directly cyclize by a SNAr reaction, this ring closure failed to proceed to completion without this 
additive.  Overall, our procedure permits the rapid construction of 1-aryl-1H-indazoles in a single 
reaction vessel without isolation or purification of intermediates. 




2.2.1.1.  Conclusions 
We have developed and optimized a two-step synthesis to prepare 1-aryl-5-nitro-1H-indazoles 
from 2'-fluoro-5'-nitroacetophenone (46) and 2-fluoro-5-nitrobenzaldehyde (47). We have further 




then 20 mol% CuI
K2CO3, 90 oC, 16 h
RArNH2NH2·HCl, 4Å MS
DMPU, 90 oC, 1.5 h
54  (X = Br, Y = CH; R = Me) 
55  (X = Br, Y = CH; R = H) 
56  (X = Cl, Y = N; R = H)






l   4-CNPh-
a  Ph-
d  4-MeOPh-
l   4-CNPh-
a  Ph-
d  4-MeOPh-




















57  (Y = CH; R = Me) 
58  (Y = CH; R = H) 













(sequential reaction) in yields that surpassed those of the two-step sequence. Our strategy 
involved initial formation of the hydrazone, followed by deprotonation and SNAr ring closure. 
Yields were 73-96% from 46 and 70-74% from 47 for the one-pot version of the synthesis, 
though two examples involving 47 failed to give an indazole product. We have also developed a 
general one-pot sequential approach to 1-aryl-1H-indazoles that is not limited by the substitution 
patterns normally required for the SNAr ring closure. Treatment of 2'-bromoacetophenone (54), 2-
bromobenzaldehyde (55) and 2-chloronicotinaldehyde (56) with ArNHNH2·HCl and 30 wt% of 
powdered 4Å molecular sieves in DMPU at 90 oC, followed by addition of CuI and K2CO3, 
afforded 1H-indazoles bearing phenyl as well as electron-rich and electron-poor aromatic groups 
at N1 in 62-87% yields. The current work provides access to a selection of 1-aryl-1H-indazoles in 
a single laboratory operation without isolation or purification of intermediates. We are continuing 
our work to devise new and efficient approaches to a broad range of heterocyclic systems. 
 
2.2.2.  4H-Benzo[d][1,3]oxazin-4-ones and dihydro analogs. 
We recently reported the high-yield synthesis of quinazolin-4(3H)-ones by reaction of 2-
aminobenzamides with orthoesters in ethanol promoted by acetic acid.105 These heterocycles have 
received considerable attention as they have demonstrated diverse biological activities. With the 
success of this previous study, we sought to evaluate a similar strategy for the synthesis of 2-alkyl 
and 2-aryl-4H-benzo[d][1,3]oxazin-4-ones (also known as 4H-3,1-benzoxazin-4-ones).106 These 
compounds are less stable, and thus, have been less well studied. An early account noted that 
several substituted structures related to compound 57 exhibited hypolipidemic activity.107 Other 
benzoxazinones demonstrated potential as protease inhibitors. In particular, 4H-benzo[d][1,3]-
oxazin-4-one 58 was shown to have substrate inhibitory activity towards the serine protease 
human leukocyte elastase which is the presumed tissue degenerating agent in the pathogenesis of 
several diseases.108 Two additional studies revealed that 59 and 60 interfered with the action of 
intramembrane serine proteases known as rhomboids that are important in the progression of 
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diseases such as cancer, diabetes, invasion of apicomplexan parasites, and Parkinson's 
disease.109,110 Thus, access to these drug candidates would allow further study of the etiology of 
these diseases and could lead to new drugs to treat them. Structures 57-60 are shown in Figure 
2.3. Apart from investigations of their potential use as drugs, 4H-benzo[d][1,3]oxazin-4-ones 
have also been used as precursors to new heterocycles111 as well as interesting peptide based 
oligomers.112   
 
Figure 2.3.  4H-Benzo[d][1,3]oxazin-4-ones with potential drug activity. 
Classic approaches to 4H-benzo[d][1,3]oxazin-4-ones involved reaction of anthranilic acid with 
two equivalents of benzoyl chloride in pyridine to afford >90 % of 2-aryl-4H-benzo-
[d][1,3]oxazin-4-ones.107 Similarly, treatment of substituted anthranilic acids with one equivalent 
of various acid chlorides to give the 2-amidobenzoic acid, followed by boiling in acetic 
anhydride, also afforded these products in good yields.113,114 A later synthesis of 4H-
benzo[d][1,3]oxazin-4-ones described a high-yield palladium-catalyzed cyclocarbonylation of o-
iodoanilines with acid chlorides.115 Furthermore, three oxidative approaches to these aryl-fused 
heterocycles have also been reported. In the first example, copper was used to promote the 
conversion of 2-alkynylanilines to 2-aryl-4H-benzo[d][1,3]oxazin-4-ones using base conditions 
under oxygen atmosphere.116 Another approach utilized oxone in nitromethane at 100 oC to 
accomplish the oxidation of 2-arylindoles to these same targets. A third oxidative procedure 
involved the water assisted oxidation of 2-arylindoles to 2-aryl-4H-benzo[d][1,3]oxazin-4-ones 


























for a small series of compounds substituted by phenyl at C2. This procedure utilized microwave 
energy to promote the formation of 2-phenyl-4H-benzo[d][1,3]oxazin-4-ones from four 
anthranilic acids and triethyl orthobenzoate.118 The yields varied in this reaction, but no problems 
were noted. In the current study, we have attempted to expand the scope of this transformation 
examining the reaction of additional aryl-substituted anthranilic acids with four orthoesters. The 
results of our study are detailed below. 
Scheme 2.2 depicts the focus and scope of the current study. We have explored the synthesis of a 
range of 4H-benzo[d][1,3]oxazin-4-ones from reaction of six anthranilic acids with a range of 
commercially available orthoesters (Tables 2.4 and 2.5). The reaction was run under two sets of 
conditions:  one under thermal conditions promoted by acid and the other under microwave 
conditions. The acid promoted conditions involved heating anthranilic acid (1 equiv) with the 
orthoester (4.5 equiv) in the presence of AcOH (2.6 equiv), neat, at 100 oC, for 4-48 h.  The 
microwave reaction was run using anthranilic acid (1 equiv) and the orthoester (2.0-2.7 equiv), 
neat, without AcOH, at 100 oC (400 W), for 0.75-3 h. Upon cooling, the products from both 
procedures crystallized from the crude reaction mixtures and were purified by trituration from 5% 
pentane in ether.  
 
Scheme 2.2. Formation of 4H-benzo[d][1,3]oxazin-4-ones and their dihydro analogs from 




























X = H, Y = CH
X = 5-Me, Y = CH
X = 4-MeO, Y = CH
X = 4-NO2, Y = CH
X = 4-Cl, Y = CH





















X = H, Y = CH
X = 6-Me, Y = CH
X = 7-MeO, Y = CH
X = 7-NO2, Y = CH
X = 7-Cl, Y = CH
X = H, Y = N
Method 1:  anthranilic acid (1 equiv), orthoester (4.5 equiv), AcOH (2.6 equiv), neat, 100 oC, 4-48 h










Contrary to what has been reported in related studies to date, we found that not all of the thermal 
reactions produced the target heterocycles cleanly. In several cases, (±)-2-substituted-1,2-
dihydro-4H-benzo[d][1,3]oxazin-4-ones, resulting from ring closure without elimination of the 
final molecule of ethanol, were isolated.  This led us to expand our study to evaluate microwave 
reactions in addition to the standard acid-promoted thermal reactions; however, both protocols 
afforded the intermediate dihydro compounds from specific substrates.  In several cases, it was 
possible to isolate either product by modification of the procedure.  For example, the reaction of 
anthranilic acid (61) with triethyl orthobenzoate (d, Scheme 2.2) for 24 h under thermal 
conditions afforded dihydro product 73d, while extending the reaction to 48 h yielded 4H-
benzo[d][1,3]oxazin-4-one 67d. In several other examples, however, it was not possible to induce 
the final elimination reaction. 
Table 2.4.  Formation of 4H-benzo[d][1,3]oxazin-4-ones. 
 
      Substrate 
 
   Product 
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  Yield (%) 
 
 
           
 
 
                    
 
a: Me 
  b: Et 
  c: Pr 
  d: Ph 
    
     
      1(2) 
      1(2) 
      1(2) 




  7(0.75) 










   
a: Me 
  b: Et 
  c: Pr 
  d: Ph 
      2 
      2 
      1(2) 
      2 
    0.75 
    0.75 
 24(0.75) 
    0.75 
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     66 
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  b: Et 
  c: Pr 
d: Ph 
     1(2) 
     1(2) 
     1(2) 
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       c 
       c 
       c 
    91 
 
   
 
   
a: Me 
  b: Et 
  c: Pr 
d: Ph 
     2 
     1(2) 
     1(2) 
     2 
    0.75 
48(0.75) 
48(0.75) 
    1.5 
    85 
       c 
       c 
    92 
 
            
 
        
 
a: Me 
  b: Et 
  c: Pr 
d: Ph 
     1 
     2 
     2 
     2 
   24 
   0.75 
   0.75 
   0.75 
       c 
       d 
       d 
       d 
(a) For anthranilic acid (1 equiv):  Method 1: orthoester (4.5 equiv), AcOH (2.6 equiv), neat, 100 oC, for the indicated 
time;  Method 2: orthoester (2.0-2.7 equiv), neat, MW, 100 oC, for the indicated time; (b) An inseparable mixture of 
the 4H-benzo[d][1,3]oxazin-4-one and the dihydro product was formed; (c) The dihydro product formed; (d) Only ethyl 













































Table 2.5.  Formation of (±)-1,2-dihydro-4H-benzo[d][1,3]oxazin-4-ones. 
 
      Substrate 
 
   Product 
   













           
          
 
 a: Me 
  b: Et 
  c: Pr 
  d: Ph 
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      b 
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 a: Me 
  b: Et 
  c: Pr 
  d: Ph 
    1 
    1 
    1(2) 
    1 
       24 
       24(0.75) 
       24 
        48 
    88 
    87 
    88(89) 
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  c: Pr 
d: Ph 














 a: Me 
  b: Et 
  c: Pr 
d: Ph 
    1(2) 
    1(2) 
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  84(87) 
  86(88) 
  85(88) 




































   
 
 a: Me 
  b: Et 
  c: Pr 
d: Ph 
   1 
   1(2) 
   1(2) 
   1 
      24 
      48(0.75) 
      48(0.75) 
       48 
  84 
  84(86) 
  83(84) 





          
 a: Me 
  b: Et 
  c: Pr 
d: Ph 
    1 
     
 
      24 
 
  85 
    d 
    d 
    d 
(a) For anthranilic acid (1 equiv):  Method 1: orthoester (4.5 equiv), AcOH (2.6 equiv), neat, 100 oC, for the indicated 
time; Method 2: orthoester (2.0-2.7 equiv), neat, MW, 100 oC, for the indicated time; (b) Only the 4H-
benzo[d][1,3]oxazin-4-one product was formed; (c) An inseparable mixture of the 4H-benzo[d][1,3]oxazin-4-one and 
the dihydro product was formed; (d) Only ethyl 2-aminonicotinate was formed from esterification of the substrate acid. 
 
The outcome of the reaction appeared to correlate with the electron density in the aromatic ring of 
the anthranilic acid. For rings substituted with electron donating groups (OMe, Me) or hydrogen, 
the 4H-benzo[d][1,3]oxazin-4-one product predominated. More electron-poor aromatic rings 
bearing a second electron-withdrawing group on the aromatic ring (NO2 and Cl), in addition to the 
ortho carbonyl group, showed a tendency to give the 1,2-dihydro-4H-benzo[d][1,3]oxazin-4-one 
product. Changing the benzene ring of the anthranilic acid to an electron-deficient pyridine, as in 
2-aminonicotinic acid (66), almost completely shut down the reaction. In most cases, it was 
possible to isolate at least one of the products in pure form. The lone exception was the attempted 
conversion of 61 to 73c with triethyl orthobutyrate (c), which gave an inseparable mixture of the 
benzoxazinone and dihydro product under all conditions. Attempts to drive the reaction to the 
benzoxazinone using 5 equiv of AcOH or spiking the reaction with H2SO4 failed to alter the 
outcome, while treatment with base (K2CO3, EtOH, molecular sieves), resulted in ring opening to 

















orthoacetate (a) proceeded to give dihydro product 77a, but all others afforded only ethyl 2-
aminonicotinate resulting from esterification of the substrate acid.  
The presumed mechanism for the formation of 4H-benzo[d][1,3]oxazin-4-ones is shown in 
Scheme 2.3. The process involves initial protonation of the orthoester and loss of ethanol to 
afford the stabilized carbocation A. Attack on A by the anthranilic acid amino group, proton 
exchange and loss of a second molecule of ethanol would then yield iminium ion B. Subsequent 
closure of the acid oxygen on the iminium carbon and proton exchange would give the ring-
closed, dihydro product C. Finally, protonation of C to give D and loss of ethanol would then 
generate the desired heterocycle E. 
 
 
Scheme 2.3.  Presumed mechanism for the formation of 4H-benzo[d][1,3]oxazin-4-ones. 
 
Difficulty was noted in the final elimination of ethanol when the aromatic ring carried a second 
electron-withdrawing group (EWG) in addition to the adjacent ester carbonyl. For this 
elimination, the availability of the unshared electron pair on N1 and its ability to align 
antiperiplanar to the departing alcohol were assumed to be keys to the success of this elimination. 
The availability of these electrons, however, would be diminished in substrates with a strongly 






















































antiperiplanar alignment of the unshared pair for efficient elimination in this system. This 
anomeric effect has been extensively studied in acetals and hemiacetals,119 but much less so for 
their nitrogen analogs since elimination is normally facile. If achievable, conformation D1 would 
result in good overlap for elimination of ethanol (see Figure 2.4). Placement of the C2 ethoxy 
group in a pseudo-axial position for this elimination should be favorable since this group is 
considered to be sterically smaller than an alkyl group.120,121 However, this conformation also 
maximizes overlap of the N1 electron pair with the aromatic ring as well as the ortho carbonyl, 
and this could slow the elimination if the aromatic ring bears an additional electron-withdrawing 
substituent. The alternative conformation D2 is not optimally aligned for elimination (see Figure 
2.4). If the ring closure and protonation steps led to this conformation, conversion to D1 could 
occur, but would likely be sluggish since flexibility in this rigid system is allowed only at the 
saturated atoms of the benzoxazinone.   
 
 
Figure 2.4.  Conformational options for intermediate D. 
 
2.2.2.1.  Conclusions 
We have studied the formation of 4H-benzo[d][1,3]oxazin-4-ones under thermal conditions with 
acetic acid as well as microwave conditions without acid. In most cases, the target heterocycle 
















•  favorable alignment of the N e– 
   pair with the EtOH leaving group
•  the e– pair is less available when 
   X = EWG
•  unfavorable alignment of the N e– 
   pair with the EtOH leaving group
•  the e– pair has less overlap with





were isolated by crystallization and trituration. The microwave reaction proceeded much faster 
(0.75-3 h) than the thermal reactions (4-48 h) and did not require extra acid. Thus, the microwave 
protocol represents the superior procedure. Stereoelectronic effects strongly impacted the 
outcome of the reaction. In addition to the benzoxazinone products, a dihydro intermediate, 
resulting from failure to undergo the final elimination, was observed in some substrates. The 
formation of the dihydro compound arose in reactants where the fused aromatic ring possessed a 
second electron-withdrawing group in addition to the conjugated carbonyl on the ortho carbon. 
This could deactivate the electron pair on N1 and slow the elimination process, even if the C2 
ethoxy group was able to adopt the required pseudo-axial conformation. The formation of these 
dihydro systems provides access to a new substitution pattern in this family of compounds and 
could yield additional candidates for biological testing. This finding, coupled with the fact that 
orthoesters are easily prepared from nitriles,122,123 should provide a route to many members of this 
novel class of structures. 
2.2.3.  Bis- and mono-1,3,4-oxadiazole synthesis promoted by catalytic NH4Cl. 
We recently reported the high-yield synthesis of 1,3,4-oxadiazoles promoted by NH4Cl in 
absolute ethanol.124 These heterocyclic scaffolds have received considerable attention in the field 
of medicinal chemistry as they possess diverse biological activities (Figure 2.5). Encouraged by 
the outcome of this previous study, we sought to evaluate a similar strategy for the synthesis of 
bis-1,3,4-oxadiazoles. Over the years, numerous methods for the synthesis of the 1,3,4-oxadiazole 
ring core have been developed as a result of their broad commercial potential. Most approaches 
involve either a multi-step strategy or the cyclization of hydrazides using harsh reagents such as 
phosphorus oxychloride, thionyl chloride, sulfuric acid, zirconium(IV) chloride, XtalFluor-E®, 
Burgess reagent, Deoxo-Fluor®, acid chlorides, Nafion® NR50, or acetic acid, under reflux or 
microwave heating.125 Consequently, sensitive functional groups are often intolerable with these 
earlier methods due to the caustic nature of these reagents. To address this problem, we 
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developed a mild alternative, which involves the formation of 1,3- and 1,4-bis-1,3,4-oxadiazoles 
from aryl or aliphatic dihydrazides and orthoesters using NH4Cl as a catalyst. 
 
Figure 2.5. Drug containing an oxadiazole ring. 
In recent years, NH4Cl has proven to be a highly efficient and mild catalyst for the synthesis of 
benzo-fused heterocycles such as benzimidazoles, benzoxazoles, and benzothiazoles.126 
Moreover, the usefulness of NH4Cl has been extended to the preparation of a-aminonitriles using 
a variant of the Strecker synthesis.127 The scope of this catalyst was broadened by performing 
optimization studies for the current reaction using terephthalic dihydrazide (1.0 equiv) and 
triethyl orthoformate (2.2 equiv). The optimized transformation occurred using 60 mol% of 
NH4Cl in DMSO at 100 oC, which afforded an 85% yield of the corresponding 1,4-bis-1,3,4-
oxadiazole in 90 minutes (Table 2.6). Lower catalyst loadings resulted in slow and often 
incomplete reaction, while more catalyst had no impact on the outcome of the reaction. Replacing 
DMSO with absolute EtOH gave similar yields, but at a much slower rate (twice as much time). 
Attempts to use other solvents (DMF, MeOH, THF, CH3CN) either produced lower yields or no 
detectable product. Moreover, the use of acetic acid (1.69 equiv) afforded only trace amounts of 













































Table 2.6. Optimization results for bis-1,3,4-oxadiazole from terephthalic dihydrazide (1.0 equiv) 










Solvent Time (h) Yield 
(%) 
1 3.0 NH4Cl 80 mol% EtOH 3.0 85 
2 2.2 NH4Cl 60 mol% EtOH 3.0 85 
3 2.2 NH4Cl 60 mol% DMF 1.5 45 
4 2.2 NH4Cl 60 mol% Acetonitrile 4.0 NDa 
5 2.2 NH4Cl 60 mol% THF 4.0 NDa 
6 2.2 NH4Cl 60 mol% MeOH 4.0 NDa 
7 2.2 Acetic acid 1.69 DMSO 1.5 Trace 
8 2.2 NH4Cl 60 mol% DMSO 1.5 85 
9 2.0 NH4Cl 60 mol% DMSO 1.5 76 
10 2.2 NH4Cl 50 mol% DMSO 5.0 42 
     aND = no detectable product. 
The scope of this reaction was extended to a series of aryl and aliphatic dihydrazides using 
various orthoesters and 60 mol% NH4Cl in DMSO at 100 oC. Our results are summarized in 
Tables 2.7–2.9. Additionally, the reaction of various orthoesters with substituted arylhydrazides, 
nicotinic and isonicotinic acid hydrazides (Tables 3.0–3.2) was also examined under similar 
optimized conditions. The reaction was tolerant of and successful with both electron-donating 
(methoxy) and electron-withdrawing (nitro) substituents on the arylhydrazide reactant. 
Table 2.7. Summary of 1,4-bis-1,3,4-oxadiazoles from terephthalic dihydrazide. 
 
Substrate    R Time (h) Product Yield (%) 
79 a:  H      1.5    80a    85 
79 b:  Me    11.0    80b    89 
79 c:  Et      6.0    80c    81 
79 d:  Pr      4.0    80d    80 













a (R = H)  
b (R = Me) 
c (R = Et)
d (R = Pr) 
e (R = Ph)
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Table 2.8. Summary of 1,3-bis-1,3,4-oxadiazoles from isophthalic dihydrazide. 
 
Substrate    R Time (h) Product Yield (%) 
81 a:  H      2.5    82a    84 
81 b:  Me    12.0    82b    88 
81 c:  Et      8.0    82c    86 
81 d:  Pr      6.0    82d    85 
81 e:  Ph    22.0    82e    77 
 
Table 2.9. Summary of 1,4-butyl-bis-1,3,4-oxadiazoles from adipic dihydrazide. 
 
Substrate    R Time (h) Product Yield (%) 
83 a:  H      1.5    84a    53 
83 b:  Me    96.0    84b    20 
83 c:  Et      4.0    84c    79 
83 d:  Pr      6.0    84d    NDa 
83 e:  Ph    22.0    84e    56 
     aND = no detectable product. 
Generally, adipic dihydrazide (83) gave low yields of bis-1,3,4-oxadiazoles (Table 2.9). In 
addition, the yield of the target molecule from isophthalic dihydrazide (81) as shown in Table 2.8 





a (R = H)  
b (R = Me) 
c (R = Et)
d (R = Pr) 
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b (R = Me) 
c (R = Et)
d (R = Pr) 
















Moreover, bis-1,3,4-oxadiazoles from 81 required much longer reaction times, and this 
presumably results from a steric effect. The proximity of the hydrazide groups in the 1,3 position 
of 81 may result in steric hindrance, which could potentially impact the reactivity of 81. 
Conversely, 79 should be more reactive because the two hydrazide groups are reasonably far 
apart (1,4) thus only minimal or no steric hindrance may be experienced. A proposed mechanism 
for the formation of the oxadiazole ring system is given in Scheme 2.4. The process involves 
initial protonation of the orthoester and loss of ethanol to afford the ether-stabilized carbocation 
A1. Attack on A1 by the hydrazide amino group, proton exchange and loss of a second molecule 
of ethanol, would then yield iminium ion B1. Subsequent closure of the amide oxygen on the 
iminium carbon and proton exchange would give the ring-closed dihydro product C1. Finally, 
loss of ethanol would then generate the desired heterocycle D1.       
 
Scheme 2.4. Proposed mechanism for the formation of 1,3,4-oxadiozole ring system. 
Extension of the current protocol to substituted aryl, nicotinic and isonicotinic hydrazides 
required 30 mol% NH4Cl and orthoesters (1.1 equiv) to afford mono 1,3,4-oxadiazoles in high 
yields (Tables 3.0–3.2). While a strong electron-releasing group such as methoxy (OCH3) at the 
para position of the arylhydrazide gave 1,3,4-oxadiazoles in high yield, the opposite was true for 
an electron-withdrawing group (NO2). This may be due to an electronic effect, which should exert 












































Table 3.0. Summary of 1,3,4-oxadiazoles from substituted arylhydrazide. 
 
 
Substrate   R Time (h) Product Yield (%) 
85 a: H      1.5    87a    92 
85 b: Me    10.0    87b    85 
85 c: Et      5.0    87c    88 
85 d: Pr      4.0    87d    90 
85 e: Ph    18.0    87e    78 
86 a: H      2.0    88a    94 
86 b: Me    10.0    88b    93 
86 c: Et      5.5    88c    92 
86 d: Pr      5.0    88d    88 
86 e: Ph    27.0    88e    80 
 
Table 3.1. Summary of 1,3,4-oxadiazoles from nicotinic acid hydrazide. 
 
Substrate    R Time (h) Product Yield (%) 
89 a:  H    5.0    90a    96 
89 b:  Me    28.0    90b    70 
89 c:  Et    12.0    90c    80 
89 d:  Pr    26.0    90d    83 
89 e:  Ph    72.0    90e    80 
EtO R
EtO OEt
85 (Y = NO2)
86 (Y = OCH3)
87a-e (Y = NO2)




a (R = H)  
b (R = Me) 
c (R = Et)
d (R = Pr) 














a (R = H)  
b (R = Me) 
c (R = Et)
d (R = Pr) 









Table 3.2. Summary of 1,3,4-oxadiazoles from isonicotinic acid hydrazide. 
 
Substrate    R Time (h) Product Yield (%) 
91 a:  H    24.0    92a    85 
91 b:  Me    48.0    92b    86 
91 c:  Et    48.0    92c    85 
91 d:  Pr    48.0    92d    86 
91 e:  Ph    72.0    92e    88 
 
2.2.3.1.  Conclusions 
We have modified the approach from our previous study for the synthesize of bis-1,3,4-
oxadiazoles using NH4Cl as an efficient catalyst. Moreover, the scope of this strategy was 
broadened for the formation of 4-substituted aryl, nicotinic and isonicotinic 1,3,4-oxadiazoles. 
The conditions were mild, and thus, compatible with a variety of functional groups. The 
optimized reaction involved the use of 30 mol% and 60 mol% of NH4Cl in DMSO for hydrazide 
and dihydrazide substrates respectively, and in most cases, the yields were high.  
2.2.4. Naphthalenes and heterocycles from Morita-Baylis-Hillman (MBH) acetates by 
domino Michael addition-elimination-SNAr reactions. 
Recent studies in our research group have focused on methodology development which involved 
a number of domino cyclizations terminated by nucleophilic aromatic substitution reactions.128 
The current work extends these previous results to the preparation of naphthalene carboxylates 








a (R = H)  
b (R = Me) 
c (R = Et)
d (R = Pr) 









approaches to the naphthalene framework have been reported.129,130 Most recently, Balamurugan 
and co-workers have developed a process for the synthesis of naphthalenes from o-
alkynylacetophenone derivatives via tandem acetal formation-intramolecular heteroalkyne 
metathesis/annulation.131 Che and co-workers have also reported a method for the synthesis of 
quinolines and 1,2-dihydroquinolines from aromatic amines and alkynes by a Au(I)-catalyzed 
tandem hydroamination-hydroarylation under microwave-assisted conditions.132 Moreover, 
Tamariz and co-workers have also developed a process for the regioselective synthesis of 1,2-
dihydroquinolines. The method involved a solvent-free MgBr2-catalyzed reaction between 
substituted aniline and two ketones.133 Microwave-mediated reactions of 3-aminomethylpyridines 
with acetylenedicarboxylates have also been reported by Ivachtchenko and co-workers as a novel 
synthetic route to dihydronaphthyridine and naphthyridine-1-ones.134 These protocols yielded 
modest to good results, but generally subjected substrates to strongly acidic reagents and harsh 
reaction conditions. Our current reaction provides a straightforward route to these heterocycles in 
good yields under mild reaction conditions. The target heterocycles are valuable building blocks 
for the synthesis of drugs used as antibacterial,135 antidiabetic136 and antioxidant agents137 as well 
as for the treatment of several other medical afflictions.138  
Formation of the naphthalene and quinoline derivatives resulted from the Michael addition-
elimination-SNAr reaction of active methylene compounds with Morita-Baylis-Hillman (MBH) 
acetates of 2-fluoro-5-nitrobenzaldehyde and 2-fluoronicotinaldehyde, respectively. Similar 
reaction of the above-mentioned acetates with primary (1o) alkyl or aromatic amines afforded the 
respective 1,2-dihydroquinolines and 1,2-dihydro-1,8-naphthyridines. Moreover, an unexpected 
formation of 4-oxo-1,4-dihydroquinolines was observed from the Michael addition-elimination-
SNAr reaction of 1o amines with MBH acetates of 2,5-difluorobenzaldehyde at high temperature. 
The MBH reaction was first introduced in 1941 and has since proven to be a valuable source of 
wide variety of pharmaceutically important scaffolds. As shown in Figure 2.6, synthetic chemists 
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have dramatically broadened the scope of the MBH reaction through extensive exploitation of its 
versatility.139-143  
 
Figure 2.6. Scope of Morita-Baylis-Hillman (MBH) reaction. 
The reaction involves a carbon-carbon bond formation between electrophiles and activated 
alkenes in the presence of a tertiary amine or phosphine catalyst to afford allylic alcohols, also 
known as MBH adducts or alcohols.27, 140-143 Acylation of these adducts gives the MBH acetates 
which are viable Michael acceptors. Both adducts and acetates have proven to be attractive 
synthons for building more complex molecular frameworks.140 A thorough review on the impact 
and importance of the MBH reaction in medicinal chemistry has been recently reported by Reddy 
and co-workers.141  
The goal of the current study was to provide naphthalene building blocks and other attractive 
heterocyclic scaffolds from MBH acetates using domino Michael addition-elimination-SNAr 
reactions. Naphthalene is the simplest bicyclic aromatic ring, and is frequently found in the 
molecular frameworks of anticancer agents (Figure 2.7).144 Earlier approaches to the synthesis of 












































TiCl4.145-147 Consequently, some type of special purification procedures were likely required to 
reduce metal contamination in the final products.  
 
Figure 2.7. Naphthalene-containing anticancer agents.  
Our strategy to prepare highly substituted naphthalene derivatives began with the MBH reaction 
between 2-fluoro-5-nitrobenzaldehyde (47) and ethyl acrylate (94a) in the presence of 1,4-
diazabicyclo[2.2.2]octane (DABCO) to afford the desired MBH alcohol 95a in excellent yield 
(Scheme 2.5). 
 
Scheme 2.5. Synthesis of MBH alcohol 95a. 
Initially, the reaction was performed at 23 oC using equimolar amounts of 47, 94a, and DABCO. 
Extractive work-up, followed by 1H NMR analysis of the product, indicated the presence of 95a 
along with some other impurities. A clean conversion to the MBH alcohol was necessary to 
minimize purification steps enroute to our target naphthalene compounds. Previous methods 
involved the use of 94a as a solvent and reactant, however, column chromatography was still 
required to obtain pure adducts.148 Moreover, recent studies have shown that the use of a polar 

























CH3CN, 24 h, rt









good yield.149 Therefore, our current strategy involves the use of equimolar equivalents of 47 and 
94a with 1.2 equivalents of DABCO in a polar aprotic solvent (i.e. CH3CN). In addition, strong 
electron-withdrawing groups at the C5 position of the aromatic electrophile (Scheme 2.5) proved 
crucial in maximizing conversion to the corresponding adduct. Moreover, introduction of an 
electron-withdrawing atom, such as nitrogen in the aromatic ring, also resulted in a similar 
observation. Encouraged by the success of the reaction between 2-fluoro-5-nitrobenzaldehyde 
(47) and ethyl acrylate (94a) to afford adduct 95a, the scope of the reaction was extended to 
access new MBH alcohols from their respective electrophiles and activated alkenes in good to 
excellent yields (Table 3.3). 












CH3CN, 24-48 h, rt
47a-c
Z = NO2, CN, F, H
Y = CH, N
94a (X = CO2Et)
94b (X = CN)
95a-h
 Z                       Entry                         Alkene                MBH adduct/Yield
NO2                 Y = CH, 47                     94b                          95b, (98%)
 
CN                   Y = CH, 47a                   94b                          95c, (96%)
CN                   Y = CH, 47a                   94a                          95d, (94%)
F                      Y = CH, 47b                   94b                          95e, (92%)
F                      Y = CH, 47b                   94a                          95f,  (90%)
H                      Y = N,   47c                   94b                          95g,  (88%)
H                      Y = N,   47c                   94a                          95h,  (86%)
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An extensive review on the mechanism of the MBH reaction has been reported.76,142-150 Thus, a 
plausible mechanism pertaining to our work is demonstrated in Scheme 2.6. 
 
Scheme 2.6. A plausible mechanism for MBH alcohol formation. 
In order to successfully access the target naphthalene analogs, the MBH alcohols 95a-h were 
converted to their respective acetates 96a-h (Scheme 2.7 and Figure 2.8).  
 
Figure 2.8. Entries of synthesized MBH acetates.  
Generally, the MBH acetates are more reactive towards Michael addition-elimination reactions 















































































chloride or acetic anhydride in dichloromethane with pyridine as a base.139-148 Current 
esterification strategy for our study involved the use of 1.5 mmol of acetic anhydride (for 1 mmol 
of MBH alcohol) in the presence of a catalytic amount of trimethylsilyl trifluoromethanesulfonate 
(TMSOTf, 1 M; 20 µL).151 The optimum condition for this reaction proved to be dichloromethane 
at 0 oC and afforded quantitative yields of the desired MBH acetates in 30 minutes (Scheme 2.7). 
However, MBH alcohols derived from 2-fluoronicotinaldehyde required stoichiometric amounts 
(6 equivalents) of the TMSOTf catalyst added portionwise over 1 h. In this reaction, nitrogen in 
the aromatic ring may be nucleophilic enough to react with the TMSOTf. A plausible reaction 
mechanism for the acylation process is shown in Scheme 2.7.  
 
Scheme 2.7. Results and plausible mechanism for esterification process. 
The MBH alcohol reacts with TMSOTf to give the TMS-ether (ROTMS) and triflic acid (TfOH). 
The latter further reacts with the acetic anhydride to form an active acylating species (AcOTf), 
which could possibly be a mixed anhydride or the acylium ion. Reaction of the active species 
with the TMS-ether gives the target ester compound, regenerating the TMSOTf catalyst which 
reenters the catalytic cycle. The silicon is thought to play a crucial role in the last step by forming 
a pentacoordinate silicon species which could potentially facilitate the remarkable reaction rate.151 
Consequently, all MBH acetates 96a-h (Figure 2.8) were furnished in >98% yields after 






















where X = CN and Z = NO2
ROH       +     TMSOTf
Ac2O       +     TfOH
ROTMS   +     AcOTf
ROTMS   +     TfOH
AcOTf      +     AcOH









Conversely, refluxing MBH alcohol 95b in acetic anhydride for 8 h afforded an unexpected 
product 97 (Scheme 2.7), which could result from a possible allylic inversion process on the 
supposed MBH acetate due to high temperature. Two isomers (Z or E) were initially considered 
as possible outcomes for 97 (Scheme 2.7). However, the 1H NMR indicated the presence of only 
one isomer, thus an X-ray crystallographic analysis will be required to determine the absolute 
stereochemistry of the product. An allylic inversion is a type of bimolecular nucleophilic 
substitution (SN2') which involves a Michael addition of a nucleophile (-OAc) at the allylic 
double-bond carbon to eliminate a leaving group, all in a single step. Usually, this reaction goes 
with syn152 arrangement of the nucleophile and leaving group which, in this case, should afford 
the E-isomer. However, anti153 arrangement could also occur to give the Z-isomer (Scheme 2.8).  
 
Scheme 2.8. Plausible mechanisms for Michael addition-elimination (SN2'). 
Our target naphthalene compounds 98a-c were synthesized via a domino Michael addition-
elimination-SNAr reaction from 96b and active methylene compounds, e.g. ethyl cyanoacetate, 
ethyl nitroacetate and methyl phenylsulfonylacetate (Figure 2.9). The reaction proceeded at room 
temperature in the presence of K2CO3 in 1 mL of DMF to afford the desired products in good 
yields after extractive work-up, followed by silica gel column chromatography. Initially, the 
reaction was anticipated to give dihydronaphthalenes, however, the elimination of nontraditional 
leaving groups such as CO2Et, SO2Ph and NO2 afforded the aromatic naphthalene analogs. 
Although SO2Ph and NO2 are reasonable leaving groups, CO2Et is a relatively rare one. However, 































was made when MBH acetate 96h reacted with active methylene compounds under the same 
conditions (Figure 2.9). Quinoline derivatives 99a and 99b were formed instead of their dihydro 
analogs. A possible mechanism to these aromatic products is shown in Scheme 2.9.  
 
Figure 2.9. Entries of synthesized naphthalene and quinoline derivatives. 
 
 




96b (X = CN, Y = CH, Z = NO2)





1 h, rt R2
a   R2 = CN 
b   R2 = CO2Me










































































The strong electron-withdrawing NO2 group para to fluoride (F-) on the aromatic ring activates 
the ring towards a nucleophilic aromatic substitution (SNAr). Thus, the active methylene 
compound would first add to the ring resulting in a formation of a NO2-stabilized carbanion 
called a Meisenheimer complex (Scheme 2.9). Typically, the addition step is the rate determining 
(or slowest) step as aromaticity is lost, and thus the energy barrier is very high. However, since 
fluorine has a high negative inductive effect due to its electronegativity, resonance stabilization of 
the Meisenheimer complex is enhanced. Thus, the activation barrier of the addition step is 
lowered for addition to occur a bit faster. Subsequent elimination of the F- ion restores 
aromaticity while Michael addition leads to the formation of the dihydro intermediate, which 
upon elimination of the leaving group, results in the target aromatic product (Scheme 2.9). 
Encouraged by the success of the aromatic products, we forged on to synthesize analogs of 1,2-
dihydroquinoline 100a-e, 101a-c and 102a,e,f and 1,2-dihydro-1,8-naphthyridine 103b,e by 
reacting the MBH acetates 96b-d,g with excess of alkyl or aryl amines in 1 mL DMF at 50 oC for 
4 h (Figure 3.0). The product was formed with or without the addition of K2CO3. Subsequently, 
extractive work-up, followed by column chromatography, afforded the target compounds in good 
yields. A plausible mechanism to these dihydroheteroaromatics is also shown in Scheme 3.0. 
 






































X = CN, CO2Et
Y = CH, N




Figure 3.0. Entries of synthesized dihydroheteroaromatics. 
Conversely, an unexpected outcome was observed when acetate 96f reacted with phenethylamine 
in 1 mL DMF in the presence of K2CO3 at 90 oC. An oxidation product, ethyl 6-fluoro-4-oxo-1-
phenyethyl-1,4-dihydroquinoline-3-carboxylate (104e) was obtained after extractive work-up, 
followed by trituration with 5% ether/pentane (Scheme 3.1). X-ray analysis of a crystal of this 
product confirmed the structure (Figure 3.1). Since the reaction was run under nitrogen for the 
most part, the source of oxygen required to facilitate the oxidation process is unknown. However, 
this reaction could offer an efficient synthetic route to ciprofloxacin (a fluoroquinolone antibiotic) 




96b (X = CN, Y = CH, Z = NO2)
96c (X = CN, Y = CH, Z = CN)
96d (X = CO2Et, Y = CH, Z = CN)
96g (X = CN, Y = N, Z = H)
Y N
X
DMF, 50 oC, 4 h
with or without K2CO3 R
a   R = methyl 
b   R = n-hexyl
c   R = isobutyl 
d   R = benzyl
e   R = phenethyl


































































ring is not as activating, thus the SNAr reaction could possibly precede the conjugate Michael 
addition only at a higher temperature. This analogy was further confirmed when the reaction was 
performed at 50 oC to give an uncyclized ethyl-2-(2,5-difluorobenzoyl) acrylate 105 as shown in 
Scheme 3.1. Although the SNAr reaction did not occur for obvious reasons, the conjugate addition 
and oxidation steps still proceeded to give the uncyclized product. The result seems to show that 
the Michael addition occurs first at a lower temperature.  
 
Scheme 3.1. Unexpected synthesis of 4-oxo-1,4-dihydroquinolines. 
 
 



















104a,    R = CH3
104c,    R = isobutyl
104d,    R = benzyl
104e,    R = phenethyl























2.2.4.1.  Conclusions 
We have studied the formation of naphthalenes and a wide range of heterocyclic compounds from 
Morita-Baylis-Hillman (MBH) acetates by a domino Michael addition-elimination-SNAr reaction. 
The MBH acetates were prepared in quantitative yields under mild conditions without allylic 
rearrangement. The use of TMSOTf as a catalyst facilitated the acylation process to give 
unrearranged product in quantitative yield in 30 minutes. The reaction of MBH acetates with 
active methylene compounds involved the elimination of several nontraditional leaving groups to 
afford naphthalenes and quinolines. Reaction with 1o alkyl or aromatic amines afforded the 
dihydroheteroaromatic compounds in good yields. These heterocycles include dihydroquinolines 
and dihydronaphthyridines. In all cases, the target naphthalene and heterocycle were formed in 
high yields. In addition, difluorosubstituted MBH acetates reacted with alkyl or aryl amines at 
higher temperature to afford 4-oxo-1,4-dihydroquinolines upon efficient oxidation. These 
oxidation products still formed in good yields even after all controls to exclude oxygen from the 
reaction system were performed. While the mechanism for this reaction is unclear, these 4-oxo-
1,4-dihydroquinolines are reminiscent of fluoroquinolone antibiotics and other related active 
compounds.  
2.3. Chemistry 
General Methods: All reactions were run under dry nitrogen in oven-dried glassware. Reactions 
were monitored by thin layer chromatography on silica gel GF plates (Analtech, No. 21521). 
Preparative separations were performed by one of the following methods: (1) preparative thin 
layer chromatography (PTLC) on 20-cm × 20-cm silica gel GF plates (Analtech, No. 02015) or 
(2) column chromatography on silica gel (grade 62, 60–200 mesh) containing UV-active 
phosphor (Sorbent Technologies, No. UV-05) packed into quartz columns. Band elution for all 
chromatographic methods was monitored using a hand-held UV lamp. Melting points were 
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uncorrected. FT-IR spectra were run as thin films on NaCl disks or as nujol mulls. Unless 
otherwise indicated, 1H and 13C NMR spectra were measured in CDCl3 using (CH3)4Si as the 
internal standard; coupling constants (J) are given in Hertz. Low-resolution mass spectra (electron 
impact/direct probe) were obtained at 70 eV. Elemental analyses (±0.4%) were performed by 
Atlantic Microlabs, Inc., Norcross, GA 30071. 
2.3.1. 1-Aryl-5-nitro-1H-indazoles and a general sequential route to 1-aryl-1H-indazoles. 
Indazoles from 2'-fluoro-5'-nitroacetophenone (46) or 2-fluoro-5-nitrobenzaldehyde (47) 
with NH2NH2·H2O. 
To a stirred solution of 46 or 47 (1.0 mmol) in DMF (5 mL) at 23 oC was added NH2NH2·H2O 
(3.0 mmol for 46, 2.0 mmol for 47). The solution was stirred at 23 oC for 2 h at which time TLC 
(20% EtOAc in hexanes) indicated complete consumption of the starting carbonyl compound. 
The crude mixture was added to water and extracted with EtOAc (2 ´ 15 mL). The combined 
organic layers were washed with water and saturated aq NaCl, dried (MgSO4), filtered, and 
concentrated under vacuum to give the pure indazole products. 
3-Methyl-5-nitro-1H-indazole (48).  Yield: 173 mg (0.98 mmol, 98%) as a yellow solid; m.p. 
213-214 oC; IR: 1517, 1332 cm-1; 1H NMR (DMSO-d6): δ 13.1 (br s, 1H), 8.79 (s, 1H), 8.18 (d, J 
= 9.1 Hz, 1H), 7.64 (d, J = 9.1 Hz, 1H), 2.59 (s, 3H); 13C NMR (DMSO-d6): δ 145.4, 143.1, 
141.3, 121.9, 121.3, 118.8, 111.2, 12.1; MS: m/z 177 (M+). Anal. Calcd for C8H7N3O2: C, 54.24; 
H, 3.98; N, 23.72. Found: C, 54.29; H, 4.01; N, 23.59. 
5-Nitro-1H-indazole (49). Yield: 147 mg (0.90 mmol, 90%) as a tan solid; m.p. 207-208 oC; IR: 
1534, 1341 cm-1; 1H NMR (DMSO-d6): δ 13.7 (br s, 1H), 8.84 (s, 1H), 8.41 (s, 1H), 8.19 (d, J = 
9.0 Hz, 1H), 7.74 (d, J = 9.0 Hz, 1H); 13C NMR (DMSO-d6): δ 142.3, 142.0, 137.2, 122.5, 121.3, 
119.3, 111.5; MS: m/z 163 (M+). Anal. Calcd for C7H5N3O2: C, 51.54; H, 3.09; N, 25.76. Found: 




Indazoles from 46 or 47 with ArNHNH2·HCl. Method A. Representative two-step 
procedure. 
To a stirred solution of the carbonyl compound (1.0 mmol) in DMF (5 mL) at 50 oC (oil bath) 
was added ArNHNH2·HCl (3.0 mmol for 46, 2.0 mmol for 47) and the solution was stirred until 
TLC (20% EtOAc in hexanes) indicated complete conversion (ca 2 h). The crude reaction 
mixture was added to water and extracted with EtOAc (2 ´ 15 mL). The combined organic layers 
were washed with water and saturated aq NaCl, dried (MgSO4), filtered, and concentrated under 
vacuum to give the crude hydrazones. The crude products were stirred with 20% ether/pentane 
for 1 h, filtered and dried to give arylhydrazones 50 and 51. Characterization data for these 
materials are given in the ESI. 
To a stirred solution of the arylhydrazone (1.00 mmol) in DMF (5 mL) at 90 oC (oil bath) was 
added anhydrous K2CO3 (3.0 mmol) and the mixture was stirred for the time indicated in Table 1. 
The reaction mixture was added to water, extracted with EtOAc, dried (MgSO4), filtered, and 
concentrated under vacuum to afford the crude product. Indazoles from 46 were stirred with 20% 
ether in pentane, filtered and dried, while those from 47 were purified by silica gel 
chromatography on a 20 cm ´ 2 cm column eluted with increasing concentrations of EtOAc in 
hexanes. Yields as well as physical and spectral data are given below. 
Indazoles from 46 or 47 with ArNHNH2·HCl. Method B. Representative one-pot procedure. 
To a stirred solution of the carbonyl compound (1.0 mmol) in DMPU (5 mL) were added 
powdered 4Å molecular sieves (30 wt% relative to the carbonyl substrate), ArNHNH2·HCl (3.0 
mmol for 46, 2.0 mmol for 47), and K2CO3 (3.0 mmol for 46, 2.0 mmol for 47). For 46, all 
reagents were placed in the flask and heated to 90 oC; for 47, the hydrazone was allowed to form 
at 90 oC (1.5 h) before K2CO3 was added. The reaction was stirred at 90 oC for the time indicated 




3-Methyl-1-phenyl-5-nitro-1H-indazole (52a).  Yield: 240 mg, (0.95 mmol, 95%) as a brown 
solid; m.p. 115-117 oC; IR: 1516, 1336 cm-1; 1H NMR (DMSO-d6): δ 8.89 (d, J = 2.2 Hz, 1H), 
8.28 (dd, J = 9.3, 2.2 Hz, 1H), 7.93 (d, J = 9.3 Hz, 1H), 7.77 (d, J = 7.8 Hz, 2H), 7.62 (t, J = 7.7 
Hz, 2H), 7.46 (t, J = 7.4 Hz, 1H), 2.69 (s, 3H); 13C NMR (DMSO-d6): δ 147.3, 142.2, 141.1, 
139.2, 130.3, 127.8, 124.4, 122.9, 122.8, 119.3, 111.7, 12.1; MS: m/z 253 (M·). Anal. Calcd for 
C14H11N3O2: C, 66.40; H, 4.38; N, 16.59. Found: C, 66.33; H, 4.34; N, 16.42. 
1-(2-Methoxyphenyl)-3-methyl-5-nitro-1H-indazole (52b).  Yield: 232 mg (0.82 mmol, 82%) 
as a light brown solid; m.p. 128-130 oC; IR: 2838, 1519, 1338 cm-1; 1H NMR (DMSO-d6): δ 8.86 
(s, 1H), 8.21 (d, J = 9.3 Hz, 1H), 7.55 (t, J = 8.0 Hz, 1H), 7.49 (d, J = 7.8 Hz, 1H), 7.38-7.28 
(overlapping signals, 2H), 7.16 (t, J = 7.7 Hz, 1H), 3.78 (s, 3H), 2.66 (s, 3H); 13C NMR (DMSO-
d6): δ 154.0, 146.6, 143.0, 141.9, 130.8, 128.6, 127.1, 123.2, 122.0, 121.4, 119.0, 113.4, 112.2, 
56.2, 12.1; MS: m/z 283 (M+). Anal. Calcd for C15H13N3O3: C, 63.60; H, 4.63; N, 14.83. Found: 
C, 63.49; H, 4.61; N, 14.88. 
1-(3-Methoxyphenyl)-3-methyl-5-nitro-1H-indazole (52c).  Yield: 229 g (0.81 mmol, 81%) as 
a light brown solid; m.p. 105-106 oC; IR: 2836, 1518, 1338 cm-1; 1H NMR (DMSO-d6): δ 8.90 (s, 
1H), 8.29 (d, J = 9.3 Hz, 1H), 7.96 (d, J = 9.3 Hz, 1H), 7.52 (t, J = 8.1 Hz, 1H), 7.34 (d, J = 8.1 
Hz, 1H), 7.28 (s, 1H), 7.04 (d, J = 8.3 Hz, 1H); 13C NMR (DMSO-d6): δ 160.6, 147.3, 142.3, 
141.2, 140.3, 131.2, 124.4, 122.9, 119.3, 114.9, 113.7, 111.9, 108.6, 56.0, 12.1; MS: m/z 283 
(M+). Anal. Calcd for C15H13N3O3: C, 63.60; H, 4.63; N, 14.83. Found:  C, 63.52; H, 4.55; N, 
14.71. 
1-(4-Methoxyphenyl)-3-methyl-5-nitro-1H-indazole (52d).  Yield: 266 mg (0.94 mmol, 94%) 
as a tan solid; m.p. 159-160 oC. IR: 2836, 1514, 1346 cm-1; 1H NMR (DMSO-d6): δ 8.88 (d, J = 
2.2 Hz, 1H), 8.26 (dd, J = 9.3, 2.2 Hz, 1H), 7.79 (d, J = 9.3 Hz, 1H), 7.65 (d, J = 8.1 Hz, 2H), 
7.15 (d, J = 8.1 Hz, 2H), 3.85 (s, 3H), 2.69 (s, 3H); 13C NMR (DMSO-d6): δ 158.9, 146.7, 142.0, 
141.2, 132.2, 124.8, 123.9, 122.5, 119.3, 1153, 111.4, 56.0, 12.1; MS: m/z 283 (M+). Anal. Calcd 




1-(4-Bromophenyl)-3-methyl-5-nitro-1H-indazole (52e).  Yield: 314 mg, (0.95 mmol, 95%) as 
a tan solid; m.p. 202-203 oC; IR: 1512, 1345 cm-1; 1H NMR (DMSO-d6): δ 8.90 (d, J = 2.2 Hz, 
1H), 8.31 (dd, J = 9.2, 2.2 Hz, 1H), 7.96 (d, J = 9.2 Hz, 1H), 7.80 (d, J = 8.8 Hz, 2H), 7.75 (d, J = 
8.8 Hz, 2H), 2.69 (s, 3H); 13C NMR (DMSO-d6): δ 147.7, 142.4, 141.1, 138.5, 133.1, 124.7, 
124.6, 123.0, 120.1, 119.3, 111.8, 12.1; MS: m/z 331 (M+). Anal. Calcd for C14H10BrN3O2: C, 
50.62; H, 3.03; N, 12.65. Found: C, 50.44; H, 2.99; N, 12.73. 
1-(3-Chlorophenyl)-3-methyl-5-nitro-1H-indazole (52f).  Yield: 250 mg, (0.87 mmol, 87%) as 
a tan solid; m.p. 135-136 oC; IR: 1517, 1339 cm-1; 1H NMR (DMSO-d6): δ 8.89 (d, J = 2.2 Hz, 
1H), 8.31 (dd, J = 9.3, 2.2 Hz, 1H), 7.98 (d, J = 9.3 Hz, 1H), 7.83 (t, J = 2.2 Hz, 1H), 7.78 (d, J = 
8.4 Hz, 1H), 7.64 (t, J = 8.1 Hz, 1H), 7.52 (d, J = 8.0 Hz, 1H), 2.69 (s, 3H); 13C NMR (DMSO-
d6): δ 146.8, 141.1, 139.3, 133.4, 130.8, 126.4, 123.6, 122.0, 121.4, 120.1, 118.2, 110.9; MS: m/z 
287 (M+). Anal. Calcd for C14H10ClN3O2: C, 58.45; H, 3.50; N, 14.61. Found: C, 58.58; H, 3.59; 
N, 14.53. 
1-(4-Chlorophenyl)-3-methyl-5-nitro-1H-indazole (52g).  Yield: 267 mg (0.93 mmol, 93%) as 
a tan solid; m.p. 217-218 oC; IR: 1511, 1339 cm-1; 1H NMR (DMSO-d6): δ 8.91 (d, J = 2.2 Hz, 
1H), 8.31 (dd, J = 9.3, 2.2 Hz, 1H), 7.95 (d, J = 9.3 Hz, 1H), 7.82 (d, J = 8.7 Hz, 2H), 7.67 (d, J = 
8.7 Hz, 2H), 2.69 (s, 3H); 13C NMR (DMSO-d6): δ 147.7, 1424, 141.1, 138.1, 131.8, 130.2, 
124.6, 124.5, 123.0, 119.4, 111.8, 12.1; MS: m/z 287 (M+). Anal. Calcd for C14H10ClN3O2: C, 
58.45; H, 3.50; N, 14.61. Found: C, 58.42; H, 3.49; N, 14.48. 
1-(2,4-Dichlorophenyl)-3-methyl-5-nitro-1H-indazole (52h). Yield: 257 mg (0.80 mmol, 80%); 
m.p. 144-145 oC; IR: 1516, 1338 cm-1; 1H NMR (DMSO-d6): δ 8.92 (d, J = 2.1 Hz, 1H), 8.27 (dd, 
J = 9.2, 2.1 Hz, 1H), 8.01 (d, J = 2.2 Hz, 1H), 7.74 (d, J = 8.5 Hz, 1H), 7.69 (dd, J = 8.5, 2.2 Hz, 
1H), 7.44 (d, J = 9.2 Hz, 1H), 2.68 (s, 3H); 13C NMR (DMSO-d6): δ 147.5, 143.1, 142.4, 135.3, 
135.0, 132.0, 131.5, 130.7, 129.3, 123.5, 122.8, 119.3, 111.6, 12.1; MS: m/z 321 (M+). Anal. 
Calcd for C14H9Cl2N3O: C, 52.20; H, 2.82; N, 13.04. Found: C, 52.11; H, 2.91; N, 13.09. 
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3-Methyl-5-nitro-1-(3-(trifluoromethyl)phenyl)-1H-indazole (52i). Yield: 282 mg (0.88 mmol, 
88%) as a white solid; m.p. 112-113 oC; IR: 1520, 1339 cm-1; 1H NMR (DMSO-d6): δ 8.90 (s, 
1H), 8.32 (d, J = 9.3 Hz, 1H), 8.13 (d, J = 7.8 Hz, 1H), 8.07 (s, 1H), 7.99 (d, J = 9.3 Hz, 1H), 
7.90-7.77 (complex, 2H), 2.70 (s, 3H); 13C NMR (DMSO-d6): δ 148.0, 142.5, 141.1, 139.8, 131.6, 
130.9 (q, J = 32.6 Hz), 126.2, 124.8, 124.2 (q, J = 272.6 Hz), 124.0 (q, J = 6.7 Hz), 123.1, 119.2 
(2C), 111.8, 12.0; MS: m/z 321 (M+). Anal. Calcd for C15H10F3N3O2: C, 56.08; H, 3.14; N, 13.08. 
Found: C, 56.02; H, 3.18; N, 13.11. 
3-Methyl-5-nitro-1-(4-(trifluoromethyl)phenyl)-1H-indazole (52j). Yield: 225 mg, (0.70 
mmol, 70%) as a white solid; m.p. 167-168 oC; IR: 1525, 1331 cm-1; 1H NMR (DMSO-d6): δ 8.89 
(d, J = 2.2 Hz, 1H), 8.31 (dd, J = 9.3, 2.2 Hz, 1H), 8.05 (d, J = 9.3 Hz, 1H), 8.02 (d, J = 8.6 Hz, 
2H), 7.95 (d, J = 8.6 Hz, 2H), 2.69 (s, 3H); 13C NMR (DMSO-d6): δ 148.3, 142.6, 142.3, 141.1, 
127.4 (q, J = 4.0 Hz), 127.1, 125.1, 124.5 (q, J = 269.1 Hz), 123.2, 122.6, 119.2, 112.0, 12.1; MS: 
m/z 321 (M+). Anal. Calcd for C15H10F3N3O2: C, 56.08; H, 3.14; N, 13.08. Found: C, 55.98; H, 
3.19; N, 13.04. 
1-(4-Cyanophenyl)-3-methyl-5-nitro-1H-indazole (52k). Yield: 222 mg (0.80 mmol, 80%) as a 
brown solid; m.p. ≥194 oC (sub), ≥ 260 oC (dec); IR: 2226, 1516, 1338 cm-1; 1H NMR (DMSO-
d6): δ 8.93 (d, J = 2.2 Hz, 1H), 8.35 (dd, J = 9.1, 2.2 Hz, 1H), 8.11 (d, J = 9.1 Hz, 1H), 8.08 (d, J 
= 8.9 Hz, 2H), 8.04 (d, J = 8.9 Hz, 2H), 2.71 (s, 3H); 13C NMR (DMSO-d6): δ 148.7, 142.8, 
142.7, 141.1, 134.5, 125.3, 123.3, 122.6, 119.3, 118.9, 112.3, 109.4, 12.1; MS: m/z 278 (M+). 
Anal. Calcd for C15H10N4O2: C, 64.74; H, 3.62; N, 20.13. Found: C, 64.69; H, 3.67; N, 20.06. 
4-(3-Methyl-5-nitro-1H-indazol-1-yl)benzenesulfonamide (52l). Yield: l249 mg (0.75 mmol, 
75%); m.p. 265-266 oC; IR: 3422, 1515, 1331, 1320, 1123 cm-1; 1H NMR (DMSO-d6): δ 8.92 (d, 
J = 2.2 Hz, 1H), 8.34 (dd, J = 9.3, 2.2 Hz, 1H), 8.09 (d, J = 9.3 Hz, 1H), 8.04 (d, J = 8.4 Hz, 2H), 
8.01 (d, J = 8.4 Hz, 2H), 7.51 (s, 2H), 2.71 (s, 3H); 13C NMR (DMSO-d6): δ 148.2, 142.54, 
145.50, 141.6, 141.0, 127.9, 125.0, 123.1, 122.3, 119.2, 112.0, 12.0; MS: m/z 332 (M+). Anal. 
Calcd for C14H12N4O4S: C, 50.60; H, 3.64; N, 16.86. Found: C, 50.70; H, 3.63; N, 16.78. 
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4-(3-Methyl-5-nitro-1H-indazol-1-yl)benzoic acid (52m). Yield: 208 mg (0.70 mmol, 70%) as 
a tan solid; m.p. ≥240 oC (sub), ≥ 320 oC (dec). IR: 3441-2352, 1697, 1514, 1346 cm-1; 1H NMR 
(DMSO-d6): δ 12.8 (br s, 1H), 8.93 (d, J = 2.2 Hz, 1H), 8.34 (dd, J = 9.3, 2.2 Hz, 1H), 8.16 (d, J 
= 8.6 Hz, 2H), 8.09 (d, J = 9.3, Hz, 1H), 7.95 (d, J = 8.6 Hz, 2H), 2.71 (s, 3H); 13C NMR 
(DMSO-d6): δ 167.1, 148.2, 142.6, 142.5, 141.1, 131.5, 125.0, 123.1, 122.0, 119.4, 119.3, 112.2, 
12.1; MS: m/z 297 (M+). Anal. Calcd for C15H11N3O4: C, 60.61; H, 3.73; N, 14.14. Found: C, 
60.53; H, 3.68; N, 14.22. 
1-Phenyl-5-nitro-1H-indazole (53a). Yield: 172 mg (0.72 mmol, 72%) as a tan solid; m.p. 169-
170 oC; IR: 1534, 1341 cm-1; 1H NMR (DMSO-d6): δ 8.95 (s, 1H), 8.70 (s, 1H), 8.30 (d, J = 9.3 
Hz, 1H), 7.98 (d, J = 9.3 Hz, 1H), 7.81 (d, J = 7.9 Hz, 2H), 7.65 (d, J = 7.7 Hz, 2H), 7.51 (t, J = 
7.4 Hz, 1H); 13C NMR (DMSO-d6): δ 142.8, 140.5, 139.1, 138.9, 130.3, 128.2, 124.8, 123.3, 
122.7, 119.9, 111.9; MS: m/z 239 (M+). Anal. Calcd for C13H9N3O2: C, 65.27; H, 3.79; N, 17.56. 
Found: C, 65.16; H, 3.77; N, 17.57. 
1-(2-Methoxyphenyl)-5-nitro-1H-indazole (53b). This reaction stopped at the hydrazone stage 
and did not give an indazole. 
1-(3-Methoxyphenyl)-5-nitro-1H-indazole (53c). Yield: 180 mg (0.67 mmol, 67%) as a yellow 
solid; m.p. 127-128 oC; IR: 1516, 1344 cm-1; 1H NMR (DMSO-d6): δ 8.94 (s, 1H), 8.69 (s, 1H), 
8.30 (d, J = 9.2 Hz, 1H), 8.01 (d, J = 9.3 Hz, 1H), 7.55 (t, J = 8.0 Hz, 1H), 7.37 (d, J = 8.0 Hz, 
1H), 7.32 (s, 1H), 7.08 (d, J = 8.2 Hz, 1H), 3.87 (s, 3H); 13C NMR (DMSO-d6): δ 160.6, 142.8, 
140.5, 140.2, 130.8, 131.2, 124.8, 122.7, 119.8, 115.3, 114.1, 112.0, 109.0, 56.0; MS: m/z 269 
(M+). Anal. Calcd for C14H11N3O3: C, 62.45; H, 4.12; N, 15.61. Found: C, 62.37; H, 4.06; N, 
15.74. 
1-(4-Methoxyphenyl)-5-nitro-1H-indazole (53d). Yield: 199 mg (0.74 mmol, 74%) as a light 
yellow solid; m.p. 181-182 oC; IR: 1516, 1342 cm-1; 1H NMR (DMSO-d6): δ 8.92 (d, J = 2.2 Hz, 
1H), 8.64 (s, 1H), 8.27 (d, J = 9.2, 2.2 Hz, 1H), 7.84 (d, J = 9.2 Hz, 1H), 7.68 (d, J = 8.7 Hz, 2H), 
7.18 (d, J = 8.7 Hz, 2H), 3.86 (s, 3H); 13C NMR (DMSO-d6): δ 159.2, 142.6, 141.6, 138.3, 132.1, 
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125.2, 124.3, 122.4, 119.8, 115.6, 111.6, 56.2, ; MS: m/z 269 (M+). Anal. Calcd for C14H11N3O3: 
C, 62.45; H, 4.12; N, 15.61. Found: C, 62.41; H, 4.07; N, 15.56. 
1-(4-Bromophenyl)-5-nitro-1H-indazole (53e). Yield: 222 mg (0.70 mmol, 70%) as a tan solid; 
m.p. 169-170 oC; IR: 1511, 1348 cm-1; 1H NMR (DMSO-d6): δ 8.95 (s, 1H), 8.71 (s, 1H), 8.32 (d, 
J = 9.3 Hz, 1H), 8.01 (d, J = 9.2 Hz, 1H), 7.84 (d, J = 8.4 Hz, 2H), 7.79 (d, J = 8.4 Hz, 2H); 13C 
NMR (DMSO-d6): δ 142.9, 140.4, 139.2, 138.4, 133.2, 125.2, 125.0, 122.8, 120.7, 119.9, 111.9; 
MS: m/z 317 (M+). Anal. Calcd for C13H8BrN3O2: C, 49.08; H, 2.53; N, 13.21. Found: C, 48.97; 
H, 2.59; N, 13.25. 
1-(3-Chlorophenyl)-5-nitro-1H-indazole (53f). Yield: 164 mg (0.60 mmol, 60%) as an off-
white solid; m.p. 143-144 oC; IR: 1514, 1346 cm-1; 1H NMR (DMSO-d6): δ 8.95 (s, 1H), 8.72 (s, 
1H), 8.32 (d, J = 9.2 Hz, 1H), 8.03 (d, J = 9.2 Hz, 1H), 7.88 (s, 1H), 7.82 (d, J = 8.0 Hz, 1H), 7.67 
(t, J = 8.1 Hz, 1H), 7.57 (d, J = 8.2 Hz, 1H); 13C NMR (DMSO-d6): δ 142.9, 140.5, 140.3, 139.4. 
134.6, 132.0, 128.0, 125.0, 123.0, 122.9, 121.7, 119.8, 112.0; MS: m/z 273 (M+). Anal. Calcd for 
C13H8ClN3O2: C, 57.05; H, 2.95; N, 15.35. Found: C, 56.96; H, 3.00; N, 15.29. 
1-(4-Chlorophenyl)-5-nitro-1H-indazole (53g). Yield: 191 mg (0.70 mmol, 70%) as a light 
yellow solid; m.p. 179-180 oC; IR: 1509, 1343 cm-1; 1H NMR (DMSO-d6): δ 8.95 (d, J = 2.2 Hz, 
1H), 8.71 (s, 1H), 8.31 (dd, J = 9.3 , 2.2 Hz, 1H), 7.99 (d, J = 9.3 Hz, 1H), 7.85 (d, J = 8.6 Hz, 
2H), 7.70 (d, J = 8.6 Hz, 2H); 13C NMR (DMSO-d6): δ 142.9, 140.5, 139.2, 138.0, 132.4, 130.3, 
124.9, 122.8, 119.9, 111.9 (one carbon unresolved); MS: m/z 273 (M+). Anal. Calcd for 
C13H8ClN3O2: C, 57.05; H, 2.95; N, 15.35. Found: C, 57.12; H, 2.97; N, 15.33. 
1-(2,4-Dichlorophenyl)-5-nitro-1H-indazole (53h). Yield: 215 mg (0.70 mmol, 70%) as a light 
pink solid; m.p. 101-102 oC. IR: 1517, 1344 cm-1; 1H NMR (DMSO-d6): δ 8.96 (s, 1H), 8.72 (s, 
1H), 8.29 (d, J = 9.2 Hz, 1H), 8.03 (s, 1H), 7.78 (d, J = 8.3 Hz, 1H), 7.73 (d, J = 8.3 Hz, 1H), 7.52 
(d, J = 9.2 Hz, 1H); 13C NMR (DMSO-d6): δ 143.0, 142.3, 139.2, 135.7, 135.0, 132.2, 131.6, 
130.8, 129.3, 123.9, 122.7, 119.8, 111.7; MS: m/z 307 (M+). Anal. Calcd for C13H7Cl2N3O2: C, 
50.68; H, 2.29; N, 13.64. Found: C, 50.67; H, 2.34; N, 13.53. 
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1-(3-(Trifluoromethyl)phenyl)-5-nitro-1H-indazole (53i).  Yield: 190 mg (0.62 mmol, 62%) as 
a light yellow solid; m.p. 118-119 oC. IR: 1513, 1347 cm-1; 1H NMR (DMSO-d6): δ 8.97 (s, 1H), 
8.75 (s, 1H), 8.35 (d, J = 9.2 Hz, 1H), 8.18 (d, J = 7.2 Hz, 1H), 8.13 (s, 1H), 8.05 (d, J = 9.3 Hz, 
1H), 7.94-7.85 (complex, 2H); 13C NMR (DMSO-d6): δ 143.0, 140.6, 139.8, 139.6, 131.7, 131.0 
(q, J = 32.7 Hz), 126.9, 125.2, 124.6 (q, J = 4.3 Hz), 124.1 (q, J = 272.6 Hz), 123.0, 119.8 (q, J = 
4.9 Hz), 112.0 (one carbon unresolved); MS: m/z 307 (M+). Anal. Calcd for C14H8F3N3O2: C, 
54.73; H, 2.62; N, 13.68. Found: C, 54.66; H, 2.64; N, 13.57. 
1-(4-(Trifluoromethyl)phenyl)-5-nitro-1H-indazole (53j).  Yield: 209 mg (0.68 mmol, 68%) as 
a light yellow solid; m.p. 151-152 oC. IR: 1519, 1327 cm-1; 1H NMR (DMSO-d6): δ 8.95 (s, 1H), 
8.76 (s, 1H), 8.34 (d, J = 9.5 Hz, 1H), 8.11 (obscured d, J = 9.5 Hz, 1H), 8.08 (d, J = 8.5 Hz, 2H), 
8.00 (d, J = 8.5 Hz, 2H); 13C NMR (DMSO-d6): δ 143.1, 142.3, 140.5, 139.8, 127.9, (q, J = 32.3 
Hz), 127.5 (q, J = 3.5 Hz), 125.4, 124.4 (q, J = 273.7 Hz), 123.3, 123.1, 119.9, 112.1; MS: m/z 
307 (M+). Anal. Calcd for C14H8F3N3O2: C, 54.73; H, 2.62; N, 13.68. Found: C, 54.68; H, 2.61; 
N, 13.64. 
1-(4-Cyanophenyl)-5-nitro-1H-indazole (53k). Yield: 158 mg (0.60 mmol, 60%) as a light 
yellow solid; m.p. 250-251 oC. IR: 2227, 1512, 1344 cm-1; 1H NMR (DMSO-d6): δ 8.97 (d, J = 
2.2 Hz, 1H), 8.78 (s, 1H), 8.36 (dd, J = 9.3, 2.2 Hz, 1H), 8.15 (d, J = 9.3 Hz, 1H), 8.12 (d, J = 8.8 
Hz, 2H), 8.07 (d, J = 8.8 Hz, 2H); 13C NMR (DMSO-d6): δ 142.1, 141.6, 139.4, 139.1, 133.6, 
124.5, 122.1, 120.0, 118.9, 117.7, 111.3, 109.0; MS: m/z 264 (M+). Anal. Calcd for C14H8N4O2: 
C, 63.64; H, 3.05; N, 21.20. Found: C, 63.55; H, 3.09; N, 21.08. 
4-(5-Nitro-1H-indazol-1-yl)benzenesulfonamide (53l). Yield: 159 mg (0.50 mmol, 50%); m.p. 
237-238 oC; IR: 3329, 3241, 1512, 1339 cm-1; 1H NMR (DMSO-d6): δ 8.97 (d, J = 2.2 Hz, 1H), 
8.76 (s, 1H), 8.35 (dd, J = 9.3, 2.2 Hz, 1H), 8.13 (d, J = 9.3 Hz, 1H), 8.06 (s, 4H), 7.53 (br s, 2H); 
13C NMR (DMSO-d6): δ 143.1, 141.60, 141.55, 140.5, 139.8, 128.0, 125.3,123.1, 122.2, 119.9, 
112.2; MS: m/z 318 (M+). Anal. Calcd for C13H10N4O4S: C, 49.05; H, 3.17; N, 17.60. Found: C, 
49.11; H, 3.16; N, 17.66. 
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4-(5-Nitro-1H-indazol-1-yl)benzoic acid (53m). This product was formed only using the two-
step procedure.  Yield: 142 mg (0.50 mmol, 50%) as a brown product; m.p. 158-159 oC; IR: 
3395-2372, 1694, 1518, 1345 cm-1; 1H NMR (DMSO-d6): δ 13.3 (br s, 1H), 8.97 (d, J = 2.2 Hz, 
1H), 8.76 (s, 1H), 8.35 (dd, J = 9.3, 2.2 Hz , 1H), 8.18 (d, J = 8.4 Hz, 2H), 8.13 (d, J = 9.3 Hz, 
1H), 7.98 (d, J = 8.4 Hz, 2H); 13C NMR (DMSO-d6): δ 167.0, 143.0, 142.5, 140.4, 139.7, 131.5, 
129.8, 125.3, 123.0, 122.5, 119.9, 112.2; MS: m/z 283 (M+). Anal. Calcd for C14H9N3O4: C, 
59.37; H, 3.20; N, 14.84. Found: C, 59.32; H, 3.23; N, 14.75. 
Representative procedure for the general indazole synthesis. 
To a stirred solution of the carbonyl compound (54, 55 or 56, 1.0 mmol) in DMPU (5 mL) were 
added powdered 4Å molecular sieves (30 wt% relative to the carbonyl substrate) and 
ArNHNH2·HCl (1.5 mmol).  The mixture was heated at 90 oC (oil bath) for 1.5 h at which time 
CuI (0.2 mmol) and K2CO3 (2.5 mmol) were added and heating was continued at this temperature 
for 16 h. The crude reaction mixture was cooled to 23 oC and filtered through a Celite® pad. The 
pad was rinsed with ether (2 ´ 20 mL) and the combined filtrate was washed with water (25 mL), 
saturated NaCl (25 mL), dried (MgSO4), filtered, and concentrated under vacuum. The products 
were purified by silica gel chromatography using increasing concentrations of EtOAc in hexanes. 
Yields as well as physical and spectral data are given below. 
3-Methyl-1-phenyl-1H-indazole (57a). Yield: 169 mg (0.81 mmol, 81%) as tan solid; m.p. 72-
73  oC (lit86 m.p. 73-74 oC);  IR: 1597, 1505 cm-1; 1H NMR (CDCl3): δ 7.75-7.96 (complex, 4H), 
7.52 (t, J = 7.3 Hz, 2H), 7.42 (t, J = 7.5 Hz, 1H), 7.32 (t, J = 7.3 Hz, 1H), 7.21 (t, J = 7.5 Hz, 1H), 
2.65 (s, 3H); 13C NMR (CDCl3): δ 144.0, 140.3, 139.5, 129.4, 127.1, 126.1, 124.9, 122.4, 120.8, 
120.6, 110.3, 12.0; MS: m/z 208 (M+). Anal. Calcd for C14H12N2: C, 80.74; H, 5.81; N, 13.45. 




1-(4-Methoxyphenyl)-3-methyl-1H-indazole (57d). Yield:   207 mg (0.87 mmol, 87%) as a 
yellow oil;  IR: 2845, 1517 cm-1; 1H NMR (CDCl3): δ 7.72 (d, J = 8.1 Hz, 1H), 7.60 (d, J = 7.7 
Hz, 1H), 7.59 (d, J = 8.9 Hz, 2H), 7.39 (t, J = 7.4 Hz, 1H), 7.18 (t, J = 7.5 Hz, 1H), 7.04 (d, J = 
8.9 Hz, 2H), 3.87 (s, 3H), 2.65 (s, 3H); 13C NMR (CDCl3): δ 158.1, 143.8, 139.7, 133.5, 126.9, 
124.4, 124.3, 120.50, 120.47, 114.6, 110.1, 56.6, 11.9; MS: m/z 238 (M+). Anal. Calcd for 
C15H14N2O: C, 75.61; H, 5.92; N, 11.76. Found: C, 75.35; H, 6.18; N, 11.25. 
4-(3-Methyl-1H-indazol-1-yl)benzonitrile (57l). Yield: 198 mg (0.85 mmol, 85%) as tan solid; 
m.p. 124-126 oC; IR: 2224, 1604, 1517 cm-1; 1H NMR (CDCl3): δ 7.91 (d, J = 8.6 Hz, 2H), 7.80 
(d, J = 8.6 Hz, 2H), 7.78 (d, J = 8.4 Hz, 1H), 7.75 (d, J = 7.9 Hz, 1H), 7.50 (t, J = 8.3 Hz, 1H), 
7.28 (t, J = 7.4 Hz, 1H), 2.65 (s, 3H); 13C NMR (CDCl3): δ 146.1, 143.9, 139.1, 133.5, 128.0, 
125.9, 121.9, 121.3, 121.1, 118.7, 110.5, 108.5, 12.0; MS: m/z 233 (M+). Anal. Calcd for 
C15H11N3: C, 77.23; H, 4.75; N, 18.01. Found: C, 77.35; H, 4.31; N, 18.32. 
1-Phenyl-1H-indazole (58a). Yield: 149 mg (0.77 mmol, 77%) as off-white solid; m.p. 77-78 oC 
(lit88 m.p. 78 oC); IR: 1595, 1500 cm-1; 1H NMR (CDCl3): δ 8.21 (s, 1H), 7.81 (d, J = 8.1 Hz, 1H), 
7.77 (d, J = 8.4 Hz, 1H), 7.75 (d, J = 8.7 Hz, 2H), 7.54 (t, J = 8.4 Hz, 2H), 7.43 (t, J = 8.3 Hz, 
1H), 7.37 (t, J = 8.3 Hz, 1H), 7.23 (t, J = 8.1 Hz, 1H); 13C NMR (CDCl3): δ 140.2, 138.8, 135.4, 
129.5, 127.1, 126.6, 125.3, 122.8, 121.5, 121.3, 110.4; MS: m/z 194 (M+). Anal. Calcd for 
C13H10N2: C, 80.39; H, 5.19; N, 14.42. Found: C, 80.15; H, 5.31; N, 14.69. 
1-(4-Methoxyphenyl)-1H-indazole (58d).  Yield: 177 mg (0.79 mmol, 79%) as a yellow oil; IR: 
2836, 1515 cm-1; 1H NMR (CDCl3): δ 8.17 (s, 1H), 7.79 (d, J = 8.1 Hz, 1H), 7.65 (d, J = 8.5 Hz, 
1H), 7.62 (d, J = 8.9 Hz, 2H), 7.41 (t, J = 8.3 Hz, 1H), 7.21 (t, J = 8.0 Hz, 1H), 7.06 (d, J = 8.9 
Hz, 2H), 3.88 (s, 3H); 13C NMR (CDCl3): δ 158.4, 139.0, 134.8, 133.4, 126.9, 124.9, 124.5, 
121.23, 121.21, 114.6, 110.2, 55.6; MS: m/z 224 (M+). Anal. Calcd for C14H12N2O: C, 74.98; H, 




 4-(1H-Indazol-1-yl)benzonitrile (58l). Yield: 164 mg (0.75 mmol, 75%) as a white solid; m.p. 
104-106 oC; IR: 2225, 1604, 1510 cm-1; 1H NMR (CDCl3): δ 8.26 (s, 1H), 7.94 (d, J = 8.6 Hz, 
2H), 7.84 (d, J = 8.6 Hz, 2H), 7.86-7.81 (complex, 2H), 7.51 (t, J = 8.4 Hz, 1H), 7.31 (t, J = 8.0 
Hz, 1H); 13C NMR (CDCl3): δ 143.8, 138.5, 137.3, 133.6, 128.1, 126.1, 122.5, 121.9, 121.8, 
118.5, 110.4, 109.3; MS: m/z 219 (M+). Anal. Calcd for C14H9N3: C, 76.70; H, 4.14; N, 19.17. 
Found: C, 76.85; H, 4.31; N, 19.32. 
1-Phenyl-1H-pyrazolo[3,4-b]pyridine (59a). Yield: 133 mg (0.68 mmol, 68%) as a white solid; 
m.p. 52-54 oC (lit86 53-55 oC);  IR: 1595, 1499 cm-1; 1H NMR (CDCl3): δ 8.65 (dd, J = 4.5, 1.7 
Hz, 1H), 8.28 (dd, J = 7.7, 1.2 Hz, 2H), 8.21 (s, 1H), 8.14 (dd, J = 8.0, 1.7 Hz, 1H), 7.54 (t, J = 
7.7 Hz, 1H), 7.33 (t, J = 7.5 Hz, 1H), 7.22 (dd, J = 8.0, 4.5 Hz, 1H); 13C NMR (CDCl3): δ 150.1, 
149.2, 139.5, 133.8, 130.2, 129.1, 126.1, 121.4, 117.6, 117.2; MS: m/z 195 (M+). Anal. Calcd for 
C12H9N3: C, 73.83; H, 4.65; N, 21.52. Found: C, 73.95; H, 4.87; N, 21.78.  
1-(4-Methoxyphenyl)-1H-pyrazolo[3,4-b]pyridine (59d). Yield: 140 mg (0.62 mmol, 62%) as a 
purple solid; m.p. 204-205 oC; IR: 2833, 1513 cm-1; 1H NMR (CDCl3): δ 9.00 (dd, J = 8.0, 1.7 
Hz, 1H), 8.70 (dd, J = 4.5, 1.7 Hz, 1H), 8.28 (d, J = 9.0 Hz, 2H), 7.35 (dd, J = 8.0, 4.5 Hz, 1H), 
7.26 (s, 1H), 7.14 (d, J = 9.0 Hz, 2H), 3.91 (s, 3H); 13C NMR (CDCl3): δ 158.0, 150.6, 149.6, 
138.7, 132.9, 132.6, 123.0, 118.3, 115.3, 114.4, 55.6; MS: m/z 225 (M+). Anal. Calcd for 
C13H11N3O: C, 69.32; H, 4.92; N, 18.66. Found: C, 69.68; H, 5.11; N, 19.82. 
4-(1H-Pyrazolo[3,4-b]pyridine-1-yl)benzonitrile (59l).  Yield: 172 mg (0.78 mmol, 78%) as a 
white solid; m.p. 125-127 oC; IR: 2222, 1603, 1450 cm-1; 1H NMR (CDCl3): δ 8.68 (dd, J = 4.5, 
1.6 Hz, 1H), 8.66 (d, J = 8.8 Hz, 2H), 8.25 (s, 1H), 8.17 (dd. J = 8.0, 1.6 Hz, 1H), 7.82 (d, J = 8.8 
Hz, 2H), 7.30 (dd, J = 8.0, 4.5 Hz, 1H); 13C NMR (CDCl3): δ 150.7, 149.4, 143.1, 135.4, 133.2, 
130.6, 120.3, 11.89, 118.4, 117.9, 108.7; MS: m/z 220 (M+). Anal. Calcd for C13H8N4: C, 70.90; 





2.3.2.  4H-Benzo[d][1,3]oxazin-4-ones and dihydro analogs. 
Representative procedure under thermal conditions. Method 1. 
The anthranilic acid (1.0 mmol) and the orthoester (4.5 mmol) were placed in a 15-mL 
Chemglass screw-cap pressure tube (CG-1880-01). Glacial acetic acid (2.6 mmol) was added, N2 
was introduced to the vessel and the cap was tightened. The vessel was heated at 100 oC under 
neat conditions for 4-48 h, and then cooled to room temperature. Upon cooling, the crude product 
crystallized from the reaction mixture and was purified by trituration from 5% ether in pentane. 
Representative procedure under microwave conditions. Method 2. 
A solution of the anthranilic acid (1.0 mmol) in the orthoester (0.45 mL, 2-0-2.7 equiv) was 
prepared in a 5-mL microwave tube and stirred for 30 s prior to irradiation at the "high 
absorption" setting. The reaction was performed under N2 at 100 oC (400 W) for 0.75-3 h. Upon 
cooling, the crude product crystallized from the reaction mixture and was purified by trituration 
from 5% ether in pentane.  
The following compounds were prepared: 
2-Methyl-4H-benzo[d][1,3]oxazin-4-one (67a). Yield: 130 mg (81%, method 1) and 132 mg 
(82%, method 2) as white crystals; m.p. 79-80 oC (lit.113 80-81 oC); IR: 1700, 1624 cm-1; 1H NMR 
(400 MHz, CDCl3): d 8.29 (dd, 1H, J = 7.5, 1.6 Hz, ArH), 7.78 (ddd, 1H, J = 8.4, 7.1, 1.6 Hz, 
ArH), 7.69 (d, 1H, J = 8.4 Hz, ArH), 7.48 (ddd, 1H, J = 8.1, 7.1, 1.2 Hz, ArH), 2.60 (s, 3H, CH3); 
13C NMR (101 MHz, CDCl3): d 164.1, 153.2, 149.4, 134.9, 127.0, 126.5, 126.3, 120.3, 22.2; 
HRMS (ESI): m/z [M+H]+ calcd for C9H7NO2: 162.0555, found: 162.0553. 
2-Ethyl-4H-benzo[d][1,3]oxazin-4-one (67b). Yield: 140 mg (80%, method 1) and 145 mg 
(83%, method 2) as white crystals; m.p. 83-84 oC (lit.113 m.p. 85-86 oC); IR: 1750, 1645 cm-1; 1H 
NMR (400 MHz, CDCl3): d 8.20 (dd, 1H, J = 7.9, 1.5 Hz, ArH), 7.80 (ddd, 1H, J = 8.4, 7.5, 1.5 
Hz, ArH), 7.57 (d, 1, J  = 8.4 Hz, ArH), 7.50 (ddd, 1H, J = 8.2, 7.5, 1.2 Hz, ArH), 2.73 (q, 2H, J 
= 7.5 Hz, CH2CH3), 1.37 (t, 3H, J = 7.5 Hz, CH2CH3); 13C NMR (101 MHz, CDCl3): d 163.9, 
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159.9, 146.5, 136.5, 128.4, 128.1, 126.6, 116.9, 28.2, 10.3; HRMS (ESI): m/z [M+H]+ calcd for 
C10H9NO2: 176.0712, found: 176.0713.  
2-Phenyl-4H-benzo[d][1,3]oxazin-4-one (67d). Yield: 174 mg (78%, method 1) and 179 mg 
(80%, method 2) as off-white crystals; m.p. 121-122 oC (lit.113 m.p. 123 oC); IR: 1762, 1615 cm-1; 
1H NMR (400 MHz, CDCl3): d 8.34-8.30 (complex, 2H, ArH), 8.25 (dd, 1H, J = 7.9, 1.5, ArH), 
7.84 (ddd, 1H, J = 8.1, 7.3, 1.5 Hz, ArH), 7.70 (d, J = 8.1 Hz, ArH), 7.62-7.48 (complex, 4H, 
ArH); 13C NMR (101 MHz, CDCl3): d 159.6, 157.1, 147.0, 136.6, 132.6, 130.3, 128.8, 128.6, 
128.32, 128.26, 127.2, 117.0; HRMS (ESI): m/z [M+H]+ calcd for C14H9NO2:  224.0712, found: 
224.0709. 
2,6-Dimethyl-4H-benzo[d][1,3]oxazin-4-one (68a). Yield: 119 mg (68%, method 2) as off-white 
crystals; m.p. 122-123 oC; IR: 1682, 1595 cm-1; 1H NMR (400 MHz, CDCl3): d 7.98 (s, 1H, 
ArH), 7.61 (d, 1H, J = 8.2 Hz, ArH), 7.44 (d, 1H, J = 8.2 Hz, ArH), 2.47 (s, 3H, CH3), 2.45 (s, 
3H, CH3); 13C NMR (101 MHz, CDCl3): d 159.9, 159.4, 144.3, 138.5, 137.7, 128.0, 126.2, 116.3, 
21.3, 21.2; HRMS (ESI): m/z [M+H]+ calcd for C10H9NO2: 176.0712, found: 176.0709. 
2-Ethyl-6-methyl-4H-benzo[d][1,3]oxazin-4-one (68b). Yield: 125 mg (66%, method 2) as 
white crystals; m.p. 103-104 oC; IR: 1686, 1596 cm-1; 1H NMR (400 MHz, CDCl3): d 7.98 (s, 1H, 
ArH), 7.60 (d, 1H, J = 8.2 Hz, ArH), 7.46 (d, 1H, J = 8.2 Hz, ArH), 2.71 (q, 2H, J = 7.5 Hz, 
CH2CH3), 2.47 (s, 3H, ArCH3), 1.36 (t, 3H, J = 7.5 Hz, CH2CH3); 13C NMR (101 MHz, CDCl3): 
d 163.1, 160.1, 144.3, 138.4, 137.7, 128.0, 126.4, 116.5, 26.1, 21.2, 10.3; HRMS (ESI): m/z 
[M+H]+ calcd for C11H11NO2: 190.0868, found: 190.0865. 
6-Methyl-2-phenyl-4H-benzo[d][1,3]oxazin-4-one (68d). Yield: 202 mg (85%, method 2) as 
off-white crystals; m.p. 144-145 oC; IR: 1752, 1607 cm-1; 1H NMR (400 MHz, CDCl3): d 8.29 (d, 
2H, J = 8.2 Hz, ArH), 8.04 (s, 1H, ArH), 7.66-7.47 (complex, 5H, ArH), 2.49 (s, 3H, ArCH3); 13C 
NMR (101 MHz, CDCl3): d 159.8, 156.4, 144.8, 138.7, 137.8, 132.4, 130.4, 128.7, 128.19, 
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128.17, 127.0, 116.7, 21.2; HRMS (ESI): m/z [M+H]+ for C15H11NO2: 238.0868, found: 
238.0870. 
7-Methoxy-2-methyl-4H-benzo[d][1,3]oxazin-4-one (69a). Yield: 166 mg (87%, method 1) and 
168 mg (88%, method 2) as light yellow crystals; m.p. 119-120 oC; IR (nujol): 2830, 1747, 1610 
cm-1; 1H NMR (400 MHz, DMSO-d6): d 8.00 (d, 1H, J = 8.8 Hz, ArH), 7.14 (dd, 1H, J = 8.8, 2.5 
Hz, ArH), 7.05 (d, 1H, J = 2.5 Hz, ArH), 3.91 (s, 3H, OCH3), 2.38 (s, 3H, CH3); 13C NMR (101 
MHz, DMSO-d6): d 166.3, 161.5, 159.2, 149.0, 130.2, 117.1, 109.5, 109.1, 56.5, 21.5; HRMS 
(ESI): m/z [M+H]+ calcd for C10H9NO3: 192.0661, found: 192.0659. 
2-Ethyl-7-methoxy-4H-benzo[d][1,3]oxazin-4-one (69b). Yield: 176 mg (86%, method 1) and 
181 mg (88%, method 2) as light yellow crystals; m.p. 89-90 oC; IR (nujol): 2840, 1767, 1644, 
1609 cm-1; 1H NMR (400 MHz, DMSO-d6): d 7.99 (d, 1H, J = 8.8 Hz, ArH) 7.14 (dd, 1H, J = 
8.8, 2.5 Hz, ArH), 7.07 (d, 1H, J = 2.5 Hz, ArH), 3.92 (s, 3H, OCH3), 2.68 (q, 2H, J = 7.5 Hz, 
CH2CH3), 1.24 (t, 3H, J = 7.5 Hz, CH2CH3); 13C NMR (101 MHz, DMSO-d6): d 166.3, 164.9, 
159.2, 149.0, 130.1, 117.3, 109.7, 109.1, 56.6, 27.7, 10.2; HRMS (ESI): m/z [M+H]+ calcd for 
C11H11NO3: 206.0817, found: 206.0817. 
7-Methoxy-2-propyl-4H-benzo[d][1,3]oxazin-4-one (69c). Yield: 189 mg (86%, method 1) and 
191 mg (87%, method 2) as light yellow crystals; m.p. 77-78 oC; IR (nujol): 2841, 1766, 1643, 
1609 cm-1; 1H NMR (400 MHz, DMSO-d6): d 8.00 (d, 1H, J = 8.8 Hz, ArH), 7.14 (dd, 1H, J = 
8.8, 2.5 Hz, ArH), 7.07 (d, 1H, J = 2.5 Hz, ArH), 3.92 (s, 3H, OCH3), 2.63 (t, 2H, J = 7.4 Hz, 
CH2CH2CH3), 1.75 (sextet, 2H, J = 7.4 Hz, CH2CH2CH3); 0.98 (t, 3H, J = 7.4 Hz, CH2CH2CH3); 
13C NMR (101 MHz, DMSO-d6): d 166.3, 163.9, 159.2, 148.9, 130.1, 117.3, 109.7, 109.1, 56.6, 
36.2, 19.2, 13.9; HRMS (ESI): m/z [M+H]+ calcd for C12H13NO3: 220.0974, found: 220.0971. 
7-Methoxy-2-phenyl-4H-benzo[d][1,3]oxazin-4-one (69d). Yield: 210 mg (83%, method 1) and 
215 mg (85%, method 2) as light yellow crystals; m.p. 149-150 oC; IR (nujol): 2842, 1744, 1607 
cm-1; 1H NMR (400 MHz, DMSO-d6): d 8.17 (d, 2H, J = 8.1 Hz, ArH), 8.03 (d, 1H, J = 9.4 Hz, 
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ArH), 7.67 (d, 1H, J = 7.3 Hz, ArH), 7.59 (t, 2H, J = 8.1 Hz, ArH), 7.15 (m, 2H, ArH), 3.94 (s, 
3H, OCH3); 13C NMR (101 MHz, DMSO-d6): d 166.4, 158.8, 157.6, 149.2, 133.2, 130.5, 130.3, 
129.4, 128.3, 117.6, 109.9, 109.6, 56.6; HRMS (ESI): m/z [M+H]+ calcd for C15H11NO3: 
254.0817, found: 254.0814. 
7-Nitro-2-phenyl-4H-benzo[d][1,3]oxazin-4-one (70d). Yield: 244 mg (91%, method 2) as light 
orange crystals; m.p. 175-176oC; IR: 1757, 1629, 1608, 1530, 1349 cm-1; 1H NMR (400 MHz, 
CDCl3): d 8.52 (d, 1H, J = 2.2 Hz, ArH), 8.41 (d, 1H, J = 8.6 Hz, ArH), 8.33 (d, 2H, J = 7.4 Hz, 
ArH), 8.29 (dd, 1H, J = 8.6, 2.2 Hz, ArH), 7.64 (t, 1H, J = 7.4 Hz, ArH), 7.55 (t, 2H, J = 7.4 Hz, 
ArH); 13C NMR (101 MHz, CDCl3): d 159.0, 157.9, 152.9, 148.1, 133.6, 130.4, 129.3, 129.0, 
128.7, 122.5, 122.0, 121.3; HRMS (ESI): m/z [M+H]+ calcd for C14H8N2O4: 269.0562, found: 
269.0558. 
7-Chloro-2-methyl-4H-benzo[d][1,3]oxazin-4-one (71a). Yield: 166 mg (85%, method 2) as 
white crystals; m.p. 149-150 oC; IR: 1762, 1696, 1642, 1596 cm-1; 1H NMR (400 MHz, CDCl3): d 
8.11 (d, 1H, J = 8.4 Hz, ArH), 7.54 (d, 1H, J = 2.0 Hz, ArH), 7.46 (dd, 1H, J = 8.4, 2.0 Hz, ArH), 
2.47 (s, 3H CH3); 13C NMR (101 MHz, CDCl3): d 161.6, 158.9, 147.5, 142.9, 129.7, 128.8, 126.3, 
115.1, 21.4; HRMS (ESI): m/z [M+H]+ calcd for C9H635ClNO2: 196.0165, found: 196.0166. 
7-Chloro-2-phenyl-4H-benzo[d][1,3]oxazin-4-one (71d). Yield: 237 mg (92%, method 2) as 
off-white crystals; m.p. 188-189 oC; IR: 1760, 1619, 1596 cm-1; 1H NMR (400 MHz, CDCl3): d 
8.31 (d, 2H, J = 7.4 Hz, ArH), 8.17 (d, 1H, J = 8.4 Hz, ArH), 7.70 (d, 1H, J = 2.0 Hz, ArH), 7.60 
(tt, 1H, J = 7.4, 1.4 Hz, ArH), 7.52 (t, 2H, J = 7.4 Hz, ArH), 7.48 (dd, 1H, J = 8.4, 2.0 Hz, ArH); 
13C NMR (101 MHz, CDCl3): d 158.8, 158.3, 148.1, 143.0, 133.0, 129.9, 129.86, 128.83, 128.79, 
128.5, 127.0, 115.4; HRMS (ESI): m/z [M+H]+ calcd for C14H835ClNO2: 258.0322, found: 
258.0317. 
(±)-2-Ethoxy-2-phenyl-1,2-dihydro-4H-benzo[d][1,3]oxazin-4-one (73d). Yield: 232 mg (86%, 
method 1) as white crystals; m.p. 92-93 oC; IR: 3254, 1668, 1595 cm-1; 1H NMR (400 MHz, 
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CDCl3): d 12.09 (br s, 1H, NH), 8.94 (dd, 1H, J = 8.5, 1.1 Hz), ArH), 8.1 (dd, 1H, J = 8.0, 1.7 Hz, 
ArH), 8.06 (dd, 2H, J = 7.8, 1.5 Hz, ArH), 7.64-7.49 (complex, 4H, ArH), 7.13 (td, 1H, J = 7.4, 
1.2 Hz, ArH), 4.43 (q, 2H, J = 7.1 Hz, OCH2CH3), 1.43 (t, 3H, J = 7.1 Hz, OCH2CH3); 13C NMR 
(101 MHz, CDCl3): d 168.6, 165.4, 141.9, 134.9, 134.7, 131.9, 130.9, 128.8, 127.4, 122.6, 120.5, 
115.5, 61.5, 14.2; HRMS (ESI): m/z [M+H]+ calcd for C16H15NO2: 254.1181, found: 254.1177. 
(±)-2-Ethoxy-2,6-dimethyl-1,2-dihydro-4H-benzo[d][1,3]oxazin-4-one (74a): Yield: 195 mg 
(88%, method 1) as white crystals; m.p. 110-111 oC; IR: 3266, 1677, 1595 cm-1; 1H NMR (400 
MHz, CDCl3): d 10.97 (br s, 1H, NH), 8.57 (d, 1H, J = 8.6 Hz, ArH), 7.83 (s, 1H, ArH), 7.34 (d, 
1H, J = 8.6 Hz, ArH), 4.37 (q, 2H, J = 7.1 Hz, OCH2CH3), 2.33 (s, 3H, ArCH3), 2.22 (s, 3H, 
CH3), 1.42 (t, 3H, J = 7.1 Hz, OCH2CH3); 13C NMR (101 MHz, CDCl3): d 168.9, 168.4, 139.2, 
135.3, 131.9, 130.8, 120.3, 115.0, 61.3, 25.5, 20.7, 14.2; HRMS (ESI): m/z [M+H]+ calcd for 
C12H15NO3: 222.1130, found: 222.1128. 
(±)-2-Ethoxy-2-ethyl-6-methyl-1,2-dihydro-4H-benzo[d][1,3]oxazin-4-one (74b). Yield: 205 
mg (87%, method 1) as white crystals; m.p. 78-79 oC; IR: 3261, 1677, 1596 cm-1; 1H NMR (400 
MHz, CDCl3): d 11.0 (br s, 1H, NH), 8.62 (d, 1H, J = 8.6 Hz, ArH), 7.83 (s, 1H, ArH), 7.34 (d, 
1H, J = 8.6 Hz, ArH), 4.37 (q, 2H, J = 7.0 Hz, OCH2CH3), 2.46 (q, 2H, J = 7.5 Hz, CH2CH3), 
2.33 (s, 3H, ArCH3), 1.42 (t, 3H, J = 7.0 Hz, OCH2CH3), 1.27 (t, 3H, J = 7.5 Hz, CH2CH3); 13C 
NMR (101 MHz, CDCl3): d 172.7, 168.4, 139.4, 135.3, 131.7, 130.8, 120.3, 114.9, 61.3, 31.7, 
20.7, 14.2, 9.7; HRMS (ESI): m/z [M+H]+ calcd for C13H17NO3: 236.1287, found: 236.1284. 
(±)-2-Ethoxy-6-methyl-2-propyl-1,2-dihydro-4H-benzo[d][1,3]oxazin-4-one (74c): Yield: 219 
mg (88%, method 1) and 222 mg (89%, method 2) as off-white crystals; m.p. 39-40 oC; IR: 3265, 
1682, 1599 cm-1; 1H NMR (400 MHz, CDCl3): d 10.98 (br s, 1H, NH), 8.62 (d, 1H, J = 8.6 Hz, 
ArH), 7.83 (s, 1H, ArH), 7.35 (d, 1H, J = 8.6 Hz, ArH), 4.38 (q, 2H, J = 7.1 Hz, OCH2CH3), 2.41 
(q, 2H, J = 7.5 Hz, CH2CH2CH3), 2.33 (s, 3H, ArCH3), 1.78 (sextet, 2H, J = 7.5 Hz, 
CH2CH2CH3), 1.42 (t, 3H, J = 7.1 Hz, OCH2CH3), 1.01 (t, 3H, J = 7.5 Hz, CH2CH2CH3); 13C 
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NMR (101 MHz, CDCl3): d 171.9, 168.4, 139.3, 135.3, 131.7, 130.8, 120.3, 114.9, 61.3, 40.6, 
20.7, 19.0, 14.2, 13.8; HRMS (ESI): m/z [M+H]+ calcd for C14H19NO3: 250.1443, found: 
250.1441. 
(±)-2-Ethoxy-6-methyl-2-phenyl-1,2-dihydro-4H-benzo[d][1,3]oxazin-4-one (74d). Yield: 249 
mg (88%, method 1) as white crystals; m.p. 117-118 oC; IR: 3249, 1662, 1602 cm-1; 1H NMR 
(400 MHz, CDCl3): d 11.98 (br s, 1H, NH), 8.82 (d, 1H, J = 8.5 Hz, ArH), 8.05 (d, 2H, J = 6.8 
Hz, ArH), 7.89 (s, 1H, ArH), 7.58-7.47 (complex, 3H), 7.42 (d, 1H, J = 8.5 Hz, ArH), 4.42 (q, 
2H, J = 7.1 Hz, OCH2CH3), 3.36 (s, 3H, ArCH3), 1.44 (q, 3H, J = 7.1 Hz, OCH2CH3); 13C NMR 
(101 MHz, CDCl3): d 168.9, 165.5, 139.5, 135.4, 135.1, 132.1, 131.8, 131.0, 128.8, 127.3, 120.4, 
115.4, 61.5, 20.8, 14.3; HRMS (ESI): m/z [M+H]+ calcd for C17H17NO3: 284.1287, found: 
284.1283. 
(±)-2-Ethoxy-2-methyl-7-nitro-1,2-dihydro-4H-benzo[d][1,3]oxazin-4-one (76a): Yield: 212 
mg (84%, method 1) and 219 mg (87%, method 2) as light tan crystals; m.p. 108-109 oC; IR: 
3270, 1702, 1604, 1538, 1350 cm-1; 1H NMR (400 MHz, CDCl3): d 11.16 (br s, 1H, NH), 9.60 (d, 
1H, J = 2.4 Hz, ArH), 8.20 (d, 1H, J = 8.8 Hz, ArH), 7.87 (dd, 1H, J = 8.8, 2.4 Hz, ArH), 4.45 (q, 
2H, J = 7.1 Hz, OCH2CH3), 2.28 (s, 3H, CH3), 1.46 (t, 3H, J = 7.1 Hz, OCH2CH3); 13C NMR (101 
MHz, CDCl3): d 169.2, 166.9, 151.2, 142.2, 131.9, 119.3, 116.4, 115.2, 62.5, 25.5, 14.1; HRMS 
(ESI): m/z [M+H]+ calcd for C11H12N2O5: 253.0825, found: 253.0824. 
(±)-2-Ethoxy-2-ethyl-7-nitro-1,2-dihydro-4H-benzo[d][1,3]oxazin-4-one (76b). Yield: 229 mg 
(86%, method 1) and 234 mg (88%, method 2) as light tan crystals; m.p. 74-75 oC; IR: 3273, 
1694, 1600, 1538, 1349 cm-1; 1H NMR (400 MHz, CDCl3): d 11.18 (br s, 1H, NH), 9.65 (d, 1H, J 
= 2.4 Hz, ArH), 8.20 (d, 1H, J = 8.8 Hz, ArH), 7.86 (dd, 1H, J = 8.8, 2.4 Hz, ArH), 4.45 (q, 2H, J 
= 7.1 Hz, OCH2CH3), 2.53 (q, 2H, J = 7.5 Hz, CH2CH3), 1.46 (t, 3H, J = 7.1 Hz, OCH2CH3), 1.30 
(t, 3H, J = 7.5 Hz, CH2CH3); 13C NMR (101 MHz, CDCl3): d 173.1, 166.9, 151.2, 142.5, 131.9, 
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119.3, 116.3, 115.3, 62.4, 31.6, 14.1, 9.3; HRMS (ESI): m/z [M+H]+ calcd for C12H14N2O5: 
267.0981, found: 267.0977. 
(±)-2-Ethoxy-2-propyl-7-nitro-1,2-dihydro-4H-benzo[d][1,3]oxazin-4-one (76c). Yield: 238 
mg (85%, method 1) and 245 mg (88%, method 2) as light tan crystals; m.p. 66-67oC; IR: 3270, 
1697, 1604, 1538, 1349 cm-1; 1H NMR (400 MHz, CDCl3): d 11.17 (br s, 1H, NH), 9.65 (d, 1H, J 
= 2.4 Hz, ArH), 8.20 (d, 1H, J = 8.8 Hz, ArH), 7.86 (dd, 1H, J = 8.8, 2.4 Hz, ArH), 4.45 (q, 2H, J 
= 7.1 Hz, OCH2CH3), 2.47 (q, 2H, J = 7.4 Hz, CH2CH2CH3), 1.81 (sextet, 2H, J = 7.4 Hz, 
CH2CH2CH3), 1.46 (t, 3H, J = 7.1 Hz, OCH2CH3), 1.04 (t, 3H, J = 7.4 Hz, CH2CH2CH3); 13C 
NMR (101 MHz, CDCl3): d 172.3, 166.9, 151.2, 142.5, 131.9, 119.3, 116.3, 115.3, 62.4, 40.4, 
18.8, 14.1, 13.7; HRMS (ESI): m/z [M+H]+ calcd for C13H16N2O5: 281.1138, found: 281.1140. 
(±)-2-Ethoxy-7-nitro-2-phenyl-1,2-dihydro-4H-benzo[d][1,3]oxazin-4-one (76d): Yield: 283 
mg (90%, method 1) as off-white crystals; m.p. 180-181 oC; IR: 3257, 1673, 1651, 1600, 1538, 
1346 cm-1; 1H NMR (400 MHz, CDCl3): d 11.62 (br s, 1H, NH), 9.31 (d, 1H, J = 2.4 Hz, ArH), 
8.20 (d, 1H, J = 8.8 Hz, ArH), 8.03 (dd, 1H, J = 8.8, 2.4 Hz, ArH), 7.97 (d, 2H, J = 7.4 Hz, ArH, 
7.69 (t, 1H, J = 7.4 Hz, ArH), 7.61 (t, 2H, J = 7.4 Hz, ArH), 4.38 (q, 2H, J = 7.1 Hz, OCH2CH3), 
1.33 (t, 3H, J = 7.1 Hz, OCH2CH3); 13C NMR (101 MHz, CDCl3): d 166.7, 165.7, 150.6, 141.0, 
134.1, 133.1, 132.7, 129.5, 127.7, 1239, 118.2, 116.0, 62.6, 14.3; HRMS (ESI): m/z [M+H]+ calcd 
for C16H14N2O5: 315.0981, found: 315.0975. 
(±)-7-Chloro-2-ethoxy-2-methyl-1,2-dihydro-4H-benzo[d][1,3]oxazin-4-one (77a). Yield: 203 
mg (84%, method 1) as white crystals; m.p. 75-76 oC; IR: 3262, 1681, 1578 cm-1; 1H NMR (400 
MHz, CDCl3): d 10.70 (br s, 1H, NH), 8.43 (d, 1H, J = 2.2 Hz, ArH), 7.92 (d, 1H, J = 8.6 Hz, 
ArH), 7.23 (dd, 1H, J = 8.6, 2.2 Hz, ArH), 4.83 (q, 2H, J = 7.1 Hz, OCH2CH3), 2.15 (s, 3H, CH3), 
1.34 (t, 3H, J = 7.1 Hz, OCH2CH3); 13C NMR (101 MHz, CDCl3): d 169.1, 167.7, 142.4, 140.8, 
131.8, 122.6, 120.1, 113.2, 61.6, 25.5, 14.2; HRMS (ESI): m/z [M+H]+ calcd for C11H1235ClNO3: 
242.0584, found: 242.0582. 
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(±)-7-Chloro-2-ethoxy-2-ethyl-1,2-dihydro-4H-benzo[d][1,3]oxazin-4-one (77b). Yield: 215 
mg (84%, method 1) and 220 mg (86%, method 2) as white crystals; m.p. 69-70 oC; IR: 3238, 
1685, 1581 cm-1; 1H NMR (400 MHz, CDCl3): d 11.17 (br s, 1H, NH), 8.86 (d, 1H, J = 2.2 Hz, 
ArH), 7.96 (d, 1H, J = 8.6 Hz, ArH), 7.04 (dd, 1H, J = 8.6, 2.2 Hz, ArH), 4.38 (q, 2H, J  = 7.1 Hz, 
OCH2CH3), 2.48 (q, 2H, J = 7.5 Hz, CH2CH3), 1.41 (t, 3H, J = 7.1 Hz, OCH2CH3), 1.27 (t, 3H, J 
= 7.5 Hz, CH2CH3); 13C NMR (101 MHz, CDCl3): d 173.0, 167.8, 142.6, 140.9, 131.8, 122.5, 
120.2, 113.2, 61.6, 31.7, 14.2, 9.5; HRMS (ESI): m/z [M+H]+ calcd for C12H1435ClNO3: 256.0741, 
found: 256.0743. 
(±)-7-Chloro-2-ethoxy-2-propyl-1,2-dihydro-4H-benzo[d][1,3]oxazin-4-one (77c). Yield: 224 
mg (83%, method 1) and 227 mg (84%, method 2) as white semisolid; m.p. 25-26 oC; IR: 3280, 
1691, 1581cm-1; 1H NMR (400 MHz, CDCl3): d 11.16 (br s, 1H, NH), 8.85 (s, 1H, ArH), 7.96 (d, 
1H, J = 8.6 Hz, ArH), 7.04 (dd, 1H, J = 8.6, 2.2 Hz, ArH), 4.38 (q, 2H, J = 7.1 Hz, OCH2CH3), 
2.42 (q, 2H, J = 7.4 Hz, CH2CH2CH3), 1.78 (sextet, 2H, J = 7.4 Hz, CH2CH2CH3), 1.42 (t, 3H, J 
= 7.1 Hz, OCH2CH3), 1.02 (t, 3H, J = 7.4 Hz, CH2CH2CH3); 13C NMR (101 MHz, CDCl3): d 
172.2, 167.7, 142.5, 140.8, 131.8, 122.5, 120.2, 113.2, 61.6, 40.5, 18.9, 14.2, 13.2; HRMS (ESI): 
m/z [M+H]+ calcd for C13H1635ClNO3: 270.0897, found: 270.0893. 
(±)-7-Chloro-2-ethoxy-2-phenyl-1,2-dihydro-4H-benzo[d][1,3]oxazin-4-one (77d).  Yield: 258 
mg (85%, method 1) as white crystals; m.p. 128-129 oC; IR: 3241, 1673, 1585 cm-1; 1H NMR 
(400 MHz, CDCl3): d 12.13 (br s, 1H, NH), 9.05 (d, 1H, J = 2.1 Hz, ArH), 8.03 (overlapping 
signals, apparent t, 3H, J ≈ 8.4 Hz, ArH), 7.60-7.49 (complex, 3H, ArH), 7.08 (dd, 1H, J = 8.6, 
2.1 Hz, ArH), 4.42 (q, 2H, J = 7.1 Hz, OCH2CH3), 1.43 (t, 3H, J = 7.1 Hz, OCH2CH3); 13C NMR 
(101 MHz, CDCl3): d 168.1, 165.7, 142.7, 141.0, 134.4, 132.2, 132.0, 128.9, 127.4, 122.8, 120.3, 




(±)-2-Ethoxy-2-methyl-1,2-dihydro-4H-pyrido[2,3-d][1,3]oxazin-4-one (78a). Yield: 177 mg 
(85%, method 1) as white crystals; m.p. 55-56 oC; IR: 3270, 1680, 1589 cm-1; 1H NMR (400 
MHz, CDCl3): d 10.79 (br s, 1H, NH), 8.59 (dd, 1H, J = 4.8, 2.0 Hz, PyH), 8.33 (dd, 1H, J = 7.9, 
2.0 Hz, PyH), 7.06 (dd, 1H, J = 7.9, 4.8 Hz, PyH), 4.41 (q, 2H, J = 2.1 Hz, OCH2CH3), 2.42 (s, 
3H, CH3), 1.42 (t, 3H, J = 7.1 Hz, OCH2CH3); 13C NMR (101 MHz, CDCl3): d 169.6, 166.6, 
152.9, 152.5, 140.0, 118.0, 111.1, 62.0, 26.0, 14.2; HRMS (ESI): m/z [M+H]+ calcd for 
C10H12N2O3: 209.0926, found: 209.0925. 
2.3.3.  Bis- and mono-1,3,4-oxadiazole synthesis promoted by catalytic NH4Cl. 
Representative procedure for the preparation bis- and mono-1,3,4-oxadiazoles. 
The orthoester (2.2 equiv for 79-83 and 1.1 equiv for 85-91) was added to a mixture of 79, 81, 83, 
85, 86, 89 or 91 (1.0 mmol) and ammonium chloride (60 mol% for 79-83 and 30 mol% for 85-91) 
in DMSO (5 mL). The reaction was heated at 100 oC (oil bath) until TLC (10% MeOH in DCM) 
indicated complete conversion (1.5-96 h). The crude reaction mixture was cooled, added to water 
and extracted with DCM (2 x 15 mL). The combined organic layers were washed with saturated 
aq NaCl, dried (MgSO4), and concentrated under vacuum to give the crude oxadiazoles. The 
crude products were stirred with 25% ether/hexane for 1 h, filtered and dried to give the bis-
oxadiazoles 80, 82 and 84 as well as the mono-1,3,4-oxadiazoles 87-90 and 92.  
1,4-Di(1,3,4-oxadiazol-2-yl)benzene (80a). Yield: 182 mg (0.85 mmol, 85%) as white crystals; 
m.p. 257-258 oC; IR (nujol): 1577 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 9.44 (s, 2H), 8.26 (s, 
4H); 13C NMR (100 MHz, DMSO-d6): δ 163.4, 155.5, 128.2, 126.5. 
1,4-Bis(5-methyl-1,3,4-oxadiazol-2-yl)benzene (80b). Yield: 216 mg (0.89 mmol, 89%) as off-
white crystals; m.p. 256-257 oC; IR (nujol): 1582 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 8.17 (s, 
4H), 2.62 (s, 6H); 13C NMR (100 MHz, DMSO-d6): δ 163.9, 162.6, 126.7, 125.4, 10.1.  
1,4-Bis(5-ethyl-1,3,4-oxadiazol-2-yl)benzene (80c). Yield: 219 mg (0.81 mmol, 81%) as a white 
solid; m.p. 163-164 oC; IR (nujol): 1570 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 8.19 (s, 4H), 
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2.98 (q, J = 7.5 Hz, 4H), 1.35 (t, J = 7.5 Hz, 6H); 13C NMR (100 MHz, DMSO-d6): δ 168.7, 
163.6, 127.8, 126.5, 18.9, 10.9.   
1,4-Bis(5-propyl-1,3,4-oxadiazol-2-yl)benzene (80d). Yield: 239 mg (0.80 mmol, 80%) as a 
white flaky solid; m.p. 128-129 oC; IR (nujol): 1582, 1562 cm-1; 1H NMR (400 MHz, DMSO-d6): 
δ 8.18 (s, 4H), 2.94 (t, J = 7.4 Hz, 4H), 1.81 (sextet, J = 7.4 Hz, 4H), 1.00 (t, J = 7.4 Hz, 6H); 13C 
NMR (100 MHz, DMSO-d6): δ 167.2, 163.6, 127.8, 126.5, 26.9, 19.8, 13.8.   
1,4-Bis(5-phenyl-1,3,4-oxadiazol-2-yl)benzene (80e). Yield: 278 mg (0.76 mmol, 76%) as a 
white solid; m.p. 321-322 oC; IR (nujol): 1585, 1559 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 
8.40 (s, 4H), 8.21-8.18 (complex, 4H), 7.70-7.64 (complex, 6H), 13C NMR (100 MHz, DMSO-
d6): δ 164.4, 156.0, 131.9, 129.2, 126.7, 126.1, 119.3.  
1,3-Di(1,3,4-oxadiazol-2-yl)benzene (82a). Yield: 180 mg (0.84 mmol, 84%) as a white solid; 
m.p. 189-190 oC; IR (nujol): 1535 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 9.45 (s, 2H), 8.59 (t, J 
= 1.8 Hz, 1H), 8.28 (dd, J = 7.9, 1.8 Hz, 2H), 7.87 (t, J = 7.9 Hz, 1H); 13C NMR (100 MHz, 
DMSO-d6): δ 162.2, 154.3, 130.3, 129.3, 123.9, 123.8. 
1,3-Bis(5-methyl-1,3,4-oxadiazol-2-yl)benzene (82b). Yield: 213 mg (0.88 mmol, 88%) as a 
white solid; m.p. 160-161 oC; IR (nujol): 1579 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 8.47 (t, J 
= 1.7 Hz, 1H), 8.20 (dd, J = 7.9, 1.7 Hz, 2H), 7.82 (t, J = 7.9 Hz, 1H), 2.62 (s, 3H); 13C NMR 
(100 MHz, DMSO-d6): δ 164.9, 163.5, 131.3, 129.6, 125.1, 124.1, 11.1. 
1,3-Bis(5-ethyl-1,3,4-oxadiazol-2-yl)benzene (82c). Yield: 232 mg (0.86 mmol, 86%) as a white 
solid; m.p. 139-140 oC; IR (nujol): 1570 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 8.48 (t, J = 1.8 
Hz, 1H), 8.20 (dd, J = 7.9, 1.8 Hz, 2H), 7.82 (t, J = 7.9 Hz, 1H), 2.99 (q, J = 7.5 Hz, 4H), 1.36 (t, 
J = 7.5 Hz, 6H); 13C NMR (100 MHz, DMSO-d6): δ 167.6, 162.4, 130.2, 128.6, 124.1, 123.1, 
17.9, 9.8.  
1,3-Bis(5-propyl-1,3,4-oxadiazol-2-yl)benzene (82d). Yield: 253 mg (0.85 mmol, 85%) as a 
white solid; m.p. 63-64 oC; IR (nujol): 1568 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 8.49 (s, 1H), 
8.21 (d, J = 7.9 Hz, 2H), 7.83 (t, J = 7.9, 2.5 Hz, 1H), 2.95 (t, J = 7.3 Hz, 4H), 1.82 (sextet, J = 
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7.3 Hz, 4H), 1.01 (t, J = 7.3 Hz, 6H); 13C NMR (100 MHz, DMSO-d6): δ 167.3, 163.5,131.2, 
129.7, 125.1, 124.2, 26.9, 19.9, 13.8.   
1,3-Bis(5-phenyl-1,3,4-oxadiazol-2-yl)benzene (82e). Yield: 282 mg (0.77 mmol, 77%) as a 
white flaky solid; m.p. 235-236 oC; IR (nujol): 1550 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 8.80 
(t, J = 1.7 Hz, 1H), 8.41 (dd, J = 7.9, 1.7 Hz, 2H), 8.23-8.19 (complex, 4H), 7.92 (t, J = 7.9 Hz, 
1H), 7.74-7.65 (complex, 6H); 13C NMR (100 MHz, DMSO-d6): δ 164.9, 163.8, 132.7, 131.3, 
130.4, 130.0, 127.4, 125.1, 124.8, 123.7. 
1,4-Di(1,3,4-oxadiazol-2-yl)butane (84a). Yield: 102 mg (0.53 mmol, 53%) as a light pink solid; 
m.p. 59-61 oC; IR (nujol): 3139, 1580, 1517 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 9.13 (s, 2H), 
2.93 (m, 4H), 1.78 (m, 4H); 13C NMR (100 MHz, DMSO-d6): δ 165.4, 153.7, 24.5, 23.2.   
1,4-Bis(5-methyl-1,3,4-oxadiazol-2-yl)butane (84b). Yield: 44 mg (0.20 mmol, 20%) as a tan 
solid; m.p. 41-42 oC; IR (nujol): 1598, 1566 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 2.85 (m, 
4H), 2.44 (s, 6H), 1.76 (m, 4H); 13C NMR (100 MHz, DMSO-d6): δ 165.5, 162.8, 24.4, 23.3, 9.8.  
1,4-Bis(5-ethyl-1,3,4-oxadiazol-2-yl)butane (84c). Yield: 198 mg (0.79 mmol, 79%) as a white 
solid; m.p. 34-35 oC; IR (nujol): 1594, 1563 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 2.86 (m, 
4H), 2.83 (q, J = 7.5 Hz, 4H), 1.76 (m, 4H), 1.24 (t, J = 7.5 Hz, 6H); 13C NMR (100 MHz, 
DMSO-d6): δ 166.7, 165.5,24.5, 23.4, 17.6, 9.9.  
1,4-Bis(5-phenyl-1,3,4-oxadiazol-2-yl)butane (84e). Yield: 194 mg (0.56 mmol, 56%) as a 
cream solid; m.p. 133-135 oC; IR (nujol): 1569, 1546 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 
7.98 (dd, J = 8.1, 1.9 Hz, 4H), 7.65-7.55 (complex, 6H), 3.03 (m, 4H), 1.91 (m, 4H); 13C NMR 
(100 MHz, DMSO-d6): δ 167.1, 164.3, 132.2, 129.9, 126.8, 124.0, 25.5, 24.6.   
2-(4-Nitrophenyl)-1,3,4-oxadiazole (87a). Yield: 176 mg (0.92 mmol, 92%) as an off-white 
solid; m.p. 152-153 oC; IR (nujol): 1554, 1538, 1525, 1341 cm-1; 1H NMR (400 MHz, DMSO-d6): 
δ 9.49 (s, 1H), 8.44 (d, J = 8.9 Hz, 2H), 8.30 (d, J = 8.9 Hz, 2H); 13C NMR (100 MHz, DMSO-
d6): δ 162.9, 155.9, 149.7, 129.2, 128.6, 125.1.  
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2-Methyl-5-(4-nitrophenyl)-1,3,4-oxadiazole (87b). Yield: 174 mg (0.85 mmol, 85%) as an off-
white solid; m.p. 163-164 oC; IR (nujol): 1573, 1551, 1522, 1354 cm-1; 1H NMR (400 MHz, 
DMSO-d6): δ 8.42 (d, J = 8.9 Hz, 2H), 8.24 (d, J = 8.9 Hz, 2H), 2.63 (s, 3H); 13C NMR (100 
MHz, DMSO-d6): δ 165.5, 163.1, 149.5, 129.5, 128.2, 125.1, 11.2.   
2-Ethyl-5-(4-nitrophenyl)-1,3,4-oxadiazole (87c). Yield: 193 mg (0.88 mmol, 88%) as an off-
white solid; m.p. 113-114 oC; IR (nujol): 1564, 1540, 1514, 1353 cm-1; 1H NMR (400 MHz, 
DMSO-d6): δ 8.42 (d, J = 8.9 Hz, 2H), 8.24 (d, J = 8.9 Hz, 2H), 2.99 (q, J = 7.5 Hz, 2H), 1.35 (t, 
J = 7.5 Hz, 3H); 13C NMR (100 MHz, DMSO-d6): δ 169.2, 163.0, 149.5, 129.5, 128.2, 125.0, 
19.0, 10.8.  
2-(4-Nitrophenyl)-5-propyl-1,3,4-oxadiazole (87d). Yield: 210 mg (0.90 mmol, 90%) as an off-
white solid; m.p. 109-110 oC; IR (nujol): 1568, 1548, 1512, 1352 cm-1; 1H NMR (400 MHz, 
DMSO-d6): δ 8.42 (d, J = 8.9 Hz, 2H), 8.24 (d, J = 8.9 Hz, 2H), 2.95 (t, J = 7.4 Hz, 2H), 1.81 
(sextet, J = 7.4 Hz, 2H), 1.00 (t, J = 7.4 Hz, 3H); 13C NMR (100 MHz, DMSO-d6): δ 168.2, 
163.0, 149.5, 129.5, 128.2, 125.1, 26.9, 19.8, 13.8.  
2-(4-Nitrophenyl)-5-phenyl-1,3,4-oxadiazole (87e). Yield: 208 mg (0.78 mmol, 78%) as yellow 
crystals; m.p. 203-204 oC; IR (nujol): 1548, 1513, 1344 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 
8.47 (d, J = 8.9 Hz, 2H), 8.41 (d, J = 8.9 Hz, 2H), 8.19 (dd, J = 6.0, 1.7 Hz, 2H), 7.72-7.64 
(complex, 3H); 13C NMR (100 MHz, DMSO-d6): δ 165.3, 163.2, 149.7, 132.9, 130.0, 129.4, 
128.5, 127.4, 125.1, 123.5.  
2-(4-Methoxyphenyl)-1,3,4-oxadiazole (88a). Yield: 166 mg (0.94 mmol, 94%) as white 
crystals; m.p. 54-55 oC; IR (nujol): 2839, 1613, 1596, 1263 cm-1; 1H NMR (400 MHz, DMSO-
d6): δ 9.27 (s, 1H), 7.97 (d, J = 8.9 Hz, 2H), 7.16 (d, J = 8.9 Hz, 2H), 3.85 (s, 3H); 13C NMR (100 
MHz, DMSO-d6): δ 164.0, 162.5, 154.5, 129.0, 116.0, 115.4, 56.0.  
2-(4-Methoxyphenyl)-5-methyl-1,3,4-oxadiazole (88b). Yield: 177 mg (0.93 mmol, 93%) as 
white crystals; m.p. 79-80 oC; IR (nujol): 2835, 1609, 1589, 1508, 1256 cm-1; 1H NMR (400 
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MHz, DMSO-d6): δ 7.91 (d, J = 8.9 Hz, 2H), 7.13 (d, J = 8.9 Hz, 2H), 3.85 (s, 3H), 2.56 (s, 3H); 
13C NMR (100 MHz, DMSO-d6): δ 1643, 163.8, 162.3, 128.6, 116.4, 115.3, 56.0, 11.1.  
2-Ethyl-5-(4-methoxyphenyl)-1,3,4-oxadiazole (88c). Yield: 188 mg (0.92 mmol, 92%) as 
white crystals; m.p. 48-49 oC; IR (nujol): 2834, 1615, 1591, 1581, 1255 cm-1; 1H NMR (400 
MHz, DMSO-d6): δ 7.92, (d, J = 8.8 Hz, 2H), 7.13 (d, J = 8.8 Hz, 2H), 3.85 (s, 3H), 2.92 (q, J = 
7.5 Hz, 2H), 1.32 (t, J = 7.5 Hz, 3H); 13C NMR (100 MHz, DMSO-d6): δ 167.6, 164.2, 162.3, 
128.6, 116.4, 115.3, 55.9, 18.9, 11.0.  
2-(4-Methoxyphenyl)-5-propyl-1,3,4-oxadiazole (88d). Yield: 192 mg (0.88 mmol, 88%) as 
white crystals; m.p. 50-51 oC; IR (nujol): 2841, 1621, 1599, 1579, 1259 cm-1; 1H NMR (400 
MHz, DMSO-d6): δ 7.91 (d, J = 8.9 Hz, 2H), 7.13 (d, J = 8.9 Hz, 2H), 3.85 (s, 3H), 2.88 (t, J = 
7.4 Hz, 2H), 1.77 (sextet, J = 7.4 Hz, 2H), 0.99 (t, J = 7.4 Hz, 3H); 13C NMR (100 MHz, DMSO-
d6): δ 165.5, 163.1, 161.2, 127.6, 115.3, 114.2, 54.9, 25.8, 18.8, 12.8.  
2-(4-Methoxyphenyl)-5-phenyl-1,3,4-oxadiazole (88e). Yield: 203 mg (0.80 mmol, 80%) as a 
white flaky solid; m.p. 141-142 oC; IR (nujol): 2840, 1611, 1551, 1263 cm-1; 1H NMR (400 MHz, 
DMSO-d6): δ 8.16-8.11 (complex, 2H), 8.10 (d, J = 8.9 Hz, 2H), 8.09 (d, J = 8.9 Hz, 2H), 7.68-
7.60 (complex, 3H), 3.87 (s, 3H); 13C NMR (100 MHz, DMSO-d6): δ 163.4, 162.9, 161.5, 131.9, 
128.8, 128.0, 126.0, 122.9, 115.1, 114.3, 55.0.  
2-(Pyridin-3-yl)-1,3,4-oxadiazole (90a). Yield: 141 mg (0.96 mmol, 96%) as a white solid; m.p. 
68-69 oC; IR: 3070, 1568, 1514, 1436 cm-1; 1H NMR (400 MHz, CDCl3): δ 9.32 (d, J = 2.1 Hz, 
1H), 8.81 (dd, J = 4.9, 1.7 Hz, 1H), 8.55 (s, 1H), 8.40 (dt, J = 8.0, 2.1 Hz, 1H), 7.50 (dd, J = 8.0, 
4.9 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ 162.8, 153.0, 152.8, 148.1, 134.4, 123.9, 120.6.  
2-Methyl-5-(pyridin-3-yl)-1,3,4-oxadiazole (90b). Yield: 113 mg (0.70 mmol, 70%) as a light 
pink solid; m.p. 109-110 oC; IR: 3073, 1585, 1430 cm-1; 1H NMR (400 MHz, CDCl3): δ 9.25 (d, J 
= 2.2 Hz, 1H), 8.77 (dd, J = 4.9, 1.7 Hz, 1H), 8.34 (dt, J = 8.1, 2.2 Hz, 1H), 7.47 (dd, J = 8.1, 4.9 
Hz, 1H), 2.66 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 164.2, 162.9, 152.3, 147.8, 134.0, 123.8, 
120.5, 11.1.  
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2-Ethyl-5-(pyridin-3-yl)-1,3,4-oxadiazole (90c). Yield: 140 mg (0.80 mmol, 80%) as a pale 
yellow slurry; IR: 3057, 1578, 1434 cm-1; 1H NMR (400 MHz, CDCl3): δ 9.25 (s, 1H), 8.76 (dd, J 
= 4.9, 1.7 Hz, 1H), 8.35 (dq, J = 8.1, 2.1 Hz, 1H), 7.47 (dd, J = 8.1, 4.9 Hz, 1H), 3.00 (q, J = 7.6 
Hz, 2H); 1.47 (t, J = 7.6 Hz, 2H); 13C NMR (100 MHz, CDCl3): δ 168.3, 162.6, 152.2, 147.7, 
134.0, 123.8, 19.2, 10.8.  
2-Propyl-5-(pyridin-3-yl)-1,3,4-oxadiazole (90d). Yield: 157 mg (0.83 mmol, 83%) as an 
orange oil; IR: 3047, 1578, 1464 cm-1; 1H NMR (400 MHz, CDCl3): δ 9.26 (d, J = 2.2 Hz, 1H), 
8.77 (dd, J = 4.9, 1.7 Hz, 1H), 8.35 (dt, J = 8.1, 2.0 Hz, 1H), 7.47 (dd, J = 8.1, 4.9 Hz, 1H), 2.94 
(t, J = 7.4 Hz, 2H), 1.90 (sextet, J = 7.4 Hz, 2H), 1.08 (t, J = 7.4 Hz, 3H); 13C NMR (100 MHz, 
CDCl3): δ 167.5, 162.7, 152.3, 147.8, 134.0, 123.8, 120.6, 27.3, 20.1, 13.6. 
2-Phenyl-5-(pyridin-3-yl)-1,3,4-oxadiazole (90e). Yield: 179 mg (0.80 mmol, 80%) as a white 
solid; m.p. 119-120 oC; IR: 3058, 1597, 1448 cm-1; 1H NMR (400 MHz, CDCl3): δ 9.37 (d, J = 
2.2 Hz, 1H), 8.81 (dd, J = 4.9, 1.7 Hz, 1H), 8.46 (dt, J = 8.0, 2.1 Hz, 1H), 8.17 (d, J = 8.1 Hz, 
2H), 7.60-7.54 (complex, 3H); 7.51 (dd, J = 8.0, 4.9 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ 
165.1, 162.5, 152.5, 147.9, 134.2, 132.1, 129.2, 127.1, 123.9, 123.5, 120.5. 
2-(Pyridin-4-yl)-1,3,4-oxadiazole (92a). Yield: 125 mg (0.85 mmol, 85%) as light tan crystals; 
m.p. 116-117 oC; IR: 3061, 1538, 1497, 1411 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.86 (br s, 
2H), 8.58 (s, 1H), 7.96 (d, J = 6.1 Hz, 2H); 13C NMR (100 MHz, CDCl3): δ 163.1, 153.4, 151.0, 
130.6, 120.5.  
2-Methyl-5-(pyridin-4-yl)-1,3,4-oxadiazole (92b). Yield: 139 mg (0.86 mmol, 86%) as a light 
tan solid; m.p. 147-148 oC; IR: 3059, 1572, 1411 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.81 (d, J 
= 6.1 Hz, 2H), 7.89 (d, J = 6.1 Hz, 2H), 2.67 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 164.7, 
163.2, 150.9, 131.0, 120.2, 11.2.  
2-Ethyl-5-(pyridin-4-yl)-1,3,4-oxadiazole (92c). Yield: 149 mg (0.85 mmol, 85%) as a pale 
yellow solid; m.p. 51-52 oC; IR: 3046, 1563, 1413 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.81 (d, J 
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= 6.1 Hz, 2H), 7.90 (d, J = 6.1 Hz, 2H), 3.00 (q, J = 7.6 Hz, 2H), 1.47 (t, J = 7.6 Hz, 3H); 13C 
NMR (100 MHz, CDCl3): δ 168.8, 163.0, 150.9, 131.2, 120.3, 19.3, 10.8.  
2-Propyl-5-(pyridin-4-yl)-1,3,4-oxadiazole (92d). Yield: 163 mg (0.86 mmol, 86%) as a pale 
yellow solid; m.p. 41-42 oC; IR: 3041, 1563, 1414 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.81 (d, J 
= 6.1 Hz, 2H), 7.90 (d, J = 6.1 Hz, 2H), 2.95 (t, J = 7.4 Hz, 2H), 1.91 (sextet, J = 7.4 Hz, 2H), 
1.08 (t, J = 7.4 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 167.9, 163.0, 150.9, 131.2, 120.2, 27.3, 
20.1, 13.6. 
2-Phenyl-5-(pyridin-4-yl)-1,3,4-oxadiazole (92e). Yield: 196 mg (0.88 mmol, 88%) as a pale 
yellow solid; m.p. 133-134 oC; IR: 3038, 1542, 1449, 1411 cm-1; 1H NMR (400 MHz, CDCl3): δ 
8.86 (d, J = 6.1 Hz, 2H), 8.17 (d, J = 7.9 Hz, 2H), 8.01 (d, J = 6.1 Hz, 2H), 7.63-7.54 (complex, 
3H); 13C NMR (100 MHz, CDCl3): δ 165.1, 162.5, 152.5, 147.9, 134.2, 132.1, 129.2, 127.1, 
123.9, 123.5, 120.5. 
 2.3.4. Naphthalenes and heterocycles from Morita-Baylis-Hillman (MBH) acetates by 
domino Michael addition-elimination-SNAr reactions. 
Representative procedure for the synthesis of MBH alcohols (95a-h). 
To a stirred solution of the aldehyde 47a-c (1 equiv) and DABCO (1.5 equiv) in CH3CN (8 mL) 
under N2 was added the corresponding acrylate 94a or acrylonitrile 94b (2 equiv) at room 
temperature. After 24-48 h, TLC analysis (10% EtOAc/hexane) indicated completion of reaction, 
and the solution was partitioned between H2O and EtOAc. The organic layer was washed with 
1M HCl (2×), and saturated NaHCO3. The combined aqueous layers were back extracted with 
EtOAc (3×), and all of the combined organic layers were washed with saturated NaCl and dried 
(Na2SO4). Removal of the solvent under vacuum resulted in pure MBH alcohols 95a-h, which 






Representative procedure for the synthesis of MBH acetates (96a-f). 
A solution of the corresponding MBH alcohol 95a-f (1 mmol) in CH2Cl2 (2 mL) was treated with 
acetic anhydride (1.5 mmol) at 0 oC, followed by a CH2Cl2 solution of TMSOTf (1 M; 20 µL). 
After 30 minutes, TLC analysis (10% ether/hexane) showed completion of reaction. Treatment of 
the reaction mixture with NaHCO3 gave two phases, of which the organic extracts were washed 
with water and dried (Na2SO4). Evaporation of the solvent under vacuum afforded clean MBH 
acetates 96a-f, which did not require any further purification. 
Ethyl 2-(acetoxy(2-fluoro-5-nitrophenyl)methyl)acrylate (96a). Yield: 305 mg (0.98 mmol, 
98%) as a colorless oil; IR: 1751, 1723, 1639, 1532, 1351 cm-1; 1H NMR (400 MHz, CDCl3): δ 
8.26 (dd, J = 6.0, 2.8 Hz, 1H), 8.23 (ddd, J = 8.9, 4.3, 2.9 Hz, 1H), 7.22 (t, J = 8.9 Hz, 2H), 6.91 
(s, 1H), 6.54 (s, 1H), 4.18 (qd, J = 7.1, 1.3 Hz, 2H), 2.15 (s, 3H), 1.25 (q, J = 7.1 Hz, 3H); 13C 
NMR (100 MHz, CDCl3): δ 182.6, 169.0, 164.22 (d, J = 232.5 Hz ), 144.2, 137.4, 127.4, 126.0 
(d, J = 10.2 Hz ), 125.2 (d, J = 5.2 Hz), 116.9, 116.7, 66.6, 61.4, 20.9, 13.9. 
2-Cyano-1-(2-fluoro-5-nitrophenyl)allyl acetate (96b). Yield: 259 mg (0.98 mmol, 98%) as  
off-white crystals; m.p. 66-67 oC; IR: 2232, 1759, 1632, 1532, 1535, 1352 cm-1; 1H NMR (400 
MHz, CDCl3): δ 8.42 (dd, J = 6.1, 2.8 Hz, 1H), 8.31 (ddd, J = 9.0, 4.4, 2.8 Hz, 1H), 7.29 (t, J = 
9.0 Hz, 1H), 6.64 (s, 1H), 6.19 (s, 1H), 6.18 (s, 1H), 2.26 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 
168.8, 163.1 (d, J = 260.1 Hz ), 144.7, 133.7, 126.8 (d, J = 10.3 Hz ), 125.3 (d, J = 15.1 Hz), 
124.1 (d, J = 4.9 Hz), 120.9, 117.1 (d, J = 23.7 Hz), 115.2, 67.8 (d, J = 3.0 Hz), 20.8. 
2-Cyano-1-(5-cyano-2-fluorophenyl)allyl acetate (96c). Yield: 259 mg (0.98 mmol, 98%) as  
off-white crystals; m.p. 74-75 oC; IR: 2255, 2235, 1757, 1613 cm-1; 1H NMR (400 MHz, CDCl3): 
δ 7.86 (dd, J = 6.6, 2.1 Hz, 1H), 7.72 (ddd, J = 8.4, 4.8, 2.1 Hz, 1H), 7.24 (t, J = 9.3 Hz, 1H), 6.60 
(s, 1H), 6.16 (s, 1H), 6.15 (s, 1H), 2.24 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 168.8, 161.9 (d, J 
= 259.0 Hz ), 135.2 (d, J = 9.8 Hz ), 133.7, 132.3 (d, J = 4.3 Hz), 125.6 (d, J = 14.2 Hz), 120.9, 
117.44 (d, J = 22.8 Hz), 117.41, 115.3, 109.6 (d, J = 4.0 Hz), 67.8 (d, J = 3.2 Hz), 20.8. 
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Ethyl 2-(acetoxy(5-cyano-2-fluorophenyl)methyl)acrylate (96d). Yield: 285 mg (0.98 mmol, 
98%) as a colorless oil; IR: 2234, 1752, 1729, 1637 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.69 
(dd, J = 6.6, 2.1 Hz, 1H), 7.64 (ddd, J = 8.5, 4.7, 2.1 Hz, 1H), 7.19 (t, J = 9.3 Hz, 1H), 6.88 (s, 
1H), 6.51 (s, 1H), 5.92 (s, 1H), 4.19 (q, J = 7.1 Hz, 2H), 2.15 (s, 3H), 1.25 (t, J = 7.1 Hz, 3H); 13C 
NMR (100 MHz, CDCl3): δ 169.0, 164.2, 162.6 (d, J = 260.3 Hz), 137.6, 134.4 (d, J = 9.8 Hz ), 
133.6 (d, J = 4.8 Hz), 127.7 (d, J = 14.9 Hz), 127.3, 117.8, 117.2 (d, J = 23.4 Hz), 108.7 (d, J = 
4.0 Hz), 66.6 (d, J = 2.9 Hz), 61.3, 20.8, 14.0. 
2-Cyano-1-(2,5-difluorophenyl)allyl acetate (96e). Yield:  232 mg (0.98 mmol, 98%) as a white 
solid; m.p. 49-50 oC; IR: 2256, 2232, 1752, 1627 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.22 (m, 
1H), 7.07 (m, 2H), 6.58 (s, 1H), 6.12 (s, 1H), 6.10 (s, 1H), 2.21 (s, 3H); 13C NMR (100 MHz, 
CDCl3): δ 168.8, 158.8 (d, J = 244.2 Hz), 155.7 (d, J = 243.7 Hz ), 133.2, 124.9 (dd, J = 15.4, 7.4 
Hz), 121.5, 117.4 (dd, J = 24.2, 8.7 Hz), 117.1 (dd, J = 24.1, 8.5 Hz), 115.6, 114.6 (dd, J = 25.6, 
3.3 Hz), 68.1 (d, J = 3.1 Hz), 20.8. 
Ethyl 2-(acetoxy(2,5-difluorophenyl)methyl)acrylate (96f). Yield: 278 mg (0.98 mmol, 98%) 
as a colorless oil; IR: 1752, 1723, 1638 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.05-6.95 (complex, 
3H), 6.88 (s, 1H), 6.47 (s, 1H), 5.82 (s, 1H), 4.18 (q, J = 7.1 Hz, 2H), 2.12 (s, 3H), 1.24 (t, J = 7.1 
Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 169.1, 164.5 (d, J = 242.2 Hz), 158.5 156.2, 148.8, 
138.2, 133.5, 126.9, 116.7 (ddd, 24.7, 24.7, 8.5 Hz), 115.4 (dd, J = 25.0, 3.8 Hz), 62.0, 61.2, 20.9, 
14.0. 
Representative procedure for the synthesis of MBH acetates (96g and 96h) using MBH 
alcohols derived from 2-fluoronicotinaldehdye. 
To a solution of the corresponding MBH alcohol 95g,h (1 mmol) in CH2Cl2 (2 mL) at 0 oC, was 
added acetic anhydride (4.5 mmol), and a CH2Cl2 solution of TMSOTf (1 M; 6 mmol), in a 
portionwise fashion over 1 h. Upon completion of reaction (TLC analysis using 20% 
EtOAc/hexane), the reaction mixture was quenched with stoichiometric amount of methanol 
(relative to acetic anhydride used). Treatment of the mixture with NaHCO3 gave two phases, of 
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which the organic extracts were washed with water, and dried (Na2SO4). Evaporation of the 
solvent under vacuum afforded clean MBH acetates 96g,h, which did not require any further 
purification. 
2-Cyano-1-(2-fluoropyridin-3-yl)allyl acetate (96g). Yield:  209 mg (0.95 mmol, 95%) as a 
colorless oil; IR: 2231, 1756, 1609 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.26 (m, 1H), 7.99 (tm, J 
= 8.5 Hz, 1H), 7.30 (m, 1H), 6.53 (s, 1H), 6.19 (m, 1H), 6.17 (m, 1H), 2.21 (s, 3H); 13C NMR 
(100 MHz, CDCl3): δ 168.8, 160.2 (d, J = 240.0 Hz), 148.4 (d, J = 15.0 Hz ), 138.8 (d, J = 3.7 
Hz), 133.8, 122.0 (d, J = 4.4 Hz), 120.9, 118.5 (d, J = 27.9 Hz), 115.4, 68.5 (d, J = 2.9, 3.3 Hz), 
20.8. 
Ethyl 2-(acetoxy(2-fluoropyridin-3-yl)methyl)acrylate (96h). Yield: 254 mg (0.95 mmol, 95%) 
as a colorless oil; IR: 1758, 1727, 1637 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.19 (m, 1H), 7.81 
(ddd, J = 9.4, 7.4, 2.0 Hz, 1H), 7.20 (ddd, J = 6.5, 4.8, 1.6 Hz, 1H), 6.81 (s, 1H), 6.50 (s, 1H), 
5.92 (s, 1H), 4.18 (q, J = 7.1 Hz, 2H), 2.14 (s, 3H), 1.24 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, 
CDCl3): δ 169.1, 164.4, 161.0 (d, J = 241.9 Hz), 147.6 (d, J = 14.9 Hz ), 140.1 (d, J = 4.3 Hz), 
137.5, 127.2 (d, J = 1.2 Hz), 121.4 (d, J = 4.4 Hz), 120.5 (d, J = 27.9 Hz), 61.2, 20.8, 14.0. 
Representative procedure for the synthesis of naphthalene derivatives using MBH acetates 
and active methylene compounds.  
A 50-mL, round-bottomed flask equipped with a condenser, stir bar and vacuum adapter, was 
charged with MBH acetate 96b (1 mmol) in 1 mL of DMF under N2. The corresponding active 
methylene compound (1.5 mmol) and K2CO3 (1.5 mmol) were added at room temperature with 
continued stirring. TLC analysis (30% EtOAc/hexane) indicated complete consumption of the 
starting material after 1 h. The solution was poured into 15 mL of de-ionized water, of which the 
mixture was extracted with EtOAc (3×). The combined organic layers were washed with 
saturated NaCl and dried (Na2SO4). Removal of the solvent under vacuum gave the crude 




6-Nitronaphthalene-1,3-dicarbonitrile (98a) from 96b and ethyl cyanoacetate. Yield: 178 mg 
(0.80 mmol, 80%) as a white solid; m.p. 224 oC (dec.); IR: 2250, 1541, 1354 cm-1; 1H NMR (400 
MHz, CDCl3): δ 8.97 (d, J = 2.2 Hz, 1H), 8.67 (s, 1H), 8.65 (dd, J = 9.1, 2.2 Hz, 1H), 8.51 (d, J = 
9.2 Hz, 1H), 8.26 (d, J = 1.6 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ 147.6, 139.7, 135.7, 135.5, 
131.4, 127.9, 125.3, 125.0, 116.0, 114.9, 113.2, 112.0. 
Methyl 3-cyano-6-nitro-1-naphthoate (98b) from 96b and methyl phenylsulfonylacetate. 
Yield: 220 mg (0.86 mmol, 86%) as a white solid; m.p. 219-220 oC; IR: 2254, 1708, 1534, 1350 
cm-1; 1H NMR (400 MHz, CDCl3): δ 9.26 (d, J = 9.5 Hz, 1H), 8.89 (d, J = 2.4 Hz, 1H), 8.58 (s, 
1H), 8.54 (d, J = 1.7 Hz, 1H), 8.51 (dd, J = 9.5, 2.4 Hz, 1H), 4.08 (s, 3H); 13C NMR (100 MHz, 
CDCl3): δ 165.3, 146.5, 139.8, 135.0, 133.8, 132.2, 129.1, 128.6, 125.0, 123.8, 117.1, 111.3, 53.1. 
Ethyl 3-cyano-6-nitro-1-naphthoate (98c) from 96b and ethyl nitroacetate. Yield: 238 mg 
(0.88 mmol, 88%) as a white solid; m.p. 156-157 oC; IR: 2254, 1722, 1629, 1535, 1350 cm-1; 1H 
NMR (400 MHz, CDCl3): δ 9.26 (d, J = 9.5 Hz, 1H), 8.89 (d, J = 2.4 Hz, 1H), 8.58 (s, 1H), 8.53 
(s, 1H), 8.51 (dd, J = 9.5, 2.4 Hz, 1H), 4.54 (q, J = 7.1 Hz, 2H), 1.50 (t, J = 7.1 Hz, 3H); 13C 
NMR (100 MHz, CDCl3): δ 164.9, 146.5, 139.6, 135.0, 133.7, 132.1, 129.5, 128.7, 125.0, 123.7, 
117.2, 111.3, 62.4, 14.3. 
Representative procedure for the synthesis of dihydroheteroaromatics using MBH acetates 
and 1o alkyl or aromatic amines.  
To a solution of MBH acetate (1 mmol) in 1 mL of DMF under N2 was added the corresponding 
amine (1.5 mmol), and the mixture was stirred at room temperature for 2 h. K2CO3 (1.5 mmol) 
was added at 23 oC, and the temperature was gradually increased to 50 oC, with continued stirring 
for 2 h (alternatively, only 2.0 equiv of the corresponding amine can be used without K2CO3, and 
the temperature can gradually be increased to 50 oC immediately after addition of the amine). 
After TLC (20% EtOAc/hexane) has indicated complete consumption of the starting material, the 
solution was poured into 15 mL of DI water, and extracted with EtOAc (3×). The organic layer 
was washed with 1M HCl (2×), followed by saturated NaHCO3 (2×). The combined organic 
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layers were washed with saturated NaCl and dried (Na2SO4). Removal of the solvent under 
vacuum gave a crude product, which was further purified by column chromatograph to afford the 
dihydroheteroaromatic compounds. 
1-Methyl-6-nitro-1,2-dihydroquinoline-3-carbonitrile (100a) from 96b and methylamine. 
Yield: 189 mg (0.88 mmol, 88%) as an orange solid; m.p. 186-187 oC; IR: 2210, 1640, 1515, 
1321 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.05 (dd, J = 9.2, 2.7 Hz, 1H), 7.82 (d, J = 2.7 Hz, 
1H), 7.00 (br s, 1H), 6.47 (d, J = 9.2 Hz, 1H), 4.41 (d, J = 1.6 Hz, 2H), 2.94 (s, 3H); 13C NMR 
(100 MHz, CDCl3): δ 150.5, 139.0, 137.7, 128.7, 125.0, 117.5, 116.5, 109.6, 103.7, 51.5,37.6. 
1-Hexyl-6-nitro-1,2-dihydroquinoline-3-carbonitrile (100b) from 96b and n-hexylamine. 
Yield: 222 mg (0.78 mmol, 78%) as a yellow solid; m.p. 110-111 oC; IR: 2228, 1647, 1532, 1344 
cm-1; 1H NMR (400 MHz, CDCl3): δ 8.02 (dd, J = 9.3, 2.7 Hz, 1H), 7.80 (d, J = 2.7 Hz, 1H), 6.97 
(br s, 1H), 6.44 (d, J = 9.3 Hz, 1H), 4.43 (s, 3H), 3.25 (t, J = 7.2 Hz, 2H), 1.62 (quintet, J = 7.5 
Hz, 2H), 1.36 (m, 6H), 0.92 (t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 149.8, 139.2, 
137.6, 128.9, 125.5, 117.4, 116.7, 109.6, 103.3, 50.9, 50.3, 31.5, 26.6, 25.0, 22.6, 14.0. 
1-isoButyl-6-nitro-1,2-dihydroquinoline-3-carbonitrile (100c) from 96b and isobutylamine. 
Yield: 203 mg (0.79 mmol, 79%) as a yellow solid; m.p. 158-159 oC; IR: 2208, 1642, 1519, 1324 
cm-1; 1H NMR (400 MHz, CDCl3): δ 8.00 (d, J = 9.3 Hz, 1H), 7.80 (s, 1H), 6.96 (s, 1H), 6.47 (d, 
J = 9.3 Hz, 1H), 4.44 (s, 2H), 3.08 (d, J = 7.5 Hz, 2H), 2.11 (septet, J = 6.7 Hz, 1H), 1.02 (d, J = 
6.7 Hz, 6H); 13C NMR (100 MHz, CDCl3): δ 150.3, 139.3, 137.6, 128.7, 125.6, 117.4, 116.7, 
110.2, 103.1, 58.4, 51.3, 26.2, 20.2. 
1-Benzyl-6-nitro-1,2-dihydroquinoline-3-carbonitrile (100d) from 96b and benzylamine. 
Yield: 233 mg (0.80 mmol, 80%) as a yellow solid; m.p. 154-155 oC; IR: 2231, 1648, 1530, 1345 
cm-1; 1H NMR (400 MHz, CDCl3): δ 7.99 (dd, J = 9.2, 2.6 Hz, 1H), 7.86 (d, J = 2.6 Hz, 1H), 
7.43-7.32 (complex, 3H), 7.23 (d, J = 8.5 Hz, 2H), 7.04 (s, 1H), 6.54 (d, J = 9.2 Hz, 1H), 4.52 (s, 
2H), 4.44 (d, J = 1.6 Hz, 2H); 13C NMR (100 MHz, CDCl3): δ 150.1, 139.0, 138.3, 133.8, 129.3, 
128.3, 126.8, 125.5, 117.6, 116.5, 110.4, 103.9, 54.1, 50.4. 
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6-Nitro-1-phenethyl-1,2-dihydroquinoline-3-carbonitrile (100e) from 96b and phenethyl-
amine. Yield: 250 mg (0.82 mmol, 82%) as a yellow solid; m.p. 121-122 oC; IR: 2239, 1623, 
1526, 1344 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.02 (dd, J = 9.2, 2.7 Hz, 1H), 7.81 (d, J = 2.7 
Hz, 1H), 7.38-7.18 (complex, 5H), 6.95 (s, 1H), 6.47 (d, J = 9.3 Hz, 1H), 4.28 (s, 2H), 3.52 (t, J = 
7.4 Hz, 2H), 2.92 (t, J = 7.4 Hz, 2H); 13C NMR (100 MHz, CDCl3): δ 149.5, 139.0, 137.9, 137.5, 
129.1, 128.9, 128.7, 127.2, 125.6, 117.5, 116.5, 109.6, 103.4, 52.6, 50.7, 31.8. 
1-Methyl-1,2-dihydroquinoline-3,6-dicarbonitrile (101a) from 96c and methylamine. Yield: 
160 mg (0.82 mmol, 82%) as a yellow solid; m.p. 205-206 oC; IR: 2253, 1625 cm-1; 1H NMR 
(400 MHz, CDCl3): δ 7.39 (d, J = 8.6 Hz, 1H), 7.15 (s, 1H), 6.94 (s, 1H), 6.48 (d, J = 8.6 Hz, 
1H), 4.33 (s, 2H), 2.87 (s, 2H); 13C NMR (100 MHz, CDCl3): δ 148.9, 139.0, 136.4, 132.7, 119.2, 
119.0, 116.8, 110.8, 103.7, 99.8, 51.4, 37.4. 
1-Hexyl-1,2-dihydroquinoline-3,6-dicarbonitrile (101b) from 96c and n-hexylamine. Yield: 
204 mg (0.77 mmol, 77%) as a yellow solid; m.p. 178-179 oC; IR: 2254, 1651 cm-1; 1H NMR 
(400 MHz, CDCl3): δ 8.76 (s, 1H), 8.09 (s, 1H), 7.96 (d, J = 8.9 Hz, 1H), 7.60 (d, J = 8.9 Hz, 
1H), 4.22 (t, J = 7.4 Hz, 2H), 1.91 (quintet, J = 7.4 Hz, 2H), 1.50-1.28 (complex, 6H), 0.91 (t, J = 
6.7 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 172.8, 149.5, 141.2, 135.5, 132.9, 127.0, 117.5, 
117.3, 114.5, 109.7, 97.9, 54.8, 31.2, 28.8, 26.3, 22.4, 13.9. 
1-isoButyl-1,2-dihydroquinoline-3,6-dicarbonitrile (101c) from 96c and isobutylamine. Yield 
192 mg (0.81 mmol, 81%) as a yellow solid; m.p. 131-132 oC; IR: 2229, 1626 cm-1; 1H NMR 
(400 MHz, CDCl3): δ 7.33 (dd, J = 8.8, 2.1 Hz, 1H), 7.14 (d, J = 2.1 Hz, 1H), 6.92 (s, 1H), 6.48 
(d, J = 8.8 Hz, 1H), 4.38 (d, J = 1.5 Hz, 2H), 3.02 (d, J = 7.5 Hz, 2H), 2.06 (septet, J = 6.6 Hz, 
1H), 1.00 (d, J = 6.6 Hz, 6H); 13C NMR (100 MHz, CDCl3): δ 148.6, 139.1, 136.1, 133.2, 119.3, 
118.7, 116.9, 111.2, 102.7, 98.9, 58.1, 50.9, 26.2, 20.2. 
Ethyl 6-cyano-1-methyl-1,2-dihydroquinoline-3-carboxylate (102a) from 96d and methyl-
amine. Yield: 209 mg (0.91 mmol, 91%) as a yellow solid; m.p. 140-141 oC; IR: 2201, 1708, 
1652 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.35 (dd, J = 8.6, 2.1 Hz, 1H), 7.23 (s, 1H), 7.17 (d, J 
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= 2.1 Hz, 1H), 6.42 (d, J = 8.6 Hz, 1H), 4.41 (d, J = 1.5 Hz, 2H), 4.27 (q, J = 7.1 Hz, 2H), 2.87 (s, 
3H), 1.34 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 164.8, 149.6, 135.9, 133.7, 133.0, 
122.7, 119.9, 119.8, 109.9, 98.6, 61.0, 51.0, 37.4. 
Ethyl 6-cyano-1-phenethyl-1,2-dihydroquinoline-3-carboxylate (102e) from 96d and phen-
ethylamine. Yield: 270 mg (0.85 mmol, 85%) as a yellow solid; m.p. 131-132 oC; IR: 2217, 
1701, 1650 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.36-7.29 (complex, 3H), 7.25-7.18 (complex, 
4H), 7.18 (d, J = 2.1 Hz, 1H), 6.44 (d, J = 8.7 Hz, 1H), 4.43 (d, J = 1.6 Hz, 2H), 4.26 (q, J = 7.1 
Hz, 2H), 3.45 (t, J = 7.9 Hz, 2H), 2.88 (t, J = 7.9 Hz, 2H), 1.33 (t, J = 7.1 Hz, 3H); 13C NMR (100 
MHz, CDCl3): δ 164.8, 148.5, 138.1, 135.8, 132.7, 133.4, 128.9, 128.7, 126.8, 122.1, 119.9, 
119.7, 109.8, 98.2, 61.0, 52.1, 49.6, 31.3, 14.3. 
Ethyl 6-cyano-1-phenyl-1,2-dihydroquinoline-3-carboxylate (102f) from 96d and aniline. 
Yield: 252 mg (0.83 mmol, 83%) as a yellow solid; m.p. 129-130 oC; IR: 2254, 1698, 1644 cm-1; 
1H NMR (400 MHz, CDCl3): δ 7.47 (t, J = 7.8 Hz, 2H), 7.36 (s, 1H), 7.33-7.24 (complex, 4H), 
7.19 (dd, J = 8.7, 2.0 Hz, 1H), 6.44 (d, J = 8.7 Hz, 1H), 4.71 (d, J = 1.5 Hz, 2H), 4.27 (q, J = 7.1 
Hz, 2H), 1.33 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 164.6, 148.8, 143.9, 134.8, 
133.22, 133.16, 130.2, 126.8, 125.4, 123.1, 121.1, 119.6, 113.8, 100.3, 61.1, 50.4, 14.3. 
1-Hexyl-1,2-dihydro-1,8-naphthyridine-3-carbonitrile (103b) from 96g and n-hexylamine. 
Yield: 198 mg (0.82 mmol, 82%) as a yellow semisolid; IR: 2254, 1639 cm-1; 1H NMR (400 
MHz, CDCl3): δ 7.97 (dd, J = 5.0, 1.8 Hz, 1H), 7.04 (dd, J = 7.3, 1.8 Hz, 1H), 6.87 (t, J = 1.4 Hz, 
1H), 6.42 (dd, J = 7.3, 5.0 Hz, 1H), 4.44 (d, J = 1.4 Hz, 2H), 3.45 (t, J = 7.4 Hz, 2H), 1.58 
(quintet, J = 7.2 Hz, 2H), 1.38-1.28 (complex, 6H), 0.90 (t, J = 6.9 Hz, 3H); 13C NMR (100 MHz, 
CDCl3): δ 155.5, 151.0, 139.8, 135.9, 117.5, 113.4, 112.7, 102.4, 49.6, 47.4, 31.7, 26.6, 25.7, 
22.6, 14.1. 
1-Phenethyl-1,2-dihydro-1,8-naphthyridine-3-carbonitrile (103e) from 96g and phen-
ethylamine. Yield: 209 mg (0.80 mmol, 80%) as a yellow semisolid; IR: 2254, 1639 cm-1; 1H 
NMR (400 MHz, CDCl3): δ 8.02 (dd, J = 5.0, 1.9 Hz, 1H), 7.35-7.21 (complex, 5H), 7.06 (dd, J = 
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7.3, 1.9 Hz, 1H), 6.86 (t, J = 1.4 Hz, 1H), 6.46 (dd, J = 7.3, 5.0 Hz, 1H), 4.32 (d, J = 1.4 Hz, 2H), 
3.68 (t, J = 7.4 Hz, 2H), 2.92 (t, J = 7.1 Hz, 2H); 13C NMR (100 MHz, CDCl3): δ 155.2, 151.1, 
139.6, 135.8, 128.9, 128.6, 126.5, 117.3, 113.5, 113.0, 102.5, 50.3, 49.6, 32.4. 
Representative procedure for the synthesis of 4-oxo-1,4-dihydroquinolines using MBH 
acetates and 1o alkyl or aromatic amines.  
To a solution of MBH acetate (1 mmol) in 1 mL of DMF under N2 was added the corresponding 
amine (1.5 mmol), and the mixture was stirred at room temperature for 2 h. K2CO3 (1.5 mmol) 
was added at 23 oC, and the temperature was gradually increased to 90 oC, with continued stirring 
for 2 h (alternatively, only 2.0 equiv of the corresponding amine can be used without K2CO3, and 
the temperature can gradually be increased to 90 oC immediately after addition of the amine). 
After TLC (20% EtOAc/hexane) has indicated complete consumption of the starting material, the 
solution was poured into 15 mL of DI water, and extracted with EtOAc (3×). The organic layer 
was washed with 1M HCl (2×), followed by saturated NaHCO3 (2×). The combined organic 
layers were washed with saturated NaCl and dried (Na2SO4). Removal of the solvent under 
vacuum gave a crude product, which was further purified by column chromatograph to afford the 
4-oxo-1,4-dihydroquinoline compounds. 
Ethyl 6-fluoro-1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate (104a) from 96f and methyl-
amine. Yield: 210 mg (0.90 mmol, 90%) as a light tan solid; m.p. 203-204 oC; IR: 1728, 1694 
cm-1; 1H NMR (400 MHz, CDCl3): δ 8.46 (s, 1H), 8.18 (d, J = 8.9 Hz, 1H), 7.44 (d, J = 5.7 Hz, 
2H), 4.40 (q, J = 7.1 Hz, 2H), 3.90 (s, 3H), 1.42 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3): 
δ 173.5 (d, J = 2.0 Hz), 165.7, 160.1 (d, J = 232.0 Hz), 149.6, 136.3 (d, J = 6.6 Hz), 130.8 (d, J = 
6.8 Hz), 121.0 (d, J = 24.7 Hz), 117.8 (d, J = 7.7 Hz), 113.0 (d, J = 23.2 Hz), 110.4, 61.6, 41.6, 
14.4. 
Ethyl 6-fluoro-1-isobutyl-4-oxo-1,4-dihydroquinoline-3-carboxylate (104c) from 96f and isobutyl-
amine. Yield: 245 mg (0.89 mmol, 89%) as a light tan solid; m.p. 150-151 oC; IR: 1727, 1695 
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cm-1; 1H NMR (400 MHz, CDCl3): δ 8.43 (s, 1H), 8.21 (m, 1H), 7.42 (m, 2H), 4.41 (q, J = 7.1 
Hz, 2H), 3.97 (d, J = 7.5 Hz, 1H), 2.26 (nonet, J = 7.0 Hz, 1H), 1.42 (t, J = 7.1 Hz, 3H), 1.02 (d, J 
= 6.6 Hz, 6H); 13C NMR (100 MHz, CDCl3): δ 173.4 (d, J = 2.4 Hz), 165.9, 159.9 (d, J = 247.8 
Hz), 149.4, 135.4 (d, J = 1.9 Hz), 131.2 (d, J = 6.8 Hz), 120.8 (d, J = 28.1 Hz), 118.1 (d, J = 7.8 
Hz), 113.1 (d, J = 23.0 Hz), 109.9, 61.6, 61.0, 19.9, 14.4. 
Ethyl 1-benzyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (104d) from 96f and benzyl-
amine. Yield: 266 mg (0.86 mmol, 86%) as a light tan solid; m.p. 169-170 oC; IR: 1727, 1691, 
1619 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.60 (s, 1H), 8.18 (dd, J = 8.9, 2.9 Hz, 1H), 7.41-7.24 
(complex, 5H), 7.16 (d, J = 6.3 Hz, 2H), 5.40 (s, 2H), 4.41 (q, J = 7.1 Hz, 2H), 1.42 (t, J = 7.1 Hz, 
3H); 13C NMR (100 MHz, CDCl3): δ 173.5 (d, J = 2.3 Hz), 165.8, 160.0 (d, J = 248.0 Hz), 149.6, 
135.6 (d, J = 1.8 Hz), 133.9, 131.2 (d, J = 7.0 Hz), 129.5, 128.8, 126.0, 121.0 (d, J = 25.3 Hz), 
118.9 (d, J = 7.8 Hz), 113.0 (d, J = 23.0 Hz), 110.6, 61.1, 57.8, 14.4. 
Ethyl 6-fluoro-4-oxo-1-phenethyl-1,4-dihydroquinoline-3-carboxylate (104e) from 96f and phen-
ethylamine. Yield: 284 mg (0.88 mmol, 88%) as a light tan solid; m.p. 151-152 oC; IR: 1736, 
1691, 1618 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.21 (dd, J = 8.9, 3.0 Hz, 1H), 8.14 (s, 1H), 7.50 
(dd, J = 9.2, 4.1 Hz, 1H), 7.44 (m, 1H), 7.33-7.23 (complex, 3H), 7.06 (d, J = 7.5 Hz, 2H), 4.40 
(t, J = 7.1 Hz, 2H), 4.34 (q, J = 7.1 Hz, 2H), 3.16 (t, J = 7.1 Hz, 2H), 1.36 (t, J = 7.1 Hz, 3H); 13C 
NMR (100 MHz, CDCl3): δ 173.3 (d, J = 2.3 Hz), 165.4, 159.9 (d, J = 247.9 Hz), 149.0, 136.1, 
135.1 (d, J = 1.8 Hz), 131.2 (d, J = 6.8 Hz), 129.1, 128.7, 127.6, 121.0 (d, J = 25.2 Hz), 117.7 (d, 
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